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Asthma 
Definition of Asthma 
Asthma is a chronic inflammatory airway disorder in which many cells and cellular 
elements play a role, and it is becoming a serious global health problem. People of all ages 
in countries throughout the world are affected by this disease that can be severe and 
sometimes fatal [1]. The prevalence of asthma is increasing everywhere, especially among 
children. Airway inflammation in asthma is associated with airway hyperresponsiveness, 
airflow limitation and respiratory symptoms. Airflow limitation is the result of acute 
bronchoconstriction, swelling of the airway wall, chronic mucus formation and airway wall 
remodelling. For developing asthma, the production of abnormal amounts of IgE 
antibodies, in response to common environmental allergens, is the strongest identifiable 
predisposing factor [2]. Bronchial asthma is recognized by recurrent episodes of airflow 
limitation that are usually reversible either spontaneously or with treatment [3] and is 
accompanied by symptoms of breathlessness, wheezing, chest tightness and cough, 
particularly at night or in the early morning. Some patients with asthma show enhanced 
production of sputum as well. Exacerbations of asthma, including severe attacks or 
worsening of asthma symptoms, can develop rapidly or gradually. Exacerbations can be 
severe and may result in death in the absence of proper treatment [2]. 
 
Pathophysiology in asthma 
Post mortem studies of patients who have died of asthma have revealed that the lung is 
overinflated. Microscopically there is usually an extensive infiltration of the airway lumen 
and wall with eosinophils and lymphocytes which is accompanied by vasodilatation, 
microvascular leakage and epithelial disruption. In addition, trophic changes have also been 
identified, including smooth muscle hypertrophy, new vessel formation, increased numbers 
of epithelial goblet cells and the deposition of interstitial collagens beneath the epithelium 
(basement membrane thickening) [2,4]. It has been demonstrated that both acute and 
chronic inflammation is irregularly distributed throughout the airways, including the 
smallest airways and the parenchyma [5]. Studies in living patients with mild asthma , 
using endobronchial biopsies, generally reflect those seen in autopsy. However, in patients 
with more severe asthma, it has been demonstrated that not only eosinophils and 
lymphocytes but also neutrophils are present and may contribute to a more severe disease 
[6].  
Mast cells and eosinophils have been implicated as the key effector cells of the 
inflammatory response. These cells have the ability to secrete a wide range of mediators 
that act on the airways both directly and indirectly through neuronal mechanisms [7]. In 
addition, using immunological and molecular biological techniques, it has been found that 
T lymphocytes play a pivotal role in orchestrating the inflammatory response by releasing General introduction 
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multifunctional cytokines [8]. Cytokines that are generated by cells of the airways, 
including fibroblasts and endothelial and epithelial cells, are considered to play a role in the 
maintenance of the inflammatory response [9]. Cytokines as well as  chemokines and 
growth factors, seem to be very important in mediating the trophic changes of the airways, 
including hyperplasia of airway smooth muscle, increase in goblet cell number, 
enlargement of submucous glands and remodeling of the airway connective tissue. These 
factors are produced by a wide variety of cells, including mast cells, lymphocytes, 
eosinophils, basophils, epithelial cells, dendritic cells and smooth muscle cells [2]. 
  
Mechanisms of asthma  
Airway obstruction 
As indicated above, multiple factors are responsible for the airway narrowing in patients 
with asthma. The major cause of airway narrowing is contraction of bronchial smooth 
muscle induced by agonists released from inflammatory cells, including histamine, tryptase, 
prostaglandin D2 and leukotriene C4 from mast cells, neuropeptides from local efferent 
nerves and acetylcholine from postganglionic parasympathetic nerves [2]. The effect of 
airway smooth muscle contraction is exaggerated by thickening of the airway wall due to 
acute edema, infiltration of various cells, chronic hyperplasia of smooth muscle, vascular 
and secretory cells (remodelling) and deposition of matrix proteins in the airway wall [10]. 
In addition, even more airflow limitation is observed when the lumen of the airways 
becomes filled with viscous secretions produced by goblet cells and submucosal glands, 
leakage of plasma proteins from the bronchial microvasculature and cellular debris [10,11]. 
As a consequence of airway narrowing airway resistance is increased and maximal 
expiratory flow is reduced. 
 
Airway inflammation 
Airway inflammation in asthma is very complex and mechanisms involve a cascade of 
events mediated by many different kinds of cells, factors and mediators that closely interact 
with each other [12]. Repeated exposure to allergens may lead to the development of 
airway inflammation and hyperresponsiveness, in which an IgE-mediated response is 
considered to play an important role [13-15]. In susceptible individuals the asthmatic 
reaction after allergen-inhalation can be divided into an early asthmatic reaction (EAR) and 
a late asthmatic reaction (LAR). The EAR develops rapidly, within minutes after inhalation 
of the allergen, and is reversible within 1 to 2 h. It is characterised by mast cell 
degranulation, mucus production and bronchoconstriction [16-18] and is followed by a late 
phase reaction (6 to 9 h after allergen challenge), which may last for up to 24 h and is 
characterised by more severe bronchoconstriction, mucus secretion, thickening of the 
bronchial wall, epithelial shedding and extensive infiltration of CD 4+ T cells and 
eosinophils in the lung tissue [19-21]. Both mast cells and dendritic cells are thought to be 
very important in the acute airway response to allergens, whereas infiltration of eosinophils Chapter 1 
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plays a role both in the early and the late asthmatic reaction [22]. Dendritic cells seem to be 
key cells for allergen presentation in asthma [23]. These allergens cause cross-linking of the 
high-affinity IgE receptor FcεR1 and as a consequence the mast cells are activated and 
degranulate. Inflammatory mediators like histamine, prostaglandins, leukotrienes, platelet-
activating factor as well as reactive oxygen species are rapidly released and cause acute 
bronchoconstriction, mucus hypersecretion, vasodilatation and microvascular leakage 
[17,24]. Mast cells are therefore very important in the acute airway responses to allergens 
and may also contribute to remodelling in chronic asthma [25]. During the late asthmatic 
reaction activated airway cells release cytokines and chemokines into the circulation, 
stimulating the release of inflammatory leukocytes, especially eosinophils and their 
precursors, from the bone marrow into the circulation[26]. Activated eosinophils secrete a 
variety of mediators, including major basic protein (MBP), eosinophilic cationic protein 
(ECP), cytokines, leukotrienes, PGE2 and PAF, causing bronchoconstriction, epithelial 
damage and airway hyperresponsiveness [22,27-31].  
An important step in the generation of an immune response is the activation of T 
lymphocytes by antigen presenting cells. T cells can be divided in cytotoxic T cells (CD8+) 
and helper T cells (CD4+), based on the function of the cells. The latter is involved in the 
regulation of the effector functions of immune cells by the secretion of cytokines. In the 
immune system both antibody-mediated and cell-mediated processes can be identified. 
Antibody-mediated processes involve the production and secretion of specific antibodies by 
B lymphocytes, while cell-mediated processes depend on T lymphocytes. Two distinct 
CD4+ T-helper (Th) subtypes (Th1 and Th2) have been characterized on the basis of their 
profile of cytokine production and it is widely acknowledged that an imbalance between 
these T-helper cells towards a Th2 activation type may contribute to the development of 
airway inflammation in asthma [32]. Both subtypes secrete IL-3 and granulocyte-
macrophage colony-stimulating factor (GM-CSF), but the Th1 cells preferentially produce 
IL-2, which stimulates T lymphocyte proliferation, interferon-γ (IFNγ) and tumour necrosis 
factor-α (TNFα). As mentioned, the Th2 cells are primary involved in asthma and secrete 
the cytokines IL-4, IL-5, IL-9, IL-13 and IL-16 [33-35]. These cytokines are responsible for 
the development of the classical delayed-type or cell-mediated hypersensitivity reaction and 
play a role in IgE production, mast cell activation and eosinophilia. In bronchoalveolar 
lavage fluid and bronchial biopsies of patients with asthma the expression levels of the 
cytokines IL-4, IL-5 and IL-13 have shown to be increased compared to healthy controls 
[8,36-39]. Both IL-4 and IL-13 promote the production of IgE by B cells [40,41] and IL-4 
has been implicated in the differentiation of naive T-helper cells (Th0) towards the Th2 
subtype [42]. IL-4 has also shown to be a growth factor for mast cells [43] and is involved 
in mucus production [44]. IL-13 is known to be involved in an enhanced mucus production, 
airway hyperresponsiveness and eosinophilia [45] and IL-5 has been implicated in 
development of airway inflammation and hyperresponsiveness by the activation and 
attraction of eosinophils [46,47]. 
 General introduction 
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Airway remodeling 
Acute inflammatory diseases obviously need various repair processes to restore normal 
structure and function. In chronic asthma, these processes are disturbed and ineffective 
repair results in remodelling of several structures. Epithelial damage leads to a loss of its 
protective barrier, exposing the deeper airway structures to environmental insults. Both 
inflammatory and structural cells produce growth factors that lead to angiogenesis, 
proliferation of airway smooth muscle cells, thickening of basement membranes and 
fibrosis [48]. Increased smooth muscle mass in airways leads to an increase in bronchial 
responsiveness as a result of increasing force in response to bronchoconstrictor stimuli and 
reduction of the airway’s diameter [49]. Prolonged epithelial repair, overproduction of 
profibrotic growth factors, such as TGF-β, and proliferation and differentiation of 
fibroblasts into myofibroblasts is thought to play an important role in the remodelling 
process. In addition, activated myofibroblasts produce a wide range of growth factors, 
chemokines and cytokines. These mediators promote proliferation of airway smooth muscle 
cells and increases in microvascular permeability [2]. Furthermore, in patients who have 
died from asthma increased deposition of matrix molecules have been observed deeper in 
the airway wall.  
Under normal circumstances the extracellular matrix is a dynamic structure, which is 
characterised by an equilibrium between the synthesis and degradation of extracellular 
matrix components. Matrix metalloproteases are able to selectively degrade extracellular 
matrix components and play an important role the dynamic equilibrium mentioned above. 
However, they have also been implicated to play a crucial role in the trafficking of 
inflammatory and structural cells [2]. Synthesis of different proteins of the extracellular 
matrix is induced by cytokines and growth factors [50]. Overall, the airways in asthma 
display various structural alterations that can al contribute to an overall increase in airway 
wall thickness and airway hyperresponsiveness. 
 
Airway hyperresponsiveness 
Airway hyperresponsiveness is a characteristic feature of asthma and involves an increased 
sensitivity of the airways to inhaled constrictor agonists. In addition, an increased slope of 
the dose-response curve and a greater maximal response to the agonist is also observed 
[51]. The severity of airway hyperresponsiveness correlates with the severity of asthma and 
with the amount of treatment needed to control symptoms [52]. The observed enhanced 
contractility of airway smooth muscle in patients with asthma could result from alterations 
in the contractile apparatus [53], in smooth muscle tissue elasticity, or in the extracellular 
matrix, and seems to be associated with increased velocity of shortening [54]. Furthermore, 
the mechanisms responsible for exaggerated reactivity may also involve smooth muscle 
growth [55] and changes in the contractility or phenotype of airway smooth muscle cells, 
with cells varying between contractile, secretory, and proliferative phenotypes in 
interaction with airway inflammation [56,57]. Moreover, inflammatory changes in the 
airway wall could strongly enhance airway narrowing during smooth muscle contraction Chapter 1 
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[58]. Changes in the organization of contractile filaments or in the plasticity of smooth 
muscle cells can underlie the maintenance of chronic airway hyperresponsiveness [59,60]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  Several inflammatory cells are recruited and/or activated in the airways, releasing a variety of 
inflammatory mediators that have acute effects on the airway (such as bronchoconstriction, plasma leakage 
vasodilatation, mucus secretion, sensory nerve activation and cholinergic reflex-induced bronchoconstriction), 
together with structural changes (remodelling) that include subepithelial fibrosis, increased numbers of blood 
vessels and mucus-secreting cells, and increased thickness of airway smooth muscle as a result of hyperplasia and 
hypertrophy. Figure adapted from Barnes et al. [61]. 
 
Asthma therapy 
Overview of therapeutic drugs 
Most asthma guidelines prefer a stepwise approach to asthma treatment. For patients 
displaying mild asthma with occasional symptoms only, the use of an inhaled β-agonist as 
needed is preferred. With increasing asthma severity further drugs are added to the 
treatment (from inhaled corticosteroids and long acting β-agonists to oral corticosteroids 
eventually) [62].  
Corticosteroids are widely used to treat various inflammatory and immune diseases. As 
discussed above, patients with asthma have a specific pattern of inflammation in the 
 General introduction 
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airways that is characterized by degranulated mast cells, an infiltration of eosinophils, and 
an increased number of activated Th2 cells. It is believed that this specific pattern of 
inflammation underlies the clinical features of asthma, including intermittent wheezing, 
dyspnoea, cough, and chest tightness. Suppression of this inflammation by corticosteroids 
controls and prevents these symptoms in most patients [63]. Inhaled corticosteroids are 
especially helpful in patients with mild to moderate asthma and are recommended to 
patients who need more than one dose of β-agonist inhalation per day [62]. These drugs 
effectively improve lung function and reduce symptoms and exacerbations in asthmatic 
patients [64-66]. There is also evidence that early use of inhaled corticosteroids may 
prevent irreversible airway obstruction and that regular treatment markedly reduces asthma 
mortality [67]. Inhaled corticosteroids have therefore become very helpful in the treatment 
of asthma. No evidence has been found that the low doses required by most patients cause 
clinical important side effects [68]. In contrast, oral corticosteroids cause more morbidity 
and have many more adverse effects, and with patients on long-term oral steroids the 
question of prophylaxis against osteoporosis needs to be considered [62].  
Theophylline has been used to treat asthma for many years as an add-on therapy for 
corticosteroids, but its mechanism of action has been difficult to elucidate. Originally, 
theophylline was used as a bronchodilator, because it relaxes airway smooth muscle by 
inhibiting phosphodiesterases [69]. In addition, low doses of theophylline have been 
demonstrated to exert anti-inflammatory effects [70], probably not mediated by 
phosphodiesterase inhibition because the inhibition of these enzymes is trivial at low 
plasma concentrations that are clinically effective [71]. Therapeutic concentrations of 
theophylline markedly potentiate the anti-inflammatory effects of corticosteroids in vitro 
[72]. This effect may explain why adding a low dose of theophylline is more effective than 
increasing the dose of inhaled corticosteroids in patients whose asthma is not adequately 
controlled [73-75]. However, theophylline seems to be less effective than long acting β-
agonists as an add-on therapy for corticosteroids [76].  
Other possible therapeutic drugs are inhaled anticholinergic agents, such as ipratropium 
bromide. These agents are bronchodilators that block the effect of acetylcholine released 
from cholinergic nerves in the airways. In asthma, inhaled anticholinergics are less potent 
bronchodilators than inhaled β-agonists, and in general, have a slower onset of action. 
However, they may serve as an alternative bronchodilator for patients who experience 
adverse effects, such as tachycardia, arrhythmia and tremor, from rapid-acting β-agonists 
[77].  
A new class of asthma medication are cysteinyl leukotriene receptor antagonists. In 
addition to their potent bronchoconstrictor properties, cysteinyl leukotrienes induce 
pathophysiologic responses similar to those associated with asthma, including edema and 
migration of eosinophils [78]. Cysteinyl leukotrienes in asthma (LTC4, LTD4 and LTE4) are 
likely to be derived predominantly from mast cells and eosinophils, with the greatest 
production being from surface mast cells in the airways, and the production has been shown 
to be increased in asthma [79]. Cysteinyl leukotriene receptor antagonists, such as 
montelukast and zafirlukast, prevent the action of cysteinyl leukotrienes at the type 1 Chapter 1 
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leukotriene receptor. Although these antagonists have had some clinical success in asthma, 
they are considerably less effective than inhaled corticosteroids [79]. Despite a large 
number of available medications, the asthma epidemic is continuing to increase. Existing 
therapies, using β2-agonists and corticosteroids, provide reliefe for patients with mild-to-
moderate asthma, reversing the bronchoconstriction and decreasing the inflammation, but 
these therapies provide little relief for chronic asthmatics. In particular, new therapy is 
needed for severe asthma that is poorly controlled by high doses of corticosteroids, as well 
as agents to counter acute emergency asthma. There are numerous therapies in clinical 
development that combat the inflammation found in asthma, specifically targeting 
eosinophils, IgE, adhesion molecules, cytokines (interleukin-4, -5, -13) and chemokines, 
inflammatory mediators, and cell signalling (kinase inhibitors). However, much is still to be 
learned about the mechanisms involved in the development and treatment of chronic 
asthma [61,80,81]. 
 
β2-adrenoceptor agonists 
Inhaled β2-adrenoceptor agonists are by far the most effective bronchodilators used for the 
relief of symptoms in patients with asthma [82]. β2-Agonists are able to relax airway 
smooth muscle, enhance mucociliary clearance, decrease vascular permeability and may 
modulate mediator release from mast cells and basophils [83]. Short acting β2-agonists, 
such as salbutamol and terbutaline, are very effective in relieving acute attacks of asthma. 
However, they do not provide benefit when given regularly [84] and it has been described 
that patients can even deteriorate [85]. As a consequence, short acting β-agonists should 
only be used as required. Moreover, excessive use of these β2-agonists may result in 
increased asthma deaths [86].  
In contrast, regular use of long acting β2-agonists, such as salmeterol and formoterol, 
improves asthma control, reduces asthma exacerbations and provide long term protection 
against bronchoconstrictor stimuli [64,65,87]. Long acting β2-agonists are more and more 
introduced at an earlier point in asthma management and can be given in combination with 
an inhaled corticosteroid. Fixed combination inhalers of long-acting β2-agonists and 
corticosteroids are available and seem to be the most effective way to control asthma 
because these two classes of drugs have complementary and synergistic effects [88]. The 
expression of β2-adrenergic receptors in the lung is increased by corticosteroids and 
downregulation and uncoupling in response to β2-agonist stimulation is inhibited [89-91]. 
In addition it has been demonstrated that β2-agonists enhance the action of corticosteroids 
by increasing the translocation of glucocorticoid receptors [92] and enhancing the 
suppression of inflammatory genes [93,94]. General introduction 
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Pharmacology of bronchoconstriction 
Airway smooth muscle 
The traditional view of airway smooth muscle in asthma was of a passive partner in airway 
inflammation, contraction and relaxation, but nowadays airway smooth muscle has been 
found to have a number of properties and functions which contribute to asthma 
pathogenesis. It undergoes changes in contractile and relaxant properties in response to 
asthmatic mediators and cytokines and airway smooth muscle remodeling is induced by 
growth factors which are present in the asthmatic airways. Airway smooth muscle cells can 
also have synthetic properties and are a rich source of cytokines and chemokines. In 
addition, airway smooth muscle cells can produce inflammatory mediators which act to 
alter contractility and the proliferation response in an autocrine manner. The production of 
chemokines by airway smooth muscle cells may be involved in an exaggerated 
inflammatory response [95] and evidence suggests that changes in airway smooth muscle 
phenotype may play a fundamental role in the pathogenesis of lung diseases such as asthma 
[96]. However, despite all these properties of airway smooth muscle cells, it is most likely 
that changes in airway smooth muscle tone are by far the most important factor in 
determining airflow [97].   
 
Receptors 
Most bronchoconstrictors activate G protein-coupled receptors on the cell membrane of 
airway smooth muscle cells that are linked to the contractile-apparatus through different 
signal transduction pathways. In asthma, many bronchoconstrictor mediators are produced 
by inflammatory cells or released from airway nerves. Agonists, such as acetylcholine, 
histamine, cysteinyl leukotrienes and thromboxane, that activate receptors on airway 
smooth muscle cells are direct bronchoconstrictors. However, bronchoconstriction can also 
be induced indirectly by agonists that release constrictor agents from other cells. For 
example, adenosine and allergens can cause bronchoconstriction by releasing mediators, 
such as histamine and cysteinyl leukotrienes, from mast cells, and bradykinin may 
indirectly constrict airway smooth muscle by releasing bronchoconstrictors, such as 
acetylcholine and tachykinins, from airway nerves [97]. Histamine-induced 
bronchoconstriction is mediated via H1 receptors [98], whereas thromboxane and other 
bronchoconstrictor prostaglandins, such as PGD2 and PGF2α, are acting via a TP receptor in 
human airways [99,100]. Another important group of constrictors in human airways are 
cysteinyl leukotrienes. Leukotriene C4, D4 and E4 all act through a common cysteinyl 
leukotriene 1 receptor [101].  Many neuropeptides, which are found in the nerves of human 
airways, are able to constrict airway smooth muscle. For example, tachykinins cause 
bronchoconstriction through the activation of NK2-receptors [102]. Bradykinin-induced Chapter 1 
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bronchoconstriction is mediated through bradykinin B2-receptors on airway smooth muscle 
cells [103]. 
The parasympathetic nervous system is the major bronchoconstrictor neural pathway in the 
airways. Acetylcholine, the principal neurotransmitter of the parasympathetic nervous 
system, leads to airway smooth muscle contraction upon muscarinic receptor stimulation, 
and is one of the most efficious contractile agents of airway smooth muscle. Four different 
subtypes of muscarinic receptors (M1-M4) have been identified in airway tissues [104]. 
However, no evidence is found for the M4-receptor subtype in human lung [105]. M1 
receptors are mainly located at parasympathetic ganglia, where they facilitate 
neurotransmission. M2 receptors are present in both postganglionic nerves, to control 
neurotransmitter release, and smooth muscle cells, and M3 receptors are primarily located at 
the airway smooth muscle, glands and epithelial cells [106,107]. The receptor subtype 
mediating bronchoconstriction is the M3-receptor [108], which is coupled to a stimulatory 
G-protein (Gq). M2-receptors are coupled via an inhibitory G-protein (Gi) to inhibit adenylyl 
cyclase, which would predict to have a bronchoconstrictor effect. However, although the 
M2-receptor predominates over the M3-receptor (in an approximate 80% to 20% ratio) in 
airway smooth muscle, it has been difficult to demonstrate any functional role of M2 
receptors [109-111]. 
  
Signal transduction 
Phosphoinositide metabolism 
Most of the bronchoconstrictor receptors discussed above, including H1 and M3-receptors, 
are coupled via the heterotrimeric G-protein Gq. Upon agonist binding, the receptor 
undergoes a conformational change that promotes its association with Gq in its GDP-bound 
inactive state. The receptor especially interacts with the α subunit of the G-protein 
heterotrimer, resulting in the release of  GDP and subsequent binding of GTP. This 
exchange of GDP for GTP induces a conformational change of Gα and causes the 
dissociation of the active GTP-bound Gα from the Gβγ dimer and in turn activates an 
effector molecule [112]. The membrane-associated enzyme phospholipase C (PLC) is the 
principle effector of Gq-mediated signalling. Eleven different isoforms of PLC have been 
identified, but members of the PLCβ subfamily tend to mediate the actions of activated Gq 
[113]. PLCβ promotes the hydrolysis of  phosphoinositide (4,5)biphosphate (PIP2) into 
inositol (1,4,5)trisphosphate (IP3) and 1,2 sn-diacylglycerol (DAG) [114-117]. 
Subsequently, IP3 diffuses into the cytosol and binds to a specific IP3-receptor (IP3R) on the 
endoplasmic/sarcoplasmic reticulum, which leads to the release of Ca
2+ from intracellular 
stores. The rapid and transient increase in intracellular Ca
2+ is followed by a sustained 
influx of extracellular calcium [118]. The increase in intracellular calcium is thought to 
activate the contractile apparatus and to induce airway smooth muscle contraction.  
Indeed, in animal [103,119-121] and human [122] airway smooth muscle it has been 
demonstrated that the phosphoinositide metabolism induced by various General introduction 
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bronchoconstrictors, including muscarinic agonists, is involved in the pharmacomechanical 
coupling of contraction. In bovine tracheal smooth muscle a direct relationship was found 
between the efficacy of different muscarinic agonists to induce inositol phosphates 
accumulation and their potency to induce contraction. A remarkable reserve of inositol 
phosphates production was found for full agonists (methacholine, oxotremorine), and no 
reserve for the partial agonist McN-A-343 [120]. As mentioned above, the formation of IP3 
parallels the production of DAG [123], which remains close to the plasmamembrane and 
has been shown to activate protein kinase C (PKC) by causing it to translocate to the cell 
membrane and by increasing its sensitivity to Ca
2+ [124]. Activated PKC is then capable of 
phosphorylating various cell membrane-associated proteins, including some receptors, G-
proteins and regulatory proteins and has been implicated in the tonic phase of contraction 
[125]. In addition, it has been demonstrated that activation of PKC exerts a feedforward 
control of both the methacholine- and histamine-induced Ca
2+-mobilization and influx, 
which suggests that PKC may be involved in the phasic contraction as well [126]. 
  
Pharmacomechanical excitation-contraction coupling 
The protein components of the contractile apparatus of airway smooth muscle are similar to 
those found in other smooth muscles and include actin, myosin, calmodulin, tropomyosin, 
caldesmon and calponin. In response to constrictor stimuli in smooth muscle, the 
intracellular Ca
2+ concentration increases and the activator Ca
2+ binds to the acidic protein 
calmodulin. Subsequently this complex activates myosin light chain kinase (MLCK), which 
rapidly phosphorylates the 20-kDa light chains of myosin (MLC 20), enabling the 
molecular interaction of myosin with actin. If the intracellular Ca
2+-concentration remains 
above basal level, myosin phosphorylation remains elevated as well. Energy released from 
ATP by myosin ATPase activity results in the cycling of the myosin cross-bridges with 
actin for contraction [127-130]. Ca
2+ probably also activates multifunctional 
Ca
2+/calmodulin-dependent kinase, which might phosphorylate other putative regulatory 
proteins such as caldesmon or calponin. Rapid phosphorylation of these proteins might 
relieve inhibition of myosin ATPase. Tropomyosin is an actin filament regulatory protein, 
which appears to modulate phosphorylation of myosin ATPase along with myosin light 
chain phosphorylation, possibly in concert with caldesmon and calponin [131]. In addition 
to the Ca
2+-dependent activation of MLCK, the state of myosin light chain phosphorylation 
is further regulated by myosin light chain phosphatase (MLCP), which removes the high-
energy phosphate from the light chain of myosin to promote smooth muscle relaxation 
[132]. 
  
PKC 
PKC is a multifunctional protein kinase that phosphorylates serine and threonine residues in 
many target proteins. Rather than being a single protein, PKC is known to comprise a large 
family of enzymes that differ in structure, cofactor requirements and function. PKC is a 
superfamily including three types of isoforms. The conventional isoforms (α, β1, β2, γ) Chapter 1 
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require Ca
2+ and DAG to become activated, whereas the novel isoforms (δ, ι, ε, θ, μ) are 
Ca
2+-insensitive and only require DAG. The atypical isoforms (ζ, τ, λ) are calcium- and 
DAG- insensitive and are activated by phosphatidylserine [133,134]. As all isoforms of 
PKC posses a binding site for phosphatidylserine, conventional and novel PKC isoforms 
can also be activated by phosphatidylserine. The general structure of a PKC molecule 
consists of a catalytic and a regulatory domain found at the C- and N-terminus respectively. 
Activation of PKC involves translocation from the cytosol to the cell membrane [124]. This 
membrane association is Ca
2+-dependent and specific anchoring proteins, including 
“receptors for activated C-kinase” (RACKS) localize the kinases at their sites of action 
[134]. With respect to conventional and novel PKC’s, the availability of DAG is essential 
for their activation, as it facilitates the penetration of these PKC’s into the cell membrane 
[135]. Activation of conventional PKC’s is critically dependent on the intracellular calcium 
concentration and needs a transient increase in calcium to promote translocation of the 
inactive PKC to the cell membrane. Resting Ca
2+-levels are insufficient to activate PKC 
[136].  
The expression and distribution of PKC isoforms varies markedly between cells and tissues 
[137]. PKC α, β1, β2, δ, ε and ζ, but not γ or ι are expressed in bovine tracheal smooth 
muscle [138], whereas PKC α, β1, β2, δ, ε, θ, ι, ζ, τ and μ have each been identified in 
human tracheal smooth muscle [138,139]. Conventional and novel PKC’s can be activated 
directly by phorbol esters, such as phorbol myristate acetate (PMA), which have therefore 
been useful in examining the role of PKC. Unfortunately, theoretically phorbol esters have 
the ability to activate all conventional and novel PKC isoforms present in airway smooth 
muscle, whereas receptor agonists, almost certainly, will selectively activate specific 
isoforms, including atypical PKC’s. Another possibility to study the role of PKC is the use 
of PKC-inhibitors. Frequently used inhibitors are staurosporin and Ro31-8220, which are 
not very selective for PKC. GF 109203X, however, is a very selective inhibitor of novel 
and conventional PKC isoforms and Gö6976 specifically inhibits conventional PKC 
isoforms  [140,141]. Unfortunately, the differential function of PKC isoforms is not clearly 
understood, because isoform-selective inhibitors are not yet available.   
PKC has been proposed to be a potential mediator of tonic contraction of airway smooth 
muscle. Thus, in airway smooth muscle from the cow [125,142,143], guinea-pig [144], 
rabbit [145], rat [146] and human [147,148], low concentrations of phorbol esters elicited a 
slow, tonic contraction, and exposure of airway smooth muscle strips to 4β-PDBu and 
carbachol resulted in the phosphorylation of five contractile proteins (caldesmon, filamin, 
synemin and α- and β-desmin), which completely paralleled the development of force 
[125,142]. In addition, using bisindolylmaleimide derivatives as inhibitors of PKC, 
including staurosporine, Ro-318220, Ro-31-7549 and GF 109203X, it has been 
demonstrated that the contraction induced by phorbol esters and some Ca
2+-mobilizing 
agents was antagonized [146,149,150]. Additional data from the studies mentioned above 
indicated that phorbol ester-induced contraction of airway smooth muscle by PKC-
dependent processes involves an increase in the open state probability of L-type voltage 
dependent calcium channels, Ca
2+-influx, MLC 20 phosphorylation and activation of the General introduction 
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contractile machinery. Moreover, it has been demonstrated that phorbol esters can contract 
smooth muscle by inhibiting the activity of MLCP, leading to MLC 20 phosphorylation and 
force development at a constant Ca
2+-concentration [151-153]. This phenomenon is known 
as Ca
2+-sensitization [154]. Studies carried out in rabbit tracheal smooth muscle have 
demonstrated that phorbol esters not only induced contraction, but at high concentrations 
also produced smooth muscle relaxation [145]. It was proposed that low levels of PKC 
activation contribute to enhanced Ca
2+-influx and maintenance of tone, whereas high 
degrees of activation stimulate the electrogenic Na
+-K
+ pump leading to relaxation.  
Besides its important role in airway smooth muscle contraction, PKC has also been 
implicated in the cross-talk between the phosphoinositide metabolism and the β-adrenergic 
receptor (see paragraph ‘regulation of the β2-adrenoceptor’). 
 
Intracellular calcium homeostasis 
Regulation of intracellular calcium 
Regulation of the intracellular calcium concentration in smooth muscle cells is a highly 
complex phenomenon. Under resting conditions only few Ca
2+-ions enter the cell and the 
intracellular calcium concentration is maintained relatively constant due to different 
homeostatic mechanisms. These includes a plasma membrane Na
+-Ca
2+ exchanger driven 
by the Na
+ gradient (maintained by the Na
+-K
+-ATPase), a Mg
2+-dependent plasma 
membrane Ca
+-H
+-ATPase and a sarcoplasmic reticulum Ca
2+-ATPase [154]. As discussed 
before, contractile agonists such as acetylcholine and histamine require an elevation of 
intracellular calcium to induce airway smooth muscle contraction. This elevation of 
intracellular calcium involves various second messengers inside the cell and results from 
several mechanisms, including influx from the extracellular space and release from 
intracellular stores, principally the sarcoplasmic reticulum (SR) [155]. Upon contractile 
agonist stimulation a characteristic biphasic profile of intracellular calcium levels is 
observed in airway smooth muscle [118,156-160]. First, there is an initial rapid rise in 
intracellular calcium level, which reaches its maximum within 10-15 s and then rapidly 
declines. This transient rise in intracellular calcium is dependent upon the release of 
calcium from intracellular stores, and is mediated by agonist-induced IP3 production and 
subsequent stimulation of IP3 receptors in the sarcoplasmic reticulum membrane 
[114,161,162]. The precise mechanism through which the calcium concentrations 
subsequently decline is less clear, although reuptake into stores is the most likely 
explanation. Plasma membrane calcium pumps can extrude calcium from the cell but time 
course of the observed response seems too rapid for this mechanism to be important [163]. 
Second, in the continued presence of the agonist, calcium levels do not completely return to 
baseline levels, but a sustained plateau response is usually observed [118]. This sustained 
calcium response is important for maintaining the contractile response to the agonist, and it 
is clear that the source of this calcium is extracellular Ca
2+-influx [118,164]. Thus, it has 
been demonstrated in airway smooth muscle that in the absence of extracellular calcium the Chapter 1 
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plateau phase is lost [118,159,160]. The amplitude of the calcium transient and the level of 
the subsequent plateau have been shown to depend on contractile agonist concentration 
[158,159,165]. 
Several models for extracellular Ca
2+-influx in smooth muscle cells have been proposed. In 
airway smooth muscle, Ca
2+-influx may occur through voltage-gated (VOCC) [166,167], 
receptor gated (ROCC) [118] and store-operated calcium channels (SOCC) [168,169]. 
However, despite their established presence, it has been demonstrated that contractile 
agonist-induced calcium entry is relatively insensitive to inhibitors of voltage-operated Ca
2+ 
channels [166,170,171] in airway smooth muscle. In most instances, the signal for Ca
2+-
entry is somehow derived from the IP3-mediated depletion of calcium from intracellular 
stores, a process called “capacitative calcium entry” or “store-operated calcium entry 
[172,173], thus allowing for replenishment of intracellular Ca
2+-stores. Two major 
categories of mechanisms to activate capacitative calcium entry have been hypothesized. 
Perhaps the simplest mechanism for linking intracellular stores to the plasma membrane is 
through the release of a diffusible messenger called calcium-influx-factor [174,175]. 
However, the more favoured model for capacitative calcium entry is conformational 
coupling, which is a more direct communication with the endoplasmic membrane channels 
with closely underlying IP3 receptors [176,177]. There is now considerable evidence for 
SOCC in smooth muscle [178-180], including airway smooth muscle [169], and it has also 
been suggested that Ca
2+-influx mediated via SOCC is involved in actual smooth muscle 
contraction [181]. Furthermore, inhibitors of sarcoplasmic reticulum ATPase have been 
shown to increase intracellular Ca
2+ in human bronchioles and bovine airway smooth 
muscle, suggesting the involvement of SOCC [182].  
A family of proteins that have been considered as candidates for capacitative calcium entry 
are transient-receptor-potential channels (TRPC) [181,183,184]. Expression of the TRPC 
genes have been demonstrated crucial for store-operated Ca
2+-influx in mammalian cells, 
suggesting that TRPC-encoded proteins are the putative SOCC responsible for the observed 
Ca
2+-influx [182,185,186]. It has been demonstrated in rat airway smooth muscle cells that 
SOCC potentially involve TRPC1-type Ca
2+-channels [182]. Recently, in Drosophila S2 
cells,  a new key player has been discovered in the process of capacitative calcium entry, 
namely the protein stromal interaction molecule (STIM). STIM1 is located both on the 
plasma membrane and intracellular membranes, and this protein may be responsible for 
bridging the two [187]. 
  
Intracellular Ca
2+-oscillations 
With the advent of real-time confocal microscopic imaging techniques, it has been shown 
for many contractile agonists in airway smooth muscle that the first transient rise in 
intracellular calcium, is followed either by a steady state rise in intracellular calcium or by 
successive transient calcium peaks, the so called calcium oscillations [188-191]. The 
occurrence of an oscillatory or non oscillatory calcium response in airway smooth muscle 
cells depends on various factors, including species variation. It has been suggested that in a General introduction 
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single species, different cell phenotypes, one characterized by oscillatory responses and the 
other by non oscillatory responses, may coexist. For example, in rat tracheal smooth 
muscle, about 50% of the cells exhibit muscarinic agonist-induced intracellular Ca
2+-
oscillations [190]. The frequency of Ca
2+-oscillations has been shown to depend on the 
contractile agonist concentration. Thus, in airway smooth muscle higher concentrations of 
contractile agonists induced a higher frequency of Ca
2+-oscillations [188,190-195]. In 
addition, the frequency of Ca
2+-oscillations has been correlated to the amplitude of the 
mechanical response towards contractile agonists [188,195,196]. Over the years, the origin 
of and the mechanisms involved in these Ca
2+-oscillations have been studied extensively in 
airway smooth muscle cells, and it has become acknowledged that ryanodine receptors 
(RyR), located on the sarcoplasmic reticulum, play a major role  [168,191,197-200]. The 
initiation of Ca
2+-oscillations appears to be critically dependent on the generation of IP3 and 
calcium release through IP3 receptor channels. However, once initiated the intracellular 
calcium oscillations are sustained even in the presence of an IP3 receptor antagonist and 
abolished in the presence of RyR antagonists [189,198], indicating that the sustained 
intracellular calcium oscillations are primarily caused by activation of RyR.  Furthermore, 
as demonstrated in porcine tracheal smooth muscle, these oscillations originate in a certain 
localized region of the cell and propagate, indicating that calcium release most likely occurs 
by stimulating calcium release from adjacent regions [194].  
This calcium induced calcium release (CICR) has been shown to involve the activation of 
RyR channels [196]. The RyR channel is activated by very low calcium concentrations, low 
pH, millimolar ATP and millimolar concentrations of caffeine. Although an endogenous 
ligand for RyR channels has remained elusive, it has recently been postulated that cyclic 
ADP-ribose (cADPR), which is a cyclized derivative of β-nicotinamide adenine 
dinucleotide (NAD) metabolism, is one of the candidate molecules involved in the 
activation of RyRs and modulation of CICR [201]. Recent studies have provided evidence 
that calcium release through RyR channels is sensitized not only to calcium but also to 
cADPR [202-205]. Furthermore, it has been demonstrated in airway smooth muscle that the 
frequency of intracellular calcium oscillations can be modulated by cADPR and abolished 
by the cADPR antagonists 8-Amino-cADP and 8-bromo-cADP. Moreover, these 
antagonists inhibited the global intracellular calcium responses elicited by acetylcholine, 
bradykinin, entothelin-1 and thrombin [206-208]. In addition, the cADPR-induced calcium 
release is also inhibited by the RyR antagonists ryanodine and ruthenium red [203]. 
Together, these data indicate the involvement of cADPR in the calcium release through 
RyR channels during agonist activation of airway smooth muscle and suggest that cADPR 
acts as a second messenger in agonist-induced intracellular calcium elevation. CD38, which 
is a bifunctional protein possessing both ADP-ribosyl cyclase and cADPR hydrolase 
activities, appears to be the primary source for cADPR in airway smooth muscle  [209], by 
converting β-NAD to cADPR using its ADP-ribosyl cyclase activity.  Thus, in isolated 
airway smooth muscle cells from CD38-deficient mice, intracellular calcium responses to 
agonists were attenuated compared with cells isolated form wild type mice [210] and 
downregulation of CD38 expression by antisense CD38 in human airway smooth muscle Chapter 1 
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cells resulted in attenuated calcium responses to various agonists [209]. Interestingly, there 
appears to be a receptor and/or receptor-subtype specificity in the use of cADPR-mediated 
calcium release [202,211]. This was illustrated by the observation that a cADPR antagonist 
inhibited acetylcholine-induced and endothelin-1-induced, but not histamine-induced, 
calcium responses in porcine airway smooth muscle [211]. Furthermore, the CD38/cADPR 
pathway is associated with activation of M2, but not M3, muscarinic receptors [211]. One 
possibility for this receptor or receptor-subtype specificity is the involvement of specific G-
proteins in the activation of CD38/cADPR signaling. However, the mechanism of G-protein 
association with the CD38/cADPR signaling needs further investigation.  
  
Calcium sensitization 
As discussed above, activation of smooth muscle involves the generation of a Ca
2+-signal 
with unique temporal and spatial properties finally leading to the phosphorylation of MLC 
20 and subsequent contraction. However, it has been shown that intracellular Ca
2+-levels 
not always correlate with the level of MLC 20 phosphorylation and contraction. Moreover, 
besides increasing intracellular calcium concentrations, contractile agonists may also 
increase the Ca
2+-sensitivity of the contractile machinery [212]. It is widely accepted that 
the degree of MLC 20 phosphorylation is the essential factor that determines the extent to 
which smooth muscle contracts. MLC 20 phosphorylation promotes smooth muscle 
contraction whereas MLC 20 dephosphorylation, following a reduction in the intracellular 
calcium concentration, results in muscle relaxation. The state of MLC 20 phosphorylation, 
however, is, in addition to the Ca
2+-dependent activation of MLCK, also regulated by 
MLCP which removes the high-energy phosphategroup from the light chain of myosin to 
promote smooth muscle relaxation. Consequently, the MLCK-to-MLCP-activity ratio is the 
major determinant of the extent of MLC 20 phosphorylation and subsequent contraction 
[212]. MLCP consists of three subunits, including a myosin-binding subunit. This myosin-
binding subunit, when phosphorylated, inhibits the enzymatic activity of MLCP, allowing 
the light chain of myosin to remain phosphorylated, and thereby promoting contraction 
[127].  
The small G-protein RhoA and its downstream target Rho kinase have been shown to play 
an important role in the regulation of MLCP activity [210,212,213]. Thus, in smooth 
muscle cells it has been demonstrated that agonist-induced activation of the RhoA/Rho 
kinase pathway enhanced MLC 20 phosphorylation at a fixed level of intracellular calcium. 
Consequently, despite the fact that the intracellular calcium concentration remained 
unchanged, these agonists augmented the level of contraction [214]. This increased calcium 
sensitivity of the contractile machinery towards contractile agonists is referred to as Ca
2+-
sensitization. Rho-kinase is able to promote the phosphorylated state of MLC 20 by a direct 
phosphorylation of MLC 20 [213], or by phosphorylating the myosin-binding subunit of 
MLCP, thereby inhibiting its activity [153,215]. However, recent studies have shown that it 
is the Rho-kinase-mediated inactivation of myosin phosphatase, rather than the direct General introduction 
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phosphorylation of MLC by Rho-kinase, that would be responsible for Ca
2+-sensitization of 
smooth muscle [153].  
A number of studies have shown that Rho-kinase is involved in airway smooth muscle 
contraction induced by either contractile agonists [153,216-220]or KCl [220,221], and it 
has even been suggested that Rho-kinase may have a pathophysiology-primed role in 
asthma. Thus, in repeated allergen-challenged rats an augmented role of Rho-kinase in 
acetylcholine-induced bronchial smooth muscle contraction has been shown [218]. In 
addition, it has been demonstrated in guinea pigs that active allergic sensitization by itself, 
i.e. without subsequent allergen exposure, was sufficient to enhance Rho-kinase-mediated 
airway smooth muscle contraction both in vivo and ex vivo [222]. Several compounds such 
as Y27632 and fasudil have been developed and found to inhibit the activity of Rho-kinase 
specifically which proved very useful for evaluating Rho-kinase functions in smooth 
muscle. Currently, it is well established that RhoA, and in turn Rho-kinase, can be activated 
by a variety of G-protein coupled receptors, particularly by those coupled to G12/13, through 
an interaction with guanine nucleotide exchange factors (RhoGEF’s) [223]. In addition, it 
was found recently that agonist-stimulated Gq/11-coupled receptors can also activate RhoA, 
involving the Gq/11-selective GEF, p63RhoGEF [224]. Another possible mechanism for 
Rho-kinase activation by contractile agonists coupled to Gq-proteins has been demonstrated 
by the observation that receptors of the vasoconstrictive agonists angiotensin II, endothelin 
and vasopressin are coupled to G12/13 as well as to Gq [225].  
In addition, PKC, which is activated by Gq coupled receptors, has been shown to cause 
enhanced contraction of vascular smooth muscle even when a rise in intracellular calcium is 
absent [226,227]. One mechanism for this Ca
2+-sensitization is related to an increase in the 
level of MLC 20 phosphorylation, which can occur directly by PKC-mediated 
phosphorylation or indirectly by PKC-mediated inhibition of MLCP. It has been 
demonstrated that PKC-induced inhibition of MLCP is mediated by CPI-17. CPI-17 is 
another potential mediator of Ca
2+-sensitization and its phosphorylation by PKC enhances 
its potency for inhibiting MLCP [228,229]. PKC-dependent and Rho kinase-dependent 
Ca
2+-sensitization may not be independent pathways. For example, CPI-17 can be 
phosphorylated by Rho-kinase [229] and conversely, arachidonic acid, which is generated 
by phospholipase A2, can, either directly or indirectly as a consequence of PKC activation, 
activate Rho kinase [230-233]. Therefore, it is possible that the mechanisms downstream of 
PKC and Rho kinase converge at the vicinity of MLCP. In rabbit aorta smooth muscle it 
has been recently reported, using the Rho-kinase inhibitor fasodil, that Rho kinase was 
indeed involved in PKC-dependent Ca
2+-sensitization [234]. Chapter 1 
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Pharmacology of bronchodilatation 
Airway smooth muscle relaxation 
Several endogenous agents act as bronchodilators, either by activating bronchodilator 
receptors on airway smooth muscle, or via the release of endogenous bronchodilators such 
as NO or PGE2 [97]. The best-studied bronchodilators are β2-agonists, which can activate 
β2-adrenergic receptors on airway smooth muscle (see paragraph ‘β2-adrenoceptor 
mediated relaxation) [235]. Another bronchodilator, PGE2, which may act as an important 
regulator of airway smooth muscle tone, especially in asthma, relaxes airway smooth 
muscle via some EP receptors of which several subtypes have been characterized. PGE2 
may be released from epithelial cells and airway smooth muscle cells and is able, in higher 
concentrations, to reduce the bronchoconstriction response seen in asthma [97]. Vasoactive 
intestinal peptide (VIP) has been demonstrated to be a potent relaxant of human bronchi in 
vitro, but is an ineffective bronchodilator in vivo as it is rapidly metabolized in the airways 
[236,237]. NO is a direct relaxant of the airways and is a neurotransmitter of bronchodilator 
nerves [238]. Under basal conditions constitutive NO synthase (cNOS) isozymes present in 
the airway epithelium and in nonadrenergic noncholinergic (iNANC) nerves synthesize 
small amounts of NO. cNOS isozymes present in the epithelium are activated by various 
contractile agonists, whereas the cNOS isozyme in iNANC nerves is activated by 
depolarization. Epithelium- and nerve-derived NO induce relaxation of the airway smooth 
muscle by increasing the production of cGMP and/or opening of Ca
2+-acitvated K
+ 
channels [239].  
  
The β2-adrenoceptor 
At least three β-adrenoceptors are now recognized and cloned [240-243], namely β1, β2 and 
β3. These subtypes were originally identified in cardiac, vascular and adipose tissue, 
respectively. Successful cloning of these receptors made it possible to elucidate the 
structure of the receptor protein, the way in which the receptor interacts with β-agonists and 
the signal transduction involved. The β2-adrenoceptor is a member of the 7-transmembrane 
family of G protein-coupled receptors and is composed of 413 amino acid residues [235]. 
The seven clusters of membrane-spanning helices are connected by alternating intra- and 
extracellular loops, with the amino (N)-terminal exposed to the outside and the carboxy 
(C)-terminal to the inside of the cell [235]. β2-Adrenoceptors are widely distributed, 
occurring not only in airway, vascular and intestinal smooth muscle cells, but also in 
epithelial and endothelial cells and in inflammatory cells, such as T cells, mast cells, 
macrophages, eosinophils and neutrophils [235]. A major effect of β2-adrenoceptor 
stimulation in the airways is smooth muscle relaxation. However, β2-adrenoceptor 
stimulation can also result in an increase in mucociliary clearance, vasodilatation and 
inhibition of vascular leakage. In vitro experiments have shown that β2-adrenoceptor General introduction 
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stimulation also has inhibitory effects on human inflammatory cells, influencing cell 
activation and mediator release, cell adhesion and chemotaxis, and cell survival 
[235,244,245]. In animal and human airway smooth muscle, autoradiographic studies have 
confirmed the presence of β-adrenoceptors from the trachea down to terminal bronchioles. 
In some species both β1- and β2-receptor subtypes have been demonstrated functionally in 
airway smooth muscle, the presence of β1-adrenoceptors being related to the presence of 
sympathetic innervation of airway smooth muscle [246-250]. The fact that human airway 
smooth muscle has no functional sympathetic innervation is consistent with both findings 
that only β2-adrenoceptors are expressed in all levels of human airway smooth muscle 
[250,251] and that mRNA expression is absent for β1-adrenoceptors in human airway 
smooth muscle [252]. Moreover, relaxation of human central and peripheral airway smooth 
muscle has shown to be mediated by a homogenous population of β2-adrenoceptors 
[253,254]. Autoradiographic and radioligand binding studies have shown that β2-
adrenoceptor density increases with increasing airway generation, thus being greater for 
small than for large airways, with high levels in the alveolar region [246,251]. 
 
β2-adrenoceptor mediated relaxation 
Signal transduction 
The β2-adrenoceptor belongs to the group of G protein-coupled receptors which are coupled 
with the heterotrimeric G-protein Gs, and its signalling and regulation have been 
extensively studied in numerous cells, including airway smooth muscle [112,235,255-257]. 
Stimulation of the β2-adrenoceptor results in Gs dependent activation of the enzyme 
adenylyl cyclase (AC) in a manner which is similar to the activation of PLC via Gq-coupled 
receptors. Thus, upon binding of the agonist to the β2-adrenoceptor, GTP binds to the α 
subunit of the heterotrimeric Gs-protein complex, resulting in the dissociation of the (GTP-
occupied)  αs-subunit from the βγ subunit. Subsequently, the αs subunit binds to and 
activates AC, which catalyses the conversion of adenosine trisphosphate (ATP) into cyclic 
adenosine monophosphate (cAMP), subsequently leading to the activation of the cAMP 
dependent protein kinase A (PKA)  [258,259]. cAMP binds to the regulatory subunit of 
PKA as a consequence of which these subunits dissociate from and thereby activate the 
catalytic subunit of PKA. Activated PKA is able to phosphorylate key intracellular proteins 
and is responsible for the majority of the physiological responses to stimulation of β2-
adrenoceptors [260]. MLCK is one of the proteins that can be phosphorylated by PKA 
[261], which leads to a decreased affinity of MLCK for Ca
2+/calmodulin, resulting in a 
decrease in smooth muscle contraction. PKA also phosphorylates large conductance Ca
2+-
dependent K
+ channels (Maxi-K channels), increasing their open-state probability (and 
therefore K
+-efflux), which results in hyperpolarization and relaxation of airway smooth 
muscle.  β2-Adrenoceptor stimulation of Maxi-K channel activity may also occur 
independently of PKA, presumably by a direct interaction of Gs and the Maxi-K channel 
[257,262-264]. Other mechanisms underlying β2-adrenoceptor-mediated airway smooth Chapter 1 
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muscle relaxation include activation of sacrolemmal Ca
2+ATPase [265], augmentation of 
Na
+-Ca
2+ exchange [266,267] and stimulation of sarcoplasmic reticulum Ca
2+ATPase [268], 
all resulting in an enhanced extrusion of Ca
2+ across the plasma membrane or enhanced 
uptake of calcium into intracellular stores.  
In addition to cell relaxation, β2-adrenoceptor-mediated activation of PKA also leads to 
phosphorylation of the transcription factor cAMP response element (CRE) binding protein 
(CREB), which has been found to induce changes in the transcription (increase as well as 
decrease) of many genes, including transcriptional autoregulation of the β2-adrenoceptor 
gene [269,270]. Expression of the β2-adrenoceptor gene is under control of CRE in the 
promoter region of the gene and is recognized by CREB. PKA phosphorylation of CREB 
permits CREB to bind to CRE, followed by its binding to CREB binding protein (CBP). 
CBP binding leads to the recruitment of the basal transcriptional apparatus to initiate gene 
transcription, thereby increasing the transcription of the gene [269,271]. Moreover,   
activation of CREB may modulate changes in the responses to activation of other 
transcriptional factors that also interact with CBP, possibly as a result of competition over 
transcription factors.  
In addition to the activation of PKA, evidence from several laboratories indicated that 
cGMP-dependent protein kinase (PKG) may be activated by physiological increases in 
cAMP [259,272], leading to relaxation of smooth muscle by decreasing the Ca
2+-sensitivity 
of the contractile machinery [273] and activation of Maxi-K channels  [274,275]. In 
HEK293 cells PKA-mediated phosphorylation of the β2-adrenoceptor itself has been shown 
to decrease the coupling efficiency to Gs, thereby reducing cAMP production in response to 
further stimulation. In addition, PKA-induced phosphorylation also resulted in a switch of 
the β2-adrenoceptor coupling from Gs to Gi, thereby providing a direct feedback inhibition 
of the AC signalling (that initiated the process) and initiating a second signalling pathway 
resulting in the activation of MAP kinases [276]. Activation of MAP kinases, specifically 
of the extracellular signal-regulated kinases 1 and 2 (ERK 1/2) is now recognized to be a 
major signal transduction pathway of many G protein-coupled receptors. In contrast to the 
observations of G-protein switching, others have shown in HEK293 cells that the activation 
of the MAP kinase pathway by β2-adrenoceptors, although PKA-dependent, was pertussis 
toxin insensitive, indicating that β2-adrenoceptors do not need to switch to Gi [277]. 
Moreover, additional studies with a PKA-insensitive mutant of the β2-adrenoceptor 
revealed that β2-adrenoceptor activation of ERK1/2 does not require PKA phosphorylation 
of the β2-adrenoceptor receptor and subsequent switching from activation of Gs to Gi [278]. 
Evidence has emerged that ERK1/2 activation of β2-adrenoceptors may be mediated by a 
family of cAMP-binding proteins termed cAMP-GEFs [279]or Epacs [280]. These proteins 
show increased GEF activity towards Rap 1, which may activate ERK1/2 through B-raf, 
upon cAMP binding [281,282]. Additionally, it has been reported in HEK-293 cells that 
ERK activation by the β2-adrenoceptor, mediated by these Epac proteins, may lead via 
Rap2B and PLCε stimulation to an increase in intracellular calcium, finally activating H-
Ras as a trigger of the MAP kinase cascade [283].  
  General introduction 
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Functional antagonism between β2-adrenoceptor and contractile stimuli 
One of the mechanisms that may contribute to the functional antagonism between 
contractile and relaxing stimuli could be a cAMP-dependent inhibition of the inositol 
phosphate (IP) response. Both in canine [266] and bovine [284-286] tracheal smooth 
muscle, it has been demonstrated that β2-adrenoceptor agonists and other cAMP elevating 
agents such as forskolin and dibutyryl cyclic AMP attenuate of histamine-induced IP 
formation. In contrast, no such effect is observed with respect to the phosphoinositol 
hydrolysis induced by the full muscarinic agonists carbachol or methacholine, whereas the 
partial muscarinic agonists pilocarpine and McN-A-343, but not oxotremorine, were 
susceptible to such an inhibition [266,286]. It could be imagined that McN-A-343 and 
pilocarpine exert their effects through a different stimulation pattern of muscarinic receptor 
subtypes, compared to oxotremorine and the full agonists methacholine and carbachol, as 
both M2 and M3 receptors are present in bovine tracheal smooth muscle [243]. Although 
methacholine-induced phosphoinositide hydrolysis and contraction are mediated by the M3-
receptor [121] M2-receptors, which are negatively coupled to AC, represent the major (70-
80%) proportion of the population. The resistance of oxotremorine-, methacholine- and 
carbachol-induced phosphoinositide metabolism to agonists that stimulate cAMP synthesis 
could therefore relate to their ability to inhibit AC via stimulation of muscarinic M2-
receptors. However, this explanation is rather unlikely as methacholine-induced IP 
formation was also resistant to cAMP elevations induced by forskolin and stable analogues 
of cAMP [266]. In addition, in guinea pig [287],  bovine [288] and human [289] airway 
smooth muscle no role for M2-receptors in the functional antagonism between contractile 
and relaxant stimuli was observed.  Interestingly, muscarinic agonist-induced contraction in 
airway smooth muscle is also relatively resistant to relaxation by β2-adrenoceptor agonists, 
compared with contractions induced by histamine [290-292], suggesting that this resistance 
is related to the lack of effect of the β-agonists on muscarinic agonist-induced IP formation. 
However, in bovine tracheal smooth muscle cells it has been demonstrated that cAMP 
dependent inhibition of contractile agonist-induced Ca
2+-responses is not primarily caused 
by attenuation of the IP production and that the relative resistance of muscarinic agonist-
induced contraction to β2-adrenoceptor agonists resides in its higher potency in inducing IP 
formation and subsequent intracellular Ca
2+-changes [158]. In fact, a striking correlation 
was found between isoprenaline-induced relaxation of bovine tracheal smooth muscle 
contraction and inhibition of Ca
2+-mobilization or influx, indicating that not IP3 formation 
but the subsequent changes of calcium homeostasis play the major role in β2-adrenoceptor-
mediated relaxation of methacholine- and histamine-induced contraction. A possible 
mechanism reducing contractile agonist-induced Ca
2+-mobilization could be a cAMP-
dependent inhibition of IP3-binding to the IP3-receptor. IP3-receptors have been identified 
as substrates for PKA [288,293], and PKA-mediated phosphorylation of the IP3-receptor 
markedly reduces the ability to release Ca
2+ from intracellular stores [293,294]. Indeed, 
using competitive binding assays it has been demonstrated in rabbit tracheal smooth Chapter 1 
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membranes that activation of the cAMP-signalling pathway inhibits IP3 binding to the 
receptor [295].  
 
Regulation of the β2-adrenoceptor 
Classification of  desensitization 
The term desensitization refers to any pathway that results in the loss of responsiveness of a 
receptor signalling system. Two basic classes of desensitization have been distinguished, 
namely homologous and heterologous desensitization [296]. The term homologous (or 
receptor-specific) desensitization indicates that when a receptor is activated by an agonist, 
only this receptor is becoming refractory to subsequent agonist application, without 
affecting other receptors or receptor systems present in the same cell. In contrast, 
heterologous (or receptor-nonspecific) desensitization indicates that stimulation of one 
receptor attenuates the response to multiple (distinct) receptors operating through the same 
or different signalling pathways. In contrast to homologous desensitization, agonist binding 
to the receptor is not necessary for heterologous desensitization. Both mechanisms have 
been studied extensively for the β2-adrenoceptor [297-299] which has often been used as a 
model for the regulation of G protein-coupled receptors. Phosphorylation appears to be an 
essential step both for homologous and heterologous desensitization, but the mechanisms 
are quite distinct. 
  
Homologous desensitization 
Homologous desensitization of the β2-adrenoceptor is primarily mediated by activation of 
G-protein-coupled receptor kinases (GRKs). GRKs phosphorylate the agonist-occupied 
form of the receptor, after translocation to the plasma membrane by anchoring to free Gβγ 
subunits generated upon receptor activation [300], but slightly uncouple the receptor from 
Gα. GRK-mediated phosphorylation also promotes binding of β-arrestins to the receptor, 
resulting in a much more effective uncoupling of the receptor from its stimulatory G-
protein by sterically interfering with the receptor-Gα interaction and thus terminating the 
β2-adrenoceptor signalling [112,256,297,301,302]. The role of GRK-mediated 
phosphorylation is to increase the affinity of the receptor for arrestins. In vitro, the β-
arrestin-1-binding affinity of β2-adrenoceptors is increased 10- to 30-fold following 
phosphorylation of the receptor by GRK [303]. It is the binding of arrestin to the receptor, 
rather than GRK-mediated phosphorylation, that leads to homologous desensitization of the 
receptor. GRK-mediated arrestin binding is followed by sequestration and downregulation 
of the receptor, which occurs via the association of the receptor-arrestin complex with 
components of clathrin-coated pits [304-306]. Only the receptor that is occupied by the 
agonist is in the appropriate conformational state to be a suitable substrate for GRKs. This 
strict agonist-binding requirement for GRK-mediated phosphorylation makes this 
mechanism homologous in that only the simulated receptor is being desensitized.  General introduction 
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The GRK family of serine/threonine kinases consists of seven isoforms that share a number 
of structural and functional similarities and GRKs 1-6 have been shown to phosphorylate 
the β2-adrenoceptor in its C-terminal cytoplasmatic tail [299,307]. Thus far, GRK2 (also 
referred to as βARK1 (β-adrenergic receptor kinase-1)) is the major kinase implicated in 
homologous desensitization of the β2-adrenoceptor. For example, reconstitution of β2-
adrenoceptors and highly purified GRK2 along with β-arrestin in vitro was sufficient to 
establish maximal β2-adrenoceptor desensitization [302], and overexpression of GRK2 in 
CHO cells enhanced desensitization of the β2-adrenoceptor to high concentrations of 
agonist [308]. However, a number of studies suggest additional roles for GRK3 (βARK2) 
and GRK5 in β2-adrenoceptor desensitization [306,309-311]. GRK2 and 3 are rapidly 
translocated from the cytosol to the plasma membrane after agonist stimulation [312,313]. 
They contain a 125-residue extension at the C-terminus that interacts with isoprenylated βγ 
subunits of trimeric G-proteins [300,309,313-317]. Free βγ subunits are only found in the 
plasma membrane at sites of receptor activation, so that this is an extremely precise 
mechanism for targeting these kinases to activated receptors. In contrast, most GRK5 is 
normally present at the cell membrane, and there appears to be a direct interaction of the C-
terminal domain with phospholipid-head groups of the membrane [318]. 
Autophosphorylation of GRK5 is required for receptor-phosphorylating activity [319]. 
Interestingly, intracellular calcium levels may regulate homologous desensitization of β2-
adrenoceptors as it has been demonstrated that all three GRKs are inhibited by ubiquitously 
expressed calmodulin in a calcium-dependent fashion [320-323].  
Arrestins not only have an important role in uncoupling β2-adrenoceptors from their 
signalling pathway, but they are also crucial mediators of receptor sequestration or 
internalization following prolonged agonist exposure [301,324-328]. Specifically, β-
arrestins function as adaptor scaffolding proteins that link β2-adrenoceptors to components 
of the endocytotic machinery, including clathrin and β2-adaptin (the β-subunit of the 
adaptor protein AP2) [329-331]. In human astrocytoma cells it was found that translocation 
of  β2-adrenoceptors from the plasma membrane to an intracellular compartment upon 
isoprenaline stimulation occurred very rapidly, exhibiting a t1/2 of ~2 min after a delay of ~1 
min [332].This sequestration process has originally been considered to be another 
mechanism of desensitization. However, the majority of sequestered receptors are already 
desensitized as the consequence of phosphorylation. In addition, in human astrocytoma 
cells, rapid β2-adrenoceptor desensitization could be observed prior to any decrease in cell 
number [332]. Moreover, inhibiting β2-adrenoceptor sequestration through clathrin coated 
pits did not inhibit its rapid agonist-induced desensitization [333]. Studies have now 
suggested that the major role of sequestration in short-term regulation of the receptor may 
be in resensitization, since it appears that the sequestered pool is the site of 
dephosphorylation of the receptor [324,326,327]. Thus, internalized β2-adrenoceptors can 
be dephosphorylated in endosomes, enriched with specific phosphatases, and subsequently 
recycled back to the cell surface as fully functional resensitized receptors [334,335]. Direct 
evidence for this hypothesis came from the observation that inhibition of β2-adrenoceptor 
internalization through clathrin-coated pits with either concanavalin A or sucrose prevented Chapter 1 
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resensitization [333,336]. More recently, a G protein-coupled receptor phosphatase (GRP) 
was identified, a member of the PP2A family, which was colocalized with the β2-
adrenoceptor in endosomes during agonist-promoted receptor internalization. This 
phosphatase dephosphorylates the receptors in acidic environments such as those found in 
endosomes, and it has been suggested that the low intraluminal pH of the endosomes 
induces conformational changes in the receptor that can be recognized by GRP [337]. 
Interestingly, sequestration does not occur under conditions that specifically induce 
heterologous desensitization (discussed below). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Upon ligand binding, the β2-adrenoceptor activates adenylyl cyclase through coupling to 
heterotrimeric Gs protein, leading to cAMP synthesis (step 1). GRK2 is recruited to the ligand-bound β2-
adrenoceptor and phosphorylates the receptor (step 2). Once phosphorylated, the receptor binds to β-arrestins, 
which sterically hinders further coupling of the receptor to G-proteins (step 3). The β-arrestin, through its binding 
to clathrin and AP2 protein, targets the phosphorylated receptor to clathrin-coated pits and promotes receptor 
internalization (step 4). Following its dephosphorylation by a protein phosphatase (step 5), the receptor is recycled 
back to the cell surface (step 6) or is degraded in the lysosomes (step 7). Figure adapted from Métayé et al. [338]. 
 
Heterologous desensitization 
In addition to GRKs, phosphorylation of the β2-adrenoceptor by second-messenger kinases 
such as PKA and PKC may also contribute to desensitization by uncoupling the receptor 
from Gs. However, this uncoupling does not need β-arrestin binding and is not associated 
with subsequent sequestration of the receptor. Agonist occupancy of the target β2-
adrenoceptor is not required for this process, thus receptors that have not bound to an General introduction 
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agonist, including receptors for other ligands, can be desensitized by the activation of PKA 
or PKC. This process is therefore termed heterologous desensitization. As described before, 
PKA is activated through the formation of cAMP upon β2-adrenoceptor stimulation and a 
variety of studies have implicated a role for PKA in β2-adrenoceptor regulation. β2-
Adrenoceptors in turkey erythrocytes [339], as well as in hamster lung, were shown to be 
phosphorylated by PKA and this phosphorylation directly reduced β2-adrenoceptor 
interaction with Gs [340]. Site-directed mutagenesis studies have indicated that PKA 
phosphorylates the serine/threonine residues in the third intracellular loop of the receptor 
and the C-terminal cytoplasmatic tail [174,341]. However, only phosphorylation at the third 
intracellular loop is required for PKA-dependent desensitization [342]. Thus, cells 
expressing  β2-adrenoceptors lacking this site, were unable to undergo desensitization 
following exposure to adrenaline, whereas cells lacking the site on the C-terminal 
cytoplasmatic tail exhibited β2-adrenoceptor desensitization comparable to that observed in 
cells expressing the wild type β2-adrenoceptor. Interestingly, it has been demonstrated that 
PKA phosphorylation of the β2-adrenoceptor involves the role of A-kinase anchoring 
proteins (AKAPs). AKAPs are a family of structural diverse proteins that compartmentalize 
PKA to specific target organelles via interaction with the RII regulatory subunit of PKA 
[343]. The first indication of the role of AKAPs in β2-adrenoceptor function was provided 
by the demonstration that AKAP250 (also termed gravin) interacts with the carboxyl 
terminal tail of the β2-adrenoceptor, which has been implicated in receptor phosphorylation, 
desensitization, internalization and resensitization [344-346]. The proposed model involves 
a constitutive binding of  AKAP250 to the β2-adrenoceptor, not only regulating receptor 
phosphorylation (via PKA or possibly PKC) and dephosphorylation (via protein 
phosphatase 2B) but also contributing to the incorporation of additional proteins such as 
GRKs and arrestins, into the complex [345]. In addition, AKAP79/150 also appears to 
constitutively associated with the β2-adrenoceptor, resulting in a complex that contains 
PKA, PKC and protein phosphatases 2B. Indeed, it has been found that AKAP79/250 
promotes β2-adrenoceptor phosphorylation after agonist stimulation and is even able to 
facilitate activation of MAPK pathways [345].  
Another important kinase involved in heterologous desensitization of the β2-adrenoceptor is 
PKC. As discussed before, PKC is activated upon stimulation of Gq-coupled receptors. 
PKC is able to phosphorylate the β2-adrenoceptor at sites in the third intracellular loop, 
leading to uncoupling of the receptor [347-349]. In airway smooth muscle, much attention 
has been paid to this mechanism of receptor cross-talk as it was observed that contractions 
induced by muscarinic agonists are relatively resistant to relaxation by β2-agonists 
compared with contractions induced by histamine. Thus, in canine and bovine tracheal 
smooth muscle it has been demonstrated that β2-adrenoceptor-mediated and non receptor-
mediated elevation of cAMP potently inhibited histamine- but not methacholine-induced 
accumulation of inositol phosphates  [266,285]. Furthermore, several studies have shown 
that exaggerated cholinergic stimulation of airway smooth muscle causes a reduced 
relaxability of the muscle by β2-adrenoceptor agonists. In human  [122,350] and animal 
[123,290,291,351-353] airway smooth muscle, both the potency and the maximal relaxation Chapter 1 
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are gradually reduced in the presence of increasing concentrations of contractile agonists. In 
addition, such diminished functional antagonism has also been observed in vivo [292]. 
Interestingly, the responsiveness of the β2-adrenoceptor in the presence of contractile 
agonists is not determined by the contraction level only, but also by the agonist under 
investigation [290-292,351]. Furthermore, in guinea pig tracheal smooth muscle it was 
found that the reduction of the isoprenaline-induced relaxation was relatively large for 
methacholine, intermediate for oxotremorine and histamine, and small for the partial 
muscarinic agonist McN-A343 [291]. Since the efficacy of the contractile agonist to induce 
IP production showed a striking correlation with their capacity to reduce isoprenaline-
induced relaxation, the possibility was considered that direct interference by 
phosphoinositide metabolism of β2-adrenoceptor function may play an important role, 
possibly through DAG-induced PKC activation. Indeed, in various cells and tissues it has 
been found that activation of PKC via agonist-induced PI metabolism or phorbol esters is 
able to desensitise the β2-adrenoceptor, presumably via phosphorylation of the receptor 
and/or Gs [354-359]. Biochemical evidence that cross-talk between PI metabolism and β2-
adrenoceptors could play a role in the regulation of the responsiveness of β2-adrenoceptors 
of airway smooth muscle by contractile agonists was obtained in bovine tracheal smooth 
muscle, showing that incubation with the phorbol ester PMA and carbachol resulted in β2-
adrenoceptor uncoupling and a reduced β-agonist-induced cAMP response [360]. 
  
Relative contributions of PKA and GRKs  in rapid β2-adrenoceptor desensitization 
The relative contributions of PKA and GRKs to the overall manifestation of desensitization 
of β2-adrenoceptors following β-agonist stimulation is complex.Using isoprenaline, it has 
been established in permeabilized A431 cells, that under conditions of selective blockade of 
PKA (with PKI, an inhibitory peptide) or GRK2 (by heparin) still significant 
desensitization was observed, indicating that both desensitization pathways are indeed 
functionally operative. However, at low receptor occupancy (agonist concentration <10 
nM) the PKA pathway was selectively activated [361]. This observation was confirmed by 
studies using mutant β2-adrenoceptors lacking putative GRK2 and PKA-phosphorylation 
sites [362,363], with the capacity for both GRK2- and PKA-mediated desensitization with 
high agonist concentrations. Using both heparin and PKI it was demonstrated in 
permeabilized A431 cells that isoprenaline-induced phosphorylation of the β2-adrenoceptor 
by GRK2 occurred with a t1/2 of <20 seconds, whereas phosphorylation by PKA had a t1/2 
of about 2 min [364]. Similarly, GRK2-mediated desensitization of the β2-adrenoceptor 
proceeded with a t1/2 of <15 sec, and PKA-mediated desensitization with a t1/2 of about 3,5 
min. Maximal desensitization, mediated by the two kinases corresponded to a reduction of 
the signal-transduction capacity of the receptor/AC system by about 60% in the case of 
GRK2 and by about 40% in the case of PKA. These findings indicate that GRK2-mediated 
phosphorylation is the most rapid and quantitatively most important factor contributing to 
the rapid desensitization [364] and are consistent with other observations in desensitization 
studies where heterologous desensitization of the β2-adrenoceptor typically is observed General introduction 
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later and of a lesser magnitude when compared to homologous desensitization [365]. In 
addition, a number of studies have confirmed that with higher agonist concentrations (>50 
nM), GRK-induced desensitization is quantitatively more important [299,366,367]. 
Evidence for acute β2-adrenoceptor desensitization in cultured human airway smooth 
muscle cells was first demonstrated by Hall and colleagues [368], showing that prior 
treatment of the cells with varying concentrations of isoprenaline for 1 to 16 hours 
produced concentration-related desensitization of cAMP responses to subsequent challenge 
with isoprenaline, ranging from 62 to 85% desensitization. It was also observed that 
exposure to PGE2 produced a concentration-related desensitization of cAMP responses to 
subsequent challenge with isoprenaline. Acute regulation of the β2-adrenoceptor in human 
airway smooth muscle was further characterised by Penn and colleagues [256], to elucidate 
mechanisms by which desensitization of β2-adrenoceptors occurs in airway smooth muscle. 
A 30 min pretreatment of the cells, with either β-agonist (isoprenaline) or with agents that 
increased intracellular cAMP response independently of β2-adrenoceptor activation 
(forskolin and PGE2), resulted in a loss of β2-adrenoceptor responsiveness to subsequent 
isoprenaline challenge, characterised by a diminished cAMP response. No significant 
changes were measured in forskoline-induced cAMP production, indicating that the β2-
adrenoceptor is the principle locus of regulation. Isoprenaline-induced desensitization was 
characterised by an ~60% loss of maximal responsiveness to isoprenaline, which was only 
minimally but significantly prevented by PKA-inhibition, indicating a quantitatively more 
important role for GRK-induced desensitization. In addition, overexpression of GRK2 in 
human airway smooth muscle cells enhanced isoprenaline-induced desensitization, 
implicating that GRK2 is indeed a mediator of β-agonist induced desensitization in human 
airway smooth muscle. Furthermore, isoprenaline-induced desensitization was associated 
with, but not dependent on a ~45% loss of cell surface β2-adrenoceptors, and rapid recovery 
from isoprenaline-induced desensitization was highly dependent on sequestration. In 
contrast, β2-adrenoceptor desensitization induced by forskolin and PGE2 was characterized 
by only ~20-30% loss of maximal responsiveness, which was largely prevented when PKA 
was inhibited, indicating a primary role for PKA in this form of heterologous β2-
adrenoceptor desensitization [256]. 
 
Heterologous regulation of homologous desensitization 
Interestingly, heterologous and homologous desensitization are not necessarily completely 
independent processes. In recent years, phosphorylation of GRKs at different sites and by a 
variety of protein kinases has emerged as an important mechanism for regulation of their 
activity, interaction with other proteins and even protein stability. In addition to the direct 
effects on receptor/G-protein coupling, PKC has been shown to increase GRK2 activity and 
enhance membrane targeting. The capacity of PKC to activate GRK2 was originally 
suggested in studies in human mononuclear leukocytes in which calcium iononophores or 
phorbol esters caused an increase in cytosolic GRK2 activity that was blocked by prior cell 
treatment with PKC inhibiters [369]. GRK2 was shown to be a substrate for PKC both in Chapter 1 
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vitro and in intact cells, and functional significance of the PKC-dependent increase in 
GRK2 activity was demonstrated by β-adrenoceptor homologous desensitization 
experiments in intact mononuclear leukocytes. Thus, β-adrenoceptor desensitization, 
induced by exposure of the cells to 10 μM isoprenaline for 5 min, was markedly increased 
in PMA-pretreated cells and this increase was inhibited by the GRK2 inhibitor heparin. In 
an additional study it has been demonstrated that PKC-induced phosphorylation of GRK2 
enhances its activation by translocating GRK2 to the cell membrane [370]. Furthermore, 
using human mononuclear leukocytes, it was shown that T-cell activation resulted in 
increases in GRK2 mRNA, which could be mimicked by the combined application of 
calcium ionophore and low doses of the PKC activator PMA, indicating that PKC is also 
involved in increasing GRK2 mRNA expression [371].  
In both in vitro and intact transfected COS-1 cell studies, PKC was also shown to 
phosphorylate GRK5 at two sites within the C-terminal 26 acids [320]. In contrast to the 
observed activation of GRK2, GRK5 phosphorylation by PKC dramatically reduced GRK5 
activity, demonstrated by the reduced binding of GRK5 to rhodopsin containing 
membranes and reduced phosphorylation of the light-activated rhodopsin receptor. In 
addition, PKC-mediated phosphorylation significantly reduced GRK5 catalytic activity 
towards non receptor substrates. As discussed before, both GRK2 and GRK5 are inhibited 
by Ca
2+/calmodulin. Together with the demonstrated effects of PKC on GRK-activity, these 
findings suggest a coordinated regulation of G protein-coupled receptors when both PKC 
and Ca
2+/calmodulin are activated by Gq-coupled receptors. However, the roles of PKC and 
Ca
2+/calmodulin in regulating GRKs under physiological conditions remain unclear. 
Interestingly, it has recently been demonstrated in vitro that the tonic inhibition of GRK2 
by Ca
2+/calmodulin was almost completely abolished when GRK2 was phosphorylated by 
PKC, indicating another possible mechanism for activation of GRK2 [372].  
In addition to PKC, PKA has also been shown to directly phosphorylate GRK2, leading to 
an enhanced GRK2 activity towards β2-adrenoceptors [373]. In fact, PKA-mediated 
phosphorylation does not actually affect the kinase activity, but rather enhances binding of 
GRK2 to Gβγ  subunits, thereby facilitating membrane targeting of GRK2 and interaction 
with activated receptors. However, the ability of PKA to phosphorylate GRK2 is dependent 
on the presence of Gβγ-bound to GRK2 and on PKA being tethered to the receptor by 
AKAP79 [373]. Thus, PKA-induced GRK2-phosphorylation increased its binding affinity 
for Gβγ subunits and thereby promoted the recruitment of GRK2 to the plasma membrane 
and into a complex with its activated receptor substrates. 
  
Downregulation 
Finally, β2-adrenoceptors may also undergo receptor downregulation. Downregulation is 
defined as a loss in receptor density and occurs as a result of increased receptor degradation 
or reduced receptor synthesis. As opposed to the relatively rapid desensitization processes 
of receptor phosphorylation, uncoupling and sequestration, receptor downregulation 
represents a chronic adaptation that occurs with prolonged agonist exposure of the cell. General introduction 
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Downregulation of the β2-adrenoceptor does not appear to require receptor phosphorylation 
since several studies have demonstrated that mutant β2-adrenoceptors containing altered 
phosphorylation sites have normal patterns of downregulation [362,374,375]. However, 
mutagenesis of the PKA phosphorylation site of the β2-adrenoceptor decreased the rate and 
extent of the agonist-induced downregulation, indicating that PKA may play a facilitatory 
role [341]. A possible mechanism of β2-adrenoceptor down-regulation may involve 
reduction in β2-adrenoceptor synthesis as a result of cAMP-mediated destabilization of β2-
adrenoceptor mRNA, as it was observed in DDT1MF-2 cells that chronic exposure to 
isoprenaline resulted in a time-dependent reduction in β2-adrenoceptor mRNA levels due to 
a reduction in mRNA stability [376-378]. Enhanced degradation of the PKA-
phosphorylated  β2-adrenoceptor could be an alternative explanation for PKA-induced 
downregulation [341]. In guinea pig lung there is a marked reduction in β2-adrenoceptor 
density after a 7 days infusion of noradrenaline, which is accompanied by a similar 
reduction in steady state β2-adrenoceptor mRNA levels, although the effect in airway 
smooth muscle was less pronounced than that observed in lung parenchyma [379]. Similar 
data were obtained in rats after prolonged infusion with isoprenaline [380]. In addition to 
the reduction in β2-adrenoceptor mRNA, there is also a reduction in the activity of the 
transcription factor CREB, which may account for the reduced rate of β2-adrenoceptor gene 
transcription. In contrast, as described before, short-term agonist stimulation of the β2-
adrenoceptor results in a transient increase in receptor mRNA levels through a direct 
increase in the rate of β2-adrenoceptor gene transcription, by enhancing the activity of 
CREB [269,271]. However, the discovery of the CRE modulator (CREM), a CREB-related 
transcription factor which binds CREs in a dominant-negative fashion, suggests that under 
certain circumstances cAMP generation could also result in downregulation of β2-
adrenoceptor gene transcription [381]. Chapter 1 
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β2-Adrenoceptor function in asthma 
Responsiveness of the β2-adrenoceptor system  
Endogenous β-agonists 
The extent of sympathetic innervation to the lung is species dependent [382]. Cats have 
extensive sympathetic innervation in the lung including the innervation of the airway 
smooth muscle [383]. In guinea pig airways, main sympathetic projections are to blood 
vessels, the bronchi being innervated only sparcely [254]. In humans, sympathetic fibers 
innervate the submucosal mucus gland, blood vessels, and the parasympathetic ganglia, but 
do not directly innervate airway smooth muscle [384-387]. In line with the lack of direct 
sympathetic innervation of airway smooth muscle, β2-adrenoceptors, but not β1-
adrenoceptors, are present throughout the human lung [248,250-252,254,385,386] and 
autoradiographic and radioligand binding studies have shown that β2-adrenoceptor density 
increases with increasing airway generation [246,251]. In addition, relaxation of human 
central and peripheral airway smooth muscle has shown to be mediated by a homogenous 
population of β2-adrenoceptors [253,254] and control of airway smooth muscle tone is 
mainly through circulating adrenaline [388], which is secreted from the adrenal medulla. 
The other endogenous catecholamine, noradrenaline, is the neurotransmitter and only 
appears in the plasma by overflow from sympathetic nerve activity. In patients with asthma, 
β-adrenoceptor blockade is known to induce bronchospasm and aggravation of the desease 
[389-392], suggesting that endogenous bronchodilating β-adrenergic activity is important in 
controlling airway smooth muscle tone in asthmatic patients. Even low systemic doses of β-
blocking eye drops may cause wheeziness in asthmatics [393] and it has been demonstrated 
that β-receptor-blockade of asthmatics causes immediate bronchoconstriction and increases 
bronchial responsiveness to methacholine and histamine [394,395]. In contrast, in non-
asthmatics large doses of beta-blocking drugs have little or no effect on airway function and 
responsiveness [396,397], suggesting a more important role for circulating adrenaline in 
patients with asthma. Although venous plasma levels of adrenaline have been demonstrated 
to be normal in asthmatic subjects [398-401], a temporal relationship has been observed 
between decreases in plasma adrenaline and decreases in peak expiratory flow rate during 
the early morning hours in patients with nocturnal asthma [402,403]. In addition to 
asthmatic patients, there is also a chronobiological rhythm in catecholamine secretion in 
normal subjects, being lowest between 1 and 5 a.m [404]. The fall in endogenous 
adrenaline level at night seems to be due to reduced secretion from the adrenal medulla, 
since plasma clearance is unchanged [405]. The reduced adrenaline level at night closely 
correlate with the decrease in peak flow, suggesting that decrease of the protective 
influence of adrenaline may be the cause of bronchoconstriction at night, in the same way 
that β-adrenoceptor antagonists produce bronchoconstriction in asthmatics, by blocking the 
effect of endogenous adrenaline.  General introduction 
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As described before, adrenaline may produce bronchodilatation directly by stimulating β2-
adrenoceptors on airway smooth muscle, and indirectly by inhibiting the release of 
inflammatory mediators from pulmonary mast cells and by modulation of cholinergic 
neurotransmission. Thus, the reduced circulating adrenaline concentrations at night may 
lead to bronchoconstriction by a permissive effect on pulmonary mast cell mediator release. 
In support of this, plasma histamine concentrations, used as an indicator of mediator 
secretion, rise at night in asthmatic patients, and the plasma histamine concentration is 
inversely correlated with the peak flow and plasma adrenaline level. Infusion of adrenaline 
in a low concentration to reverse the fall in endogenous adrenaline reduces the elevated 
plasma histamine concentration at night [402]. In normal subjects, no significant variations 
in plasma histamine concentration are seen, supporting the idea that the increased secretion 
of bronchoconstrictor mediators from the sensitized mast cells of asthmatic airways amplify 
the nocturnal changes in airway tone.  
An important regulator of the actions of circulating adrenaline at the airway smooth muscle 
site is catechol-O-methyltransferase (COMT). Circulating adrenaline, but also other 
neurotransmitters and drugs with a catechol structure, are rapidly inactivated by COMT. 
Positron emission tomography studies have demonstrated high COMT activity in kidney, 
liver, intestine, stomach, spleen, lungs and heart of mice [406]. In addition, rather high 
COMT activities have been described in human lung [407] and rat lung [408]. COMT 
transfers a methyl group from 5-adenyl methionine to the 3-OH position of the 
catecholamine. As a consequence, the conjugated compound has no adrenergic activity and 
may be either excreted or further metabolized by monoamine oxidase [409]. Indeed, it has 
been demonstrated that 3H-noradrenaline in isolated rat lungs [408]and 3H-isoprenaline in 
isolated guinea pig tracheal rings [410] and rabbit tracheal smooth muscle [411] is O-
methylated, which could be prevented by COMT-inhibition. Interestingly, in guinea pigs 
the  O-methylation activity of the “smooth muscle-rich” component of the trachea was 
approximately three-times higher than for complete tracheal rings [410]. Various functional 
studies in airway smooth muscle have indicated that COMT-activity is counteracting 
catecholamine-induced smooth muscle relaxation. Thus, in pig bronchus the COMT-
inhibitor U-0521 caused a 6 fold increase in potency of isoprenaline-induced relaxation 
[412] and the potency of isoprenaline was increased 7 fold in the presence of U-0521 in 
guinea pig tracheal smooth muscle rings after 50% carbachol contraction with no effect on 
maximum relaxation [413]. Based on the evidence presented above, COMT-activity seems 
to play an important role in counteracting the relaxing ability of endogenous and exogenous 
catecholamines and therefore may be involved in creating a disbalance between contractile 
and relaxing pathways in patients with asthma. In support of this hypothesis it is 
interestingly to know that increased activation of COMT has been found in children with 
asthma [414]. 
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Possible cross-talk between PI metabolism and the β2-adrenoceptor system  
As discussed before, inhaled β2-adrenoceptor agonists are effective bronchodilators and 
widely used to control airway function in asthma and chronic obstructive pulmonary 
disease (COPD) [415,416]. The efficacy of these drugs in asthma is mainly due to the 
functional antagonism counteracting the bronchoconstrictor effects of neurotransmitters and 
mediators released in airway inflammation [97]. However, it is well known that patients 
during a severe exacerbation of asthma have a reduced bronchodilator response to β2-
adrenoceptor agonists [417]. In addition, studying β2-adrenoceptor abnormalities in 
leukocytes of non-treated asthmatic patients, it was demonstrated that a loss in β2-
adrenoceptor function indeed may occur, predominantly in those with active and severe 
asthma [418-421]. Evidence has emerged that the described mechanisms of cross-talk 
between PI metabolism and the β2-adrenoceptor system may play a role in asthmatic 
airways. In isolated preparations of patients with fatal [422-424] or non-fatal [251,425] 
active and severe asthma, the relaxant response to isoprenaline is reduced, whereas a 
normal response has been found in patients with mild to moderate asthma [426,427]. 
Importantly, the reduced β2-adrenoceptor relaxation was found in these studies irrespective 
of prior use of β-agonists. Evidence for β2-adrenoceptor uncoupling from Gs has been 
suggested in autoradiographic and functional studies in lungs and bronchial preparations 
from patients with fatal and non-fatal asthma, since normal [428] or even enhanced 
[251,429] β2-adrenoceptor densities were found in airway smooth muscle, while the β2-
adrenoceptor relaxation was reduced. These results indicate that the β2-adrenoceptor is 
uncoupled from its effector system in patients with severe asthma. In addition, in 
lymphocytes from asthmatic patients it has been found that the β2-adrenoceptor cAMP 
response was reduced after allergen challenge [392,430]. Since PKC activation, via 
receptor-mediated stimulation of PI metabolism, is involved in the activation of various 
cells involved in the allergic response, including airway smooth muscle and inflammatory 
cells, it can be imagined that PKC-induced (heterologous) desensitization could cause a 
reduced  β2-adrenoceptor responsiveness of these cells and thus contribute to enhanced 
airway reactivity in patients with active and severe asthma. Indeed, using a guinea pig 
model of allergic asthma, it has been found that single or repeated allergen challenge may 
lead to a reduced isoprenaline-induced relaxation of methacholine- and histamine-
contracted preparations [431]. As the reduced β2-adrenoceptor sensitivity in vitro was 
paralleled by a progressive infiltration of inflammatory cells in the airways, it was 
suggested that mediators from these cells may decrease airway smooth muscle β2-
adrenoceptor sensitivity. PKC seems to be the most likely candidate involved in this 
process (see paragraph ‘β2-adrenoceptor function in asthma’). 
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Adverse effects of β2-adrenoceptor agonist therapy in asthma 
Regular treatment with β2-agonists 
Almost since the use of inhaled β-agonists in asthma started, there has been a concern that 
regular use or overuse may increase asthma morbidity and mortality [432]. This was largely 
initiated by the epidemics of asthma deaths following the introduction of high-dose 
isoprenaline in the UK and other countries in the 1960s and following the introduction of 
fenoterol in New Zeeland in the late 1970s [433]. In case-control studies the risk of death or 
near-death from asthma was shown to be significantly greater in patients prescribed inhaled 
fenoterol [434]. It has also been found that asthma control was worse in patients receiving 
regular inhaled fenoterol for 24 weeks than when they used the bronchodilator “as needed” 
[85], thus questioning the safety of the short acting β-agonist fenoterol. Meanwhile, 
increases in asthma morbidity and mortality were also occurring in countries in which 
fenoterol was not widely prescribed, but where there was a progressive rise in the overall 
use of inhaled β-agonists [435], suggesting that the increased use of relatively high doses of 
β-agonists as a class and not just fenoterol might cause these adverse epidemiological 
trends. This suggestion was supported by epidemiological surveys which detected an 
association between the intensity of inhaled β-agonist drug therapy and asthma death or 
near death [86,436]. Furthermore, 1 year of regular inhalation of salbutamol by patients 
with asthma and COPD increased bronchial responsiveness to histamine [437], while 
during a 2-year treatment period a rapid decline in lung function was found compared to 
symptomatic use of salbutamol [438]. In addition, treatment of patients with mild to 
moderate persistent asthma with long acting β-agonists induced deterioration of lung 
function, bronchial hyperresponsiveness, as well as an increased number of exacerbations 
[439-441]. Moreover, rebound increase in bronchial reactivity [442,443], hyperreactivity to 
histamine and methacholine [444-446] and increased bronchial responses to allergens [447-
449] were reported after discontinuation of regular treatment with β-agonists.  
A well-recognized effect of the regular administration of β-agonists is the development of 
tolerance, which underlyie the worsening of asthma following long-term treatment with β-
agonists. For both short- and long-acting β-agonists decreased bronchodilator responses 
have been demonstrated in asthmatic patients treated on a regular basis [450-458]; however 
the outcome differed among these studies [459-464] and some studies even showed no 
tendency to develop tolerance for formoterol [465-467] and salmeterol [468,469].  
Several studies have examined the effect of chronic exposure to β-agonists on 
bronchodilator and bronchoprotective responses. Remarkably, a dissociation has been 
observed in the efficacy of β-agonists to induce bronchodilatation in asthmatic patients 
after prolonged treatment with these agonists, and changes in their capacity to protect 
against bronchoconstrictor stimuli. Thus, regular use of several β-agonists caused a 
significant reduced protection against methacholine- [449,461-463] and/or adenosine 
monophosphate (AMP) [461,464]-induced bronchoconstriction, with no effect on the 
bronchodilator effect of these β-agonists.  Chapter 1 
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A possible explanation for the dissociation in desensitization susceptibility between the 
bronchodilator and bronchoprotective effects might be that most studies investigating the 
bronchodilator response have been performed in patients with mild to moderate asthma 
with a good reversibility of airway obstruction. Therefore, it could be suggested that more 
severe bronchoconstriction induced by contractile agonists may be necessary to reveal 
reduced functional antagonism upon β2-adrenoceptor desensitization [470]. Interestingly, 
when AMP was used as the provocation stimulus, loss of protection was significantly more 
pronounced compared to methacholine [461]. Since AMP is thought to produce 
bronchoconstriction indirectly by releasing mediators from airway mast cells, this finding 
suggests that tolerance of the mast cell-stabilizing effects of β-agonists may be important 
for the deterioration of asthma symptoms and bronchial hyperreactivity after long-term 
treatment and that β2-adrenoceptors on mast cells may be more susceptible to tolerance than 
those on airway smooth muscle. Evidence for this hypothesis was found in sensitized 
guinea pigs showing that β2-adrenoceptors mediating inhibition of allergen-induced 
mediator release were more susceptible to desensitization than β2-adrenoceptor mediating 
airway smooth muscle relaxation [471]. 
An alternative mechanism was recently suggested by McGraw and colleages [472], 
whereby chronic exposure to β-agonists might alter airway responses. Using different 
mouse models to examine β2-adrenoceptor function, they found that β2-adrenoceptor 
knockout mice have reduced responses to bronchoconstrictor stimuli compared with wild-
type mice, whereas mice overexpressing the β2-adrenoceptor have increased 
bronchoconstrictor responses. This increase in bronchoconstrictor responses in mice 
overexpressing the β2-adrenoceptor was associated with an increased expression of the 
relevant isoform of PLC (PLCβ), which was thought to account for the enhanced response 
to contractile agents in this system. If such mechanism is also present in human airways, 
one might predict that chronic exposure of airway smooth muscle to β2-adrenoceptor 
stimulation might also lead to increased expression of PLCβ and hence increased contractile 
responses. 
  
Enantiomers of β2-agonists 
A number of possible mechanisms have been discussed above to explain the adverse effects 
of chronic β-agonist therapy. Another explanation for the detrimental effects of β-agonists 
may involve their racemic nature. Although endogenous adrenaline, which is importantly 
involved in bronchodilatation and suppression of mast cell activation, is always in the 
single R-enantiomer form, all marketed selective β-agonists are racemic, composed of 
equal amounts of the R-enantiomer and its nonsuperimposable mirror image, the S-
enantiomer. The R-enantiomer of β-agonists is thought to exhibit the observed 
bronchodilatation and clinical benefit of the racemate [473], whereas the S-enantiomer is 
devoid of clinical benefit and is assumed to be virtually inert. In recent years, the suspicion 
has been raised that the S-enantiomer of β-agonists is responsible for induction of airway 
hyperreactivity and may contribute to increased asthma morbidity and mortality [474-478]. General introduction 
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The first indication that the S-enantiomer of a racemic β-agonist might cause 
hyperreactivity originates from experiments in guinea pigs, demonstrating that infusion of 
S-isoprenaline for 1 hour increased airway reactivity to histamine [479] or the peptide 
bombesin [480]. Salbutamol, worldwide the most commonly used β-agonist, is studied 
most extensively for possible detrimental effects of the S-enantiomer. In vitro radioligand 
binding assays have shown that R-salbutamol is a potent ligand for the β2-adrenoceptor, 
having approximately 100 times greater receptor affinity than S-salbutamol [481]. Concerns 
about potential adverse effects of S-salbutamol seem to be supported by a number of results 
obtained from animal and in vitro models. Preincubation with S-salbutamol increased 
reactivity to carbachol, but not histamine or ovalbumin, in tracheal smooth muscle 
preparations from guinea pigs sensitized to ovalbumin [482]. In addition, in human isolated 
bronchus, an increased response to histamine and LTC4, but not to methacholine, electric 
field stimulation or bradykinin, was observed after preincubation with S-salbutamol. In 
contrast, however, the contractile response to anti-human IgE was attenuated by S-
salbutamol [483]. Some studies have demonstrated proallergic properties of S-salbutamol. 
Thus, S-salbutamol increased the IgE-induced production of histamine and IL-4 in murine 
mast cells [484], activated pro-constrictory and pro-inflammatory pathways in human 
bronchial smooth muscle cells [485] and additional presence of S-salbutamol eliminated the 
anti-inflammatory influences of R-salbutamol on antigen specific T-cell lines, including 
inhibition of proliferation and cytokine production [486]. Enhanced airway hyperreactivity 
in guinea pigs also has been demonstrated in vivo [487] and changes in the cholinergic 
system may be of importance, as indicated by the observation that S-salbutamol-induced 
airway hyperreactivity to histamine was inhibited by vagotomy in guinea pigs [488]. 
Recently, it has been observed in a mouse asthma model that both R- and S-salbutamol 
reduced airway eosinophil trafficking and mucus hypersecretion. However, S-salbutamol 
increased allergen-induced airway edema and hyperresponsiveness [489]. 
Another approach to study the effects of the enantiomers of salbutamol in airway smooth 
muscle is measuring changes in the intracellular calcium concentration. It was 
demonstrated in isolated bovine tracheal smooth muscle cells, that S-salbutamol, but not R-
salbutamol, enhanced the increase in intracellular calcium induced by carbachol [490]. 
Furthermore it was shown that S- and RS-salbutamol increased basal intracellular calcium 
levels concentration dependent in the nanomolar range, which was accompanied by 
shortening of the cells [491]. This increase in intracellular calcium was insensitive to the 
β2-adrenoceptor antagonist ICI 118,551, whereas the muscarinic receptor antagonist 
atropine inhibited this increase completely, suggesting involvement of a cholinergic 
component. This was supported by the observed binding of S-salbutamol to muscarinic 
receptors. Recently, in line with these results it has been reported that treatment of human 
bronchial smooth muscle cells for 24 hours with S-salbutamol significantly increased 
intracellular Ca
2+-responses of these cells upon stimulation with methacholine [485]. Over 
the years, clinical data have suggested that the S-enantiomer of racemic β2-adrenoceptor 
agonists may cause airway hyperreactivity [473] and even contribute to increased asthma 
death [478]. Furthermore, studies in children [492-494] and adults [495,496] with asthma or Chapter 1 
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chronic obstructive pulmonary disease (COPD) have suggested that R-salbutamol offers 
better efficacy and safety benefits compared with racemic salbutamol. In addition, it has 
been suggested that adverse effects of S-salbutamol might result from differences in 
pharmacokinetics. Thus, the metabolic clearance of S-salbutamol is slower than that of R-
salbutamol, causing much higher plasma levels of S-salbutamol than R-salbutamol 
[474,497-501]. The resultant accumulation of S-salbutamol could therefore contribute to 
the potential adverse effects.  
Epidemiological, animal, in vitro and clinical studies purporting to show deleterious effects 
of S-salbutamol are still in discussion and adverse effects of the S-enantiomer present in 
racemic β-agonist drugs are still subject of controversy. Thus, in guinea pigs it has been 
found that both basal airway reactivity and allergen-induced hyperreactivity towards 
histamine were not affected by S-salbutamol [502]. In patients with mild to moderate 
asthma other groups failed to find any adverse effects of S-salbutamol on 
bronchoprotection and bronchodilation [503,504] and several clinical studies in patients 
with asthma or COPD were unable to demonstrate advantage of R-salbutamol over the 
racemate regarding bronchodilation and airway reactivity [475,505-508]. Taken together, 
although some preclinical data remain intriguing, available clinical data provide little 
convincing support for adverse effects of S-salbutamol in asthmatic patients and the issue is 
at best inconclusive. General introduction 
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Scope of the thesis 
β-Adrenergic agonists are being in use to treat asthma for more than a century. Inhalation 
of β-agonists has proven to be very effective for the acute relief of bronchoconstriction. In 
this respect, chronic use of β-agonists is not infrequent for patients with asthma 
[82,415,416]. However, since the increased death rates in asthma in the mid-1960s was 
associated with the increased use of β2-agonists, waves of concern regarding adverse effects 
of β-agonists have emerged.  
The efficacy of these drugs in asthma mainly resides on the functional antagonism 
counteracting the bronchoconstrictor effects of mediators and neurotransmitters released in 
airway inflammation [97]. However, it is well known that during a severe exacerbation 
patients with asthma have a reduced bronchodilator response to β2-adrenoceptor agonists 
[417]. Since many mediators and neurotransmitters in allergic airway inflammation can 
activate PKC, this enzyme may be active in inducing heterologous β2-adrenoceptor 
desensitization. Indeed, in airway smooth muscle [360,509] and in peripheral blood 
lymphocytes [510], it has been demonstrated that Gq coupled receptor-mediated or phorbol 
ester-induced PKC activation may lead to heterologous β2-adrenoceptor desensitization. To 
investigate the functional role of contractile agonist-induced activation of PKC, we 
examined in chapter 2  the effects of the specific PKC-inhibitor GF 109203X on 
isoprenaline-induced relaxation of bovine tracheal smooth muscle contracted by various 
concentrations of methacholine and histamine.  
In addition to an acutely reduced bronchodilator response to β-agonists during severe 
exacerbations, presumably as a result of heterologous β2-adrenoceptor desensitization, it 
has been shown that prolonged β-agonist therapy can diminish the efficacy of these drugs 
[85,511], possibly as a consequence of homologous β2-adrenoceptor desensitization 
involving activated GRKs [256,297]. Heterologous and homologous desensitization, 
however, appear not to be completely independent processes and the interaction between 
the two processes may contribute additionally to the adverse effects of β-agonists. It has 
been reported that PKC-mediated phosphorylation upregulates the activity of GRK2 [369] 
and also targets this kinase to the plasma membrane [370]. Little is known, however, about 
the functional consequences of these interactions. To examine whether this concept is 
functionally operative in airway smooth muscle, we investigated in chapter 3 the capacity 
of PKC to regulate homologous β2-adrenoceptor desensitization in bovine tracheal smooth 
muscle. 
In  chapter 4, we explored the concept of heterologous regulation of homologous 
desensitization of the β2-adrenoceptor into further detail on the level of intracellular Ca
2+-
homeostasis, by investigating the role of PKC in attenuating the effectiveness of 
isoprenaline against methacholine-induced Ca
2+-mobilization and Ca
2+-influx in isolated 
bovine tracheal smooth muscle cells.  
Another concern of prolonged use of β-agonists is the possibility of a paradoxical up-
regulation of neural and non-neural processes that counteract β2-adrenoceptor function, Chapter 1 
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possibly by the S-enantiomer present in the racemic mixture of β2-agonists that are 
currently being used [477]. To date, a lot of controversial evidence has been found with 
regard to the putative adverse effects of S-salbutamol and possible mechanisms remain 
unclear. Among all diverse observations made, the finding that S-salbutamol increases the 
intracellular free Ca
2+-concentration [485,491] and enhances contractile agonist-induced 
Ca
2+-mobilization [490] in native airway smooth muscle cells, possibly by means of a 
cholinergic mechanism, is a fascinating observation which deserves further investigation. 
To this purpose, in chapter 5 we have thoroughly compared the effects of R- and S-
salbutamol on methacholine and histamine-induced Ca
2+ responses in Fura- 2AM-loaded 
bovine tracheal smooth muscle cells, using both cell suspension spectrofluorometry and 
single cell fluorescence microscopy.  
COMT is a very important enzyme in the inactivation of endogenous and exogenous 
catecholamines. Preliminary results obtained in our laboratory had shown a possible link 
between PKC and COMT, in that activated PKC may potentiate COMT activity. By 
reducing the β-adrenergic response, both PKC and COMT, as well as the possible 
interaction between the two, may play an important role in diminishing an important 
endogenous β-adrenergic defence in (severe) asthma. In chapter 6, we investigated the 
interactive role of PKC and COMT in reducing the β2-adrenoceptor responsiveness in 
bovine tracheal smooth muscle towards the catecholamine isoprenaline. 
Finally, to exert their relaxing effects, β-agonists have to counteract mechanisms involved 
in airway smooth muscle contraction. Interestingly, airway smooth muscle contraction 
caused by full muscarinic agonists is relatively resistant to relaxation by β2-adrenoceptor 
agonists, compared to partial muscarinic agonists, possibly as a result of the considerable 
transduction reserve of full muscarinic agonists [120]. Indeed, it has been demonstrated that 
the full agonist acetylcholine induces maximal force development by occupying only 4 % 
of the available muscarinic receptors (large receptor reserve), whereas partial agonist McN-
A-343 has to occupy 80 % of the receptors (low receptor reserve) to achieve the same 
degree of muscle shortening [512,513]. In addition, large differences between full and 
partial muscarinic agonists regarding Ca
2+-mobilizing capacity have been described [157]. 
Remarkably, despite these large differences, the partial agonists pilocarpine and McN-A-
343 are still capable to induce approximately 85% of the maximal contraction induced by 
the full agonist methacholine. A putative explanation for this phenomenon is that partial 
muscarinic agonists are more depend on Ca
2+-sensitization than full muscarinic agonists, as 
it was recently reported that contractile stimuli do not exert their effects only by increasing 
the intracellular Ca
2+-concentration, but also by increasing Ca
2+-sensitivity of the smooth 
muscle. One of the main regulators involved in this Ca
2+-sensitization is Rho-kinase. To 
further elucidate mechanisms underlying the differences between full and partial 
muscarinic receptor agonists, we investigated in chapter 7 the contribution of Rho-kinase to 
ASM-contraction, Ca
2+-mobilization and Ca
2+-influx in response to the full muscarinic 
agonist methacholine and the partial muscarinic agonists pilocarpine and McN-A-343. In 
this context, it is very conceivable that contractile agonists that significantly rely on Ca
2+-General introduction 
 
45
sensitization for their contraction are more easily counteracted by β-agonists, as small 
changes in intracellular Ca
2+ would have large effects on airway smooth muscle tone. 
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Summary 
To examine the role of contractile agonist-induced activation of protein kinase C (PKC) in 
functional antagonism of airway smooth muscle contraction by β-adrenoceptor agonists, we 
examined the effects of the specific PKC-inhibitor GF 109203X (2-[1-(3-
dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide) on isoprenaline-
induced relaxation of bovine tracheal smooth muscle contracted by various concentrations 
of methacholine and histamine. In the absence of GF 109203X, the potency of isoprenaline 
(pD2) was gradually reduced at increasing methacholine- and histamine-induced smooth 
muscle tones, but the maximal relaxation (Emax) was decreased only at higher 
concentrations of methacholine. In the presence of GF 109203X, pD2-values were 
significantly increased for both methacholine- and histamine-induced contractions. 
Moreover, isoprenaline Emax-values in the presence of high concentrations of methacholine 
were also increased. Although both methacholine- and histamine-induced contractions were 
slightly reduced by GF 109203X, the changes in isoprenaline pD2 could only partially be 
explained by reduced contractile tone. In contrast to isoprenaline, forskolin-induced 
relaxations were not affected by GF 109203X. The results indicate that PKC-activation 
contributes to the reduced β-adrenergic responsiveness induced by methacholine and 
histamine, which may involve uncoupling of the β-adrenoceptor from the effector system. 
Since many mediators and neurotransmitters in allergic airway inflammation can activate 
PKC, this cross-talk may be important in the reduced bronchodilator response of patients 
with severe asthma. 
 
Introduction 
Inhaled β2-adrenergic agonists are effective bronchodilators and widely used to control 
airway function in asthma and chronic obstructive pulmonary disease (COPD) [1,2]. The 
efficacy of these drugs in asthma is mainly due to the functional antagonism counteracting 
the bronchoconstrictor effects of neurotransmitters and mediators released in airway 
inflammation [3].  
However, it is well known that patients during a severe exacerbation of asthma have a 
reduced bronchodilator response to β2-adrenoceptor agonists [4]. Most bronchoconstrictive 
receptors, including muscarinic M3- and histamine H1-receptors, activate Gq-protein 
coupled receptors and cause bronchoconstriction through phosphatidyl inositide hydrolysis, 
resulting in the formation of inositol trisphosphate which releases Ca
2+ from internal stores 
to initiate contraction. Subsequently, a sustained influx of extracellular Ca
2+ and a sn-1,2-
diacylglycerol (DAG)-induced activation of protein kinase C (PKC) follows, which are 
both implicated in the tonic phase of contraction [5,6]. 
β2-Adrenergic agonists mediate relaxation of airway smooth muscle by stimulation of Gs-
coupled  β2-adrenoceptors, which results in the activation of adenylyl cyclase (AC) to 
generate cyclic adenosine 3’,5’-monophosphate (cAMP), which in turn activates cAMP-
dependent protein kinase A (PKA) [7]. Phosphorylation of specific target proteins by PKA  Modulation of β-adrenoceptor function by PKC 
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results in various biochemical responses that induce smooth muscle relaxation, by reducing 
intracellular [Ca
2+] and diminishing the Ca
2+-sensitivity of the contractile elements.  
Both signalling pathways, however, do not appear to be independent, but are likely to 
interact at different homeostatic levels. It is well known that contractions induced by 
muscarinic agonists are relatively resistant to relaxation by β2-agonists compared with 
contractions induced by histamine. Thus, in canine and bovine tracheal smooth muscle it 
has been demonstrated that β2-adrenoceptor-mediated and nonreceptor-mediated elevation 
of cAMP potently inhibited histamine- but not methacholine-induced accumulation of 
inositol phosphates [8,9].  Furthermore, several studies have shown that exaggerated 
cholinergic stimulation of airway smooth muscle causes a reduced relaxability of the 
muscle by β2-adrenoceptor agonists. In human [10,11] and animal  [7,12-14] airway smooth 
muscle, it has been found that both the potency and the maximal relaxation are gradually 
reduced in the presence of increasing concentrations of contractile agonists. Such 
diminished functional antagonism has also been observed in vivo [15] which may explain 
why  β2-adrenoceptor agonists become less effective during severe asthmatic episodes, 
whereas their efficacy is unchanged in patients with mild or asymptomatic asthma [16,17].  
Although it has been found in various cells and tissues that activation of PKC may lead to 
uncoupling of the β2-adrenoceptor, presumably via phosphorylation of the β2-adrenoceptor 
and/or Gs [18-20], the specific role of contractile agonist induced PKC-activation in 
functional antagonism has never been addressed in the airways. In this study we present 
direct evidence for the involvement of PKC in the (acute) functional antagonism of 
contractile agonist-induced bovine airway smooth muscle contraction by β2-adrenoceptor 
agonists, using a specific, nonselective PKC inhibitor GF 109203X (2-[1-(3-
dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide) [21], which inhibits all 
conventional (α, β1 and β2) and novel (δ, ε and θ)  PKC isozymes present in bovine tracheal 
smooth muscle [22]. The marked involvement of PKC in the cross-talk between contractile 
agonist induced contraction and β2-adrenoceptor agonist induced relaxation of airway 
smooth muscle may be of considerable importance by reducing the bronchodilator response 
of  patients with severe asthma. 
 
Materials and methods 
Tissue preparation 
Fresh bovine tracheas were obtained from the slaughterhouse and were transported to the 
laboratory within 30 min at room temperature in Krebs-Henseleit (KH) buffer of the 
following composition (nM): NaCl 177.5, KCl 5.6, MgSO4 1.2, CaCl2 2.5, NaH2PO4 1.3, 
NaHCO3 25.0, glucose 5.5, pregassed with 95% O2 and 5% CO2; pH 7.4. The tracheal 
smooth muscle was dissected carefully and smooth muscle strips (12x3 mm) were prepared 
free of mucosa and serosal connective tissue in KH buffer gassed with 95% O2/5% CO2 at 
room temperature. Subsequently, all strips were maintained overnight in Dulbecco’s Chapter 2 
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modified Eagle’s medium (DMEM) supplemented with 10 mM NaHCO3, 20 mM HEPES, 
100 U/ml penicillin, 100 μg/ml streptomycin and 10% fetal bovine serum at 37°C (55 rpm). 
 
Mechanical responses 
After washing in several volumes of KH-buffer, gassed with 95% O2 and 5% CO2, pH 7.4 
at 37°C, the bovine tracheal smooth muscle strips were mounted in 15 ml organ baths 
containing gassed KH-buffer (37°C) for isotonic recording, using a preload of 500 mg. No 
basal myogenic tone was observed in bovine tracheal smooth muscle. After a 60 min 
equilibration period the strips were precontracted twice with methacholine (0.1, 1, 10 and 
0.1, 1, 10, 100 μM, respectively) with a 60 min washing period in between. Maximal 
relaxation was established with isoprenaline (0.1 μM), immediately followed by a 30 min 
washing period. Cumulative concentration response curves were made with methacholine 
(1 nM – 100 μM) and histamine (10 nM-100 μM) in the absence and presence of 10 μM 
GF 109203X. In separate experiments it was found that this concentration of GF 109203X 
caused complete inhibition of 10 μM phorbol 12-myristate 13-acetate (PMA)-induced 
contraction. 
For relaxation studies, the preparations were precontracted with different concentrations of 
methacholine (100 nM – 100 μM) or histamine (3 μM – 1 mM) in the absence or presence 
of 10 μM GF 109203X, increasing smooth muscle tone gradually in 2-4 concentration 
steps. Subsequently, cumulative concentration-relaxation curves were obtained with 
isoprenaline (using 1 nM – 100 μM for methacholine-induced tone and 0.1 nM – 10 μM for 
histamine-induced tone) or forskolin (0.1 nM – 10 μM). After the maximal relaxation had 
been obtained, the preparations were washed twice and maximal relaxation of the smooth 
muscle strips was re-established with 10 and 100 μM isoprenaline. When used, GF 
109203X was administered 45 min before building up smooth muscle tone with 
methacholine or histamine. 
In separate experiments, the reduction of methacholine- and histamine-induced contractile 
tone in the presence of GF 109203X was carefully compensated for by additional 
administration of small amounts of agonist, before isoprenaline relaxation curves were 
obtained. 
 
Data analysis 
Contractile responses were expressed as percentages of the response to 100 μM 
methacholine in the second precontraction curve in each experiment. Maximal relaxant 
effects of isoprenaline were expressed as percentages of contractile agonist induced tone.  
All data are presented as mean ± S.E.M. Curves were fitted using the logistic 4-parameter 
model (Sigmaplot 8.0). Statistical analysis was performed by means of the two-tailed 
Student’s  t test for paired or unpaired observations. P values < 0.05 were considered 
statistically significant.  Modulation of β-adrenoceptor function by PKC 
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Materials 
Dulbecco’s modification of Eagle’s Medium (DMEM), foetal bovine serum, NaHCO3 
solution (7.5%), penicillin/streptomycin solution (5000 U/ml
 ; 5000 μg/ml) and HEPES 
solution (1 M) were obtained from Gibco BRL Life Technologies (Paisley, U.K.). 
Methacholine chloride, histamine dihydrochloride, (-)-isoprenaline hydrochloride and 
forskolin were obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.) and GF 
109203X (2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide) was 
purchased from Boehringer (Mannheim, Germany). All other chemicals were of analytical 
grade. 
 
Results 
Effect of GF 109203X on methacholine- and histamine-induced contraction  
GF 109202X caused a small but significant shift to the right of the cumulative 
concentration-contraction curve of methacholine, with a reduction in pD2 (i.e. –log EC50) 
from 7.05 ± 0.07 to 6.67 ± 0.06 (P<0.05), while the maximal contractile effect (Emax) was 
unchanged (Fig. 1). For histamine-induced contraction, a pD2 change from 5.88 ± 0.10 to 
5.36 ± 0.11 (P<0.05) was observed, which was accompanied by a small but significant 
decrease in Emax, from 107 ± 3 to 95 ± 5% (P<0.05) (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Functional antagonism of methacholine- and histamine-induced contraction by 
isoprenaline 
Both for methacholine and histamine, it was found that at increasing smooth muscle tone 
isoprenaline-induced relaxation was gradually reduced (Fig. 2A and 2B, open symbols).  
Figure 1   Cumulative concentration-res-
ponse curves of methacholine (MCh)- and
histamine (His)-induced bovine tracheal
smooth muscle contraction in the absence and
presence of 10 μM GF 109203X (GF).
Results are means ± S.E.M. of 4-6
experiments each performed in duplicate. 
 Chapter 2 
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Figure 2 (-)-Isoprenaline-induced relaxation of bovine tracheal smooth muscle preparations precontracted with 
various concentrations of methacholine (MCh) (A) and histamine (His) (B) in the absence and presence of 10 μM 
GF 109203X. Results are means ± S.E.M. of 4-14 experiments each performed in duplicate. 
 
 
However, the maximal changes in isoprenaline pD2 and Emax values were considerably 
larger for methacholine than for histamine. Thus, for methacholine, a gradual fall of the pD2 
value of 3.4 log units was observed at contraction levels increasing from 24.9% (at 30 nM) 
to 108.9% (at 100 μM methacholine), while for histamine the pD2 decrease amounted to 2.2 
log units at smooth muscle tone ranging from 28.9% (1 μM) to 102.6% (1 mM histamine). 
In addition, at high contraction levels, the Emax of isoprenaline-induced relaxation was 
gradually reduced to only 5.6% in the presence of 100 μM methacholine, while with 
histamine only at the highest concentration a very small but significant decrease in Emax to 
95.3% was observed (Table 1; Fig. 2A and 2B). Fig. 3A and B (open symbols) show that 
the isoprenaline pD2 values were lower with methacholine than with histamine at equal 
levels of contractile tone.  Modulation of β-adrenoceptor function by PKC 
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Table 1 (-)-Isoprenaline pD2 and Emax values obtained after contraction of bovine tracheal smooth muscle strips 
with different concentrations of methacholine (MCh) and histamine (His) in the absence and presence of 10 μM 
GF 109203X (GF). 
MCh 
(μM) 
Contraction level 
(%) 
pD2 
(-log M) 
∆pD2 
Emax 
(%) 
  Control  + GF  Control  + GF 
 
Control +  GF 
0.1    51.4±3.7    21.6±8.1  7.69±0.08  8.70±0.04
 b  1.01    99.4±0.4  100 
0.3    90.9±1.6    73.9±5.9  6.59±0.10  8.11± 0.19
 b  1.52    95.2±0.9  100 
1    95.1±2.4    82.0±4.6  6.39±0.10  7.72±0.20
 b  1.43    75.5±2.6    96.2 ± 1.8
 b 
3  103.1±2.1     93.9±1.2 5.97±0.10 7.39±0.13
 b  1.42    33.2±4.4    64.4 ± 7.8
 a 
10  108.0±1.4 102.9±2.6 5.57±0.06 6.93±0.14
 b  1.36    17.8±2.2    47.2 ± 4.4
 b 
100  108.9±1.7 103.3±1.4 5.06±0.13 6.86±0.12
 b  1.80    5.62±1.3    22.0 ± 4.3
 a 
His (μM)           
3    41.5±1.7    30.0±6.5  9.06±0.08  9.84±0.06
 b  0.78 100  100 
10    71.9±3.4    54.7±4.7  8.72±0.08  9.61±0.07
 b  0.89 100  100 
100    90.7±2.9    71.4±2.6  8.08±0.13  9.17±0.13
 b  1.09    99.6±0.1  100 
1000  102.6±2.6  -  7.33±0.05  -      95.3±1.5  - 
Date represent means ± S.E.M. of 4-14 experiments each performed in duplicate. Significantly different from 
control:  
a P<0.01; 
b P<0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Relationship between contraction levels of bovine tracheal smooth muscle induced by various 
concentrations of methacholine (A) and histamine (B) and (-)- isoprenaline relaxation potencies (pD2) in the 
absence and presence of 10 μM GF 109203X. Chapter 2 
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Effect of GF 109203X on isoprenaline-induced relaxation 
In the presence of the specific PKC inhibitor, both the pD2 and the Emax values of 
isoprenaline-induced relaxations were significantly enhanced at the different concentrations 
of methacholine used (Fig. 2A and 3A). Similarly, at 3, 10 and 100 μM histamine-induced 
contractile tones, significant increases in the isoprenaline pD2 values were found (Fig. 2B 
and 3B). Although methacholine-and histamine-induced contractile tones were reduced in 
the presence of GF 109203X, the increased sensitivity to the β-agonist could not solely be 
explained by the reduced contraction levels. Thus, both for methacholine and histamine, 
isoprenaline pD2 values were higher in the presence of the PKC inhibitor compared to 
control at equal levels of contractile tone (Fig. 3A and 3B). To overcome the effects of a 
reduced methacholine-induced contraction in the presence of GF 109203X on the potency 
and maximal relaxation of isoprenaline, in separate experiments the reduced contractile 
tones were compensated for by additional agonist administration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 (-)-Isoprenaline-induced relaxation of bovine tracheal smooth muscle strips following contraction by 
various concentrations of methacholine (MCh) (A) and histamine (His) (B) in the absence and presence of 10 μM 
GF 109203X, with readjustments of smooth muscle tone, if necessary (see Methods). Results are means ± S.E.M. 
of 3-14 experiments each performed in duplicate. 
  Modulation of β-adrenoceptor function by PKC 
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Effect of GF 109203X on isoprenaline-induced relaxation after readjustment of contractile 
tone 
In accordance with the results described above, both at methacholine- and histamine- 
induced contractions significantly higher isoprenaline pD2 values were obtained in the 
presence of GF 109203X, when reduced contraction levels were readjusted by additional 
agonist administration (Fig. 4A and 4B; Table 2). However with histamine, the effects of 
GF 109203X were considerably smaller than with methacholine (Fig. 4A and 4B; Table 2). 
Fig. 4A also indicates that the potentiating effect of GF 109203X on the maximal 
isoprenaline-induced relaxation increased with increasing levels of the adjusted 
methacholine-induced smooth muscle tone. As before, with all histamine-induced 
contraction levels, both in the absence and presence of GF 109203X, maximum relaxation 
by isoprenaline was achieved. 
 
 
Table 2 (-)-Isoprenaline pD2 and Emax values obtained after contraction of bovine tracheal smooth muscle strips 
with different concentrations of methacholine (MCh) and histamine (His) in the absence and presence of 10 μM 
GF 109203X (GF), after readjustment of contractile tone if necessary (see Methods). 
MCh 
(μM) 
Contraction level 
(%) 
pD2 
(-log M) 
ΔpD2 
Emax 
(%) 
  Control  + GF  Control  + GF    Control  + GF 
0.1   59.1 ± 4.9    57.5 ± 4.6  7.75 ± 0.10  8.36 ± 0.14
 b  0.61  99.7 ± 0.2  99.9 ± 0.1 
1.0   94.5 ± 1.3    93.0 ± 1.1  6.32 ± 0.10  7.39 ± 0.09
 c  1.07  80.9 ± 2.4  91.9 ±1.9
 b 
10   101.7 ± 1.2  101.5 ± 1.2  5.94 ± 0.14  6.61 ± 0.12
 b  0.67  32.3 ± 3.6  48.5 ± 4.9
  
His(μM)         
3  39.7 ± 2.0    40.4 ± 1.9  8.85 ± 0.21  9.22 ± 0.16
 a  0.37 100 100 
10  65.6 ± 2.9    65.3 ± 2.4  8.70 ± 0.05  9.04 ± 0.15
 a  0.34 100 100 
100  86.2 ± 3.3    85.8 ± 3.1  8.08 ± 0.14  8.74 ± 0.14
 b  0.66 100 100 
Date represent means ± S.E.M. of 4-14 experiments each performed in duplicate. Significantly different from 
control:  
a P<0.01; 
b P<0.001 
 
Effect of GF 109203X on forskolin-induced relaxation  
In contrast to isoprenaline, forskolin-induced relaxation of 1 μM methacholine-induced 
contraction was not affected by GF 109203X (Fig. 5), indicating a specific effect of 
methacholine-induced PKC activation on the β-adrenoceptor system. Chapter 2 
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Discussion 
Stimulation of muscarinic M3-receptors and histaminic H1-receptors in bovine, human and 
canine tracheal smooth muscle activate phospholipase C (PLC), producing a rapid and 
dose-related increase of inositol phosphates including inositol 1,4,5-trisphosphate (IP3) 
[5,8,9,23-26]. The formation of IP3 is accompanied by a parallel increase in sn-1,2-
diacylglycerol (DAG)  [13]. It has been reported that activation and translocation of PKC 
by DAG and Ca
2+ is involved in the tonic phase of smooth muscle contraction [27,28]. 
Thus, concentration-dependent methacholine-induced contraction of bovine tracheal 
smooth muscle is correlated with the translocation of PKC from the cytosol to the plasma 
membrane [28]. Furthermore, in human airway smooth muscle PKC is involved in the 
sustained phase of histamine-induced contraction [6]. Overall, these data indicate that 
methacholine- and histamine-induced inositol phosphates production, over a wide 
concentration-range, is paralleled by the increase in DAG, resulting in the activation of 
PKC. 
Using the specific PKC inhibitor GF 109203X, we found that the cumulative concentration-
contraction curve of methacholine in bovine tracheal smooth muscle strips slightly but 
significantly shifted to the right, with no changes in maximal effect (Fig. 1), whereas for 
histamine also a significant decrease in maximal effect in the presence of GF 109203X was 
observed. This reduced contraction confirms that PKC-activation by DAG is implicated in 
the tonic phase of the contraction and that PKC exerts a feedforward control of agonist-
induced Ca
2+ mobilisation and influx [29], the more pronounced attenuation of the 
histamine-induced response by GF 109203X being in line with the lower phosphoinositide 
metabolism seen with this agonist [5,12]. In addition, we found that at increasing 
concentrations of the contractile agonists, the isoprenaline-induced relaxation was gradually 
Figure 5  (-)-Isoprenaline- and forskolin-
induced relaxation of bovine tracheal smooth
muscle strips following contraction by 1 μM
methacholine in the absence and presence of
10  μM GF 109203X, with readjustment of
smooth muscle tone (see Methods). Results
are means ± S.E.M. of 4-14 experiments each
performed in duplicate. 
  Modulation of β-adrenoceptor function by PKC 
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reduced (Fig. 2A and 2B). Similar findings were shown in other studies, using human [10] 
and animal [7,12,13] airway smooth muscle. Remarkably, in the presence of increasing 
concentrations of methacholine, in contrast to histamine, not only the potency (pD2) of 
isoprenaline but also the maximal relaxation was gradually reduced. Again, this is in line 
with the markedly higher inositol phosphates responses of bovine tracheal smooth muscle 
seen with methacholine compared to histamine, at all concentrations used [12]. The 
resulting Ca
2+-mobilization and -influx induced by methacholine have shown to be less 
susceptible towards cAMP elevation indeed [5].  Interestingly, in human bronchial smooth 
muscle, showing similar inositol phosphates responses with histamine and methacholine, 
very similar correlations between inositol phosphates production induced by various 
concentrations of the two agonists and the reduction of isoprenaline pD2 and Emax values 
were found [10].  
In addition to cAMP-induced PKA mediated inhibition of the Ca
2+-responses [5], direct 
interference by phosphoinositide metabolism of β2-adrenoceptor function through DAG-
induced PKC activation may also play an important role. It has been demonstrated that 
PKC may desensitise β-adrenoceptors, presumably via phosphorylation of the β-
adrenoceptor and/or Gs-protein [30]. Thus, phorbol-ester-induced PKC activation attenuates 
β-adrenoceptor function in human lymphocytes because of uncoupling of the receptor from 
the Gs-protein [31]. In the present study we found a significant increase in sensitivity to 
isoprenaline when PKC was inhibited by GF 109203X, with bovine tracheal smooth muscle 
strips precontracted with methacholine and histamine (Fig. 2). Although methacholine- and 
histamine-induced contractions were reduced by GF 109203X to some extent, the enhanced 
responsiveness to the β-agonist could only partially be explained by the reduced smooth 
muscle tone. When the reduced contractile tone in the presence of GF 109203X was 
carefully compensated for by additional agonist administration to reach the same 
contraction levels compared to controls (Fig. 4; Table 2), still significantly enhanced pD2 
values were obtained, both for methacholine and histamine. In addition, at all histamine-
evoked contraction levels, in the absence and presence of GF 109203X, maximal relaxation 
by isoprenaline was achieved, whereas with  methacholine the Emax values for isoprenaline 
were consistently enhanced in the presence of GF 109203X.  This enhancement increased 
with increasing levels of contraction, supporting the idea that β-adrenoceptor function 
worsens in parallel with increasing DAG-induced PKC activation. Remarkably, in contrast 
to isoprenaline, forskolin-induced relaxation of preparations precontracted by methacholine 
was not affected at all by GF 109203X (Fig. 5), strongly suggesting that uncoupling of the 
β-adrenoceptor from Gs by PKC-induced phosphorylation of the receptor- and/or the Gs-
protein is indeed involved. In line with these results, it has been recently demonstrated in 
rat oesophagus smooth muscle that the PKA-dependent but β-adrenoceptor-independent 
relaxation by IBMX (3-isobutyl-1-methyl-xanthine) is not modulated by 10 μM 
GF109203X either [32]. These findings demonstrate that in intact airway and oesophagus 
smooth muscle PKA-activity is not inhibited by 10 μM GF 109203X. 
In conclusion, using the specific PKC inhibitor GF 109203X, we found direct evidence for 
the involvement of PKC in the acute functional antagonism of contractile agonist-induced Chapter 2 
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bovine airway smooth muscle contraction by β-adrenoceptor agonists.  Since PKC, via 
receptor-mediated phosphoinositide metabolism, is activated by many mediators and 
neurotransmitters in airway inflammation, this could lead to reduced airway smooth muscle 
responsiveness toward β-adrenoceptor agonists in asthma. Therefore, this cross-talk may be 
of considerable importance in the reduced bronchodilator response of  patients with severe 
asthma. 
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Summary 
Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 
1 and 10 μM) of fenoterol decreased isoprenaline-induced maximal relaxation (Emax) of 
methacholine-contracted preparations in a concentration dependent fashion, indicating 
desensitization of the β2-adrenoceptor. Preincubation with 1 μM of the protein kinase C 
(PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant 
decrease in isoprenaline-induced Emax, indicating activated PKC-mediated heterologous β2-
adrenoceptor desensitization. To investigate the capacity of activated PKC to regulate 
homologous desensitization, we incubated the smooth muscle strips with the combination 
of both 1 μM PMA and 1 μM fenoterol. This combined treatment synergistically decreased 
the isoprenaline-induced maximal relaxation, as compared to the individual effects of PMA 
and fenoterol alone, indicating a common pathway for heterologous and homologous 
desensitization. Moreover, the specific PKC- inhibitor 2-[1-(3-dimethylaminopropyl)-1H-
indol-3-yl]-3-(1H-indol-3-yl) maleimide (GF 109203X) markedly increased the potency 
and Emax of isoprenaline for all conditions used, including control conditions, and the 
synergistic effects of PMA and fenoterol were completely prevented. In conclusion, the 
present study demonstrates that homologous desensitization of the β2-adrenergic receptor 
can be enhanced by PKC activation. For the first time we have provided evidence that this 
concept is functionally operative in airway smooth muscle, and it may explain the reduced 
bronchodilator response to β2-adrenoceptor agonists in patients with asthma during a severe 
exacerbation. 
 
Introduction 
Inhaled β2-adrenoceptor agonists are by far the most effective bronchodilators used for the 
relief of symptoms in patients with asthma [1]. However, it has been shown that chronic β-
agonist therapy can diminish the efficacy of these drugs [2,3] and it is well known that 
patients with asthma have a reduced bronchodilator response to β-agonists during a severe 
exacerbation [4,5]. Possible mechanisms, which could account for these effects, are the 
development of homologous and/or heterologous desensitization of the β2-adrenoceptor. 
Various roles for intracellular kinases, such as G protein-coupled receptor kinases (GRKs), 
protein kinase A (PKA) and protein kinase C (PKC) have been described in modulating the 
function of the β2-adrenoceptor.  
Homologous desensitization of the β2-adrenoceptor is characterized by a rapid loss in 
agonist-stimulated cAMP generation, primarily mediated by GRKs, which recognise the 
agonist-occupied form of the receptor, and involves phosphorylation of the receptor. Such 
phosphorylation results in the binding of β-arrestin which prevents coupling of the receptor 
to its stimulatory G  protein (Gs), subsequently followed by sequestration and/or 
downregulation of the receptor [6,7].  
Heterologous desensitization is initiated by second messenger dependent kinases such as 
PKA and PKC. Cyclic AMP-activated PKA can phosphorylate the β2-adrenoceptor, thereby PKC potentiates homologous desensitization of the β2-adrenoceptor 
 
83
causing uncoupling of the receptor from its Gs protein, which results in a diminished 
adenylyl cyclase response [6]. Agents which activate PKC, such as muscarinic agonists and 
phorbol esters, have also been shown to attenuate responses to β-agonists [8], presumably 
by phosphorylation of the β2-adrenoceptor and subsequent uncoupling from Gs [9]. 
Recently, we have presented direct functional evidence for the involvement of PKC in the 
cross-talk between the muscarinic M3 receptor and β2-adrenoceptor in bovine tracheal 
smooth muscle [10] and rat oesophagus smooth muscle [11]. Heterologous desensitization 
does not promote β-arrestin binding to the receptor and subsequent rapid internalization 
[12,13].  
Interestingly, heterologous and homologous desensitization are not necessarily completely 
independent processes. Thus, it has been shown that PKC can mediate changes in the 
cellular expression and activity of GRKs [14]. PKC-mediated phosphorylation not only 
upregulates the activity of GRK2 [15] but also targets this kinase to the plasma membrane 
[16]. In addition, it has been suggested that PKA can induce β-arrestin1 expression [17,18] 
and PKA-mediated phosphorylation has been also shown to promote the translocation of 
GRK2 to the plasma membrane [19]. Little is known, however, about the functional 
consequences of these interactions. In this study, we present direct evidence for the capacity 
of PKC to regulate homologous β2-adrenoceptor desensitization in bovine tracheal smooth 
muscle, using the specific PKC activator phorbol 12-myristate 13-acetate (PMA) and a 
specific nonselective PKC inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-
indol-3-yl) maleimide (GF 109203X) [20].  GF 109203X inhibits all conventional (α, β1 
and β2) and novel (δ, ε and θ)  PKC isozymes present in bovine tracheal smooth muscle 
[21], and is 200-fold more selective in inhibiting PKC compared to PKA [20]. 
 
Materials and methods 
Tissue preparation 
Fresh bovine tracheas were obtained from the slaughterhouse and were transported to the 
laboratory within 30 min at room temperature in Krebs-Henseleit (KH) buffer of the 
following composition (nM): NaCl 177.5, KCl 5.6, MgSO4 1.2, CaCl2 2.5, NaH2PO4 1.3, 
NaHCO3 25.0, glucose 5.5, pregassed with 95% O2 and 5% CO2; pH 7.4. The tracheal 
smooth muscle was dissected carefully and smooth muscle strips (12x3 mm) were prepared 
free of mucosa and serosal connective tissue in KH buffer gassed with 95% O2/5% CO2 at 
room temperature. Subsequently, all strips were maintained overnight in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10 mM NaHCO3, 20 mM HEPES, 
100 U/ml penicillin, 100 μg/ml streptomycin and 10% fetal calf serum at 37°C (55 rpm). 
 
Experimental procedure 
After washing in several volumes of KH-buffer, gassed with 95% O2 and 5% CO2, pH 7.4 
at 37°C, the bovine tracheal smooth muscle strips were mounted in 20 ml organ baths 
containing gassed KH-buffer (37°C) for isotonic recording, using a preload of 500 mg. Chapter 3 
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After a 60 min equilibration period the strips were precontracted twice with cumulatively 
administered methacholine (0.1, 1, 10 and 0.1, 1, 10, 100 μM, respectively) with a 60 min 
washing period in between. After washing, basal tone was established with isoprenaline 
(0.1 μM), immediately followed by a 30 min washing period.  
After preincubation for 45 min in the absence or presence of 10 μM GF 109203X, smooth 
muscle strips were incubated with KH-buffer (35 min), 1 μM PMA (35 min), 0.1, 1 or 10 
μM fenoterol (30 min), or 1 μM PMA (35 min) plus 1 μM fenoterol (30 min), immediately 
followed by a thorough washing period of 45 min. In separate experiments it was found that 
this concentration of GF 109203X caused complete inhibition of 10 μM phorbol 12-
myristate 13-acetate (PMA)-induced contraction (data not shown). Subsequently, smooth 
muscle tone was raised with methacholine at 1 μM, which concentration was built up 
gradually in 3 concentration steps. Cumulative concentration-relaxation-curves were 
constructed using (-)-isoprenaline (0.1 nM – 100 μM), added in 0.5 log increments. At the 
end of each experiment the smooth muscle strips were washed twice and basal tone was re-
established with 10 and 100 μM isoprenaline. In all experiments, the reduction of 
methacholine-induced smooth muscle tone, as a consequence of the preincubation 
condition, was carefully compensated for by additional administration of small amounts of 
the contractile agonist, before isoprenaline relaxation curves were obtained. 
 
Data Analysis 
Responses were expressed as percentages of the response to 100 μM methacholine in the 
second precontraction in each experiment, with reference to basal tone as established at the 
end of each experiment. All data are presented as mean ± S.E.M. Curves were fitted using 
the logistic 4-parameter model (Sigmaplot 8.0). Statistical analysis was performed by 
means of the two-tailed Student’s t-test for paired or unpaired observations. P values < 0.05 
were considered statistically significant. 
 
Materials 
Dulbecco’s modification of Eagle’s Medium (DMEM), foetal bovine serum, NaHCO3 
solution (7.5%), penicillin/streptomycin solution (5000 U/ml
 ; 5000 μg/ml) and HEPES 
solution (1 M) were obtained from Gibco BRL Life Technologies. (Paisley, U.K.). 
Methacholine chloride, (-)-isoprenaline hydrochloride and PMA (phorbol 12-myristate 13-
acetate) were obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.), GF 109203X (2-
[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide) was purchased 
from Boehringer (Mannheim, Germany) and fenoterol hydrobromide was a generous gift 
from Boehringer-Ingelheim (Ingelheim, Germany) All other chemicals were of analytical 
grade. 
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Results 
Effect of fenoterol treatment on isoprenaline-induced relaxation  
In order to establish fenoterol-induced desensitization of the isoprenaline-induced 
relaxation of bovine tracheal smooth muscle, contracted by 1 μM methacholine, smooth 
muscle strips were preincubated with various concentrations of fenoterol for 30 min. (Table 
1). Both 1 and 10 μM fenoterol significantly reduced the maximal response (Emax) of the 
isoprenaline-induced relaxation from 71.4 ± 2.8% to 64.7 ± 4.2% (P<0.05) and 34.6 ± 2.9% 
(P<0.001), respectively (Fig. 1, Table 1), whereas 0.1 μM fenoterol was ineffective. In 
contrast, the potency (pD2) of isoprenaline to induce relaxation remained unchanged (Table 
1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Maximal effect (Emax) and potency (pD2) of  (-)-isoprenaline-induced relaxation of bovine tracheal 
smooth muscle contracted by 1 μM methacholine, after preincubation with vehicle (control) or 0.1, 1 and 10 μM 
fenoterol (Feno).  
Data represent means ± S.E.M. of 3-14 experiments, each performed in duplicate. Significantly different from 
control:  
a P<0.05; 
b P<0.001. 
  Preincubation  Emax (%)  pD2 (-log M) 
      
  Control  71.4 ± 2.8  6.1 ± 0.1 
  0.1 μM Feno  73.9 ± 5.1  6.0 ± 0.1 
     1 μM Feno  64.7 ± 4.2
a  6.3 ± 0.1 
   10 μM Feno  34.6 ± 2.9
b  5.9 ± 0.2 
 
Figure 1  (-)-Isoprenaline-induced relax-
ation of bovine tracheal smooth muscle
preparations precontracted by 1 μM
methacholine after preincubation with vehicle
(control) and 0.1, 1 or 10 μM fenoterol
(Feno). Results are means ± S.E.M. of 3-14
experiments, each performed in duplicate. 
 Chapter 3 
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Figure 2 (-)-Isoprenaline-induced relaxation of bovine tracheal smooth muscle preparations precontracted by 1 
μM methacholine after preincubation with vehicle (control) and 1 µM PMA (A) or with vehicle (control), 1μM 
fenoterol (Feno) and 1 μM PMA + 1 μM fenoterol (B) in the absence and presence of 10 μM GF 109203X. 
Results are means ± S.E.M. of 4-11 experiments, each performed in duplicate 
 
Effect of PMA treatment on isoprenaline-induced relaxation 
We also examined the effect of pretreatment with 1 μM PMA, an activator of PKC, on the 
isoprenaline-induced relaxation. Figure 2A shows a small but significant reduction of the 
isoprenaline-induced Emax from 71.2 ±3.2% to 64.2 ± 3.4% (P<0.05). No change was found 
in the pD2 value of isoprenaline (Table 2). 
 
 
Table 2. Maximal effect (Emax) and potency (pD2) of  (-)-isoprenaline-induced relaxation of bovine tracheal 
smooth muscle contracted by 1 μM methacholine, in the absence (n = 11) and presence (n = 4) of 10 μM GF 
109203X (GF) and after preincubation with vehicle (control), 1 μM PMA,  1 μM fenoterol (Feno) or 1 μM PMA + 
1 μM fenoterol.  
Data represent means ± S.E.M. of 4-11 experiments, each performed in duplicate. ( 
a P<0.05; 
b P<0.001 compared 
to Control, 
c P<0.05; 
d P<0.01; 
e P<0.001 compared to the absence of GF 109203X) 
     -  GF  +  GF  
  Preincubation     Emax (%)  pD2 (-log M)  Emax (%)  pD2 (-log M)   
              
  Control   71.2 ± 3.2  6.1 ± 0.1  85.6 ± 4.1
 c  7.7 ± 0.2
 e   
  1 μM PMA    64.2 ± 3.4
 a  6.4 ± 0.2  85.3 ± 5.9
 d  7.5 ± 0.3
 d   
  1 μM Feno    64.7 ± 4.2
 a  6.3 ± 0.1  88.2 ± 1.6
 d  7.2 ± 0.1
 a,d    
  1 μM PMA + 1 μM Feno    48.0 ± 4.4
 b  6.1 ± 0.1  83.8 ± 2.4
 e  7.0 ± 0.2
 a,d   
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Effect of the combination of PMA and fenoterol on isoprenaline-induced relaxation in the 
absence and presence of GF 109203X 
In Figure 2B it is shown that combined pretreatment of PMA (1 μM) and fenoterol (1 μM) 
caused a significant potentiation of the desensitization of isoprenaline-induced relaxation 
by fenoterol (Fig. 2B) or PMA (Fig. 2A) alone. The decrease in Emax for the combined 
treatment was significantly (P<0.05) different from the sum of the individual effects of 
fenoterol and PMA preincubation (Table 2). Again, the potency of isoprenaline was not 
significantly changed.  
In the presence of GF 109203X, isoprenaline-induced relaxation was potentiated for all 
conditions studied, as visualised by the marked left shifts of the concentration-relaxation-
curves of isoprenaline and the enhancement of Emax (Figs 2A, B). Both Emax and pD2 values 
were significantly increased compared to their respective controls in the absence of GF 
109203X (Table 2). Interestingly, after pretreatment of 1 μM fenoterol with or without 1 
μM PMA, the potency of isoprenaline in the presence of GF 109203X was significantly 
decreased (Fig. 2B, Table 2), whereas after pre-treatment with 1 μM PMA alone the 
concentration-relaxation-curve of isoprenaline in the presence of GF 109203X was 
identical to the control (non-PMA-pretreated) curve (Fig. 2A, Table 2). 
 
Discussion 
The present study has established that activation of PKC by PMA causes a marked 
aggravation of β2-agonist-induced β2-adrenoceptor desensitization. Preincubation of bovine 
tracheal smooth muscle with 1 μM fenoterol for 30 minutes caused a small but significant 
decrease of the isoprenaline-induced maximal relaxation of the methacholine-induced 
contraction, whereas no effect was found on the potency of isoprenaline. With 10 μM 
fenoterol the Emax of isoprenaline was markedly reduced, indicating a concentration-
dependent desensitization of the β2-adrenoceptor. Both PKA- and GRK-mediated 
phosphorylation of the β2-adrenoceptor could account for this effect. For isoprenaline, it 
has been established that at low receptor occupancy (agonist concentration <10 nM) the 
PKA pathway is selectively activated [22], whereas with higher agonist concentrations (>50 
nM), GRK-induced desensitization is quantitatively more important [23-25]. This would 
imply that at both concentrations used, fenoterol caused a desensitization of the β2 
adrenoceptor with a substantial GRK-mediated contribution. To date seven members of the 
GRK family have been identified, but only GRK2 (βARK 1), GRK3 (βARK 2) and GRK5 
appear to be involved in agonist-induced β2-adrenoceptor phosphorylation [26-28]. To 
investigate a putative contribution of PKC-activation in this homologous desensitization by 
GRKs, we considered 1 μM fenoterol to be most appropriate, as the desensitization induced 
by this concentration was only small. Moreover, in separate experiments we found that this 
concentration of fenoterol causes a submaximal (85.7% ± 2.0) relaxation of 1 μM 
methacholine-induced tone (data not shown), indicating that this concentration is relevant 
with regard to the relief of bronchoconstriction in severe asthma. Chapter 3 
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Exposure of bovine tracheal smooth muscle to 1 μM PMA for 35 minutes caused a small 
but significant decrease in isoprenaline-induced maximal relaxation, with no effect on the 
pD2. Activated PKC is most likely responsible for this heterologous desensitization, as it 
has been demonstrated in various cells and tissues that activation of PKC via agonist-
induced PI metabolism or phorbol esters may lead to uncoupling of the β-adrenoceptor, 
presumably as a result of phosphorylation of the receptor and/or Gs [8,29-35]. In addition, 
we have recently demonstrated the functional relevance of this receptor cross-talk in bovine 
tracheal smooth muscle by the marked potentiation of β-agonist-induced relaxation of 
cholinergic smooth muscle tone in the presence of the specific PKC inhibitor GF 109203X 
[10]. To investigate the capacity of activated PKC to regulate homologous desensitization, 
we incubated the bovine tracheal smooth muscle preparations with the combination of both 
1 μM PMA and 1 μM fenoterol.  This combined treatment synergistically attenuated the 
isoprenaline-induced maximal relaxation, as compared to the individual effects of PMA and 
fenoterol, indicating a common pathway for heterologous and homologous desensitization 
in bovine tracheal smooth muscle. Although in Chinese hamster ovary cells, coexpressing 
the M3-muscarinic and β2-adrenoceptor, activation of the PLC pathway appeared to have no 
effect on homologous β2-adrenoceptor desensitization [35], it has been shown in 
mononuclear leukocytes that activated PKC not only increased the expression of GRK2 
[14], but also increased its phosphorylation and activation, resulting in an enhanced 
homologous desensitization of the β2-adrenoceptor. Thus, pretreatment of mononuclear 
leukocytes with 1 μM PMA significantly potentiated the degree of homologous 
desensitization induced by the incubation of 10 μM isoprenaline for 5 minutes [15]. Our 
results are in agreement with these findings. Moreover, we have found that GF 109203X 
markedly increased the potency and maximal relaxation of isoprenaline for all conditions 
used, including control conditions. As expected, the 1 μM PMA- induced desensitization, 
due to PKC-mediated phosphorylation of the β2-adrenoceptor and/or Gs, was completely 
prevented in the presence of GF 109203X, the two concentration-relaxation-curves of 
isoprenaline becoming superimposed (Fig. 2A). In contrast, the fenoterol-induced 
homologous desensitization as well as the synergistic effects of PMA and fenoterol were 
incompletely prevented, the positions of the two concentration-relaxation-curves in the 
presence of GF 109203X being significantly right from the corresponding control curve 
(Fig. 2B, Table 2). These findings indicate that part of the GRK-mediated desensitization 
induced by fenoterol, alone or in combination with PMA, is not susceptible to potentiation 
by PKC. It is also possible, however, that this PKC-insensitive component represents the 
PKA-mediated desensitization. Interestingly, PKA-mediated phosphorylation of GRK2, 
enhancing  β2-adrenoceptor phosphorylation and desensitization, was recently found in 
HEK 293 cells [19]. This opens the fascinating possibility that both PKC and PKA are able 
to potentiate desensitization by phosphorylation of GRKs.  
In conclusion, the present study not only confirms our previous findings, showing that PKC 
is directly involved in the acute functional cross-talk between the muscarinic M3 receptor 
and  β2-adrenoceptor in bovine tracheal smooth muscle [10], but also that homologous 
desensitization of the β2-adrenoceptor can be enhanced by PKC-activation, presumably by PKC potentiates homologous desensitization of the β2-adrenoceptor 
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phosphorylation and activation of GRKs, indicating that the efficacy of homologous 
desensitization indeed can be modulated heterologously. For the first time we have 
provided evidence that this concept is functionally operative in airway smooth muscle. It 
may be of great functional importance for the development of a reduced bronchodilator 
response in patients with severe asthma. Thus, various inflammatory mediators and 
neurotransmitters released during a severe exacerbation are known to cause activation of 
PKC in airway smooth muscle cells [36]. Prolonged inhalation of β2-agonists during such 
an exacerbation may therefore lead to aggravation of the homologous β2-agonist-induced 
desensitization due to the mediator- and neurotransmitter-induced activation of PKC, 
causing further activation of GRKs.  
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Summary 
It has been shown that patients with asthma have a reduced bronchodilator response to β-
agonists during a severe exacerbation and that chronic β-agonist therapy can diminish the 
efficacy of these drugs.  In the present study, we considered the possibility that a novel 
form of transductional cross-talk, in which contractile agonist-induced protein kinase C 
(PKC) activation enhances homologous β-agonist-induced desensitization, could contribute 
to these effects. In isolated bovine tracheal smooth muscle cells we investigated the effect 
of the specific PKC inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-
yl) maleimide (GF 109203X) on isoprenaline-mediated inhibition of methacholine-induced 
extracellular Ca
2+-influx, using the fluorescent dye Fura-2/AM. Single concentrations of 
isoprenaline (1 nM - 10 μM) were administered on the methacholine (100 μM)-induced 
Ca
2+-plateau at t = 150 or 340 seconds after methacholine. 
Isoprenaline caused a rapid and transient inhibition of the methacholine-induced Ca
2+-
influx at all concentrations of the β-agonist, indicating rapid desensitization of this 
response. This β2-adrenoceptor desensitization was markedly reduced in the presence of GF 
109203X, indicating that methacholine-induced activation of PKC was importantly 
involved.GF 109203X had no significant effect on the isoprenaline-induced peak-inhibition 
of Ca
2+-influx and no differences were found between the two different application times of 
isoprenaline (t = 150 or 340 seconds), suggesting that direct heterologous desensitization of 
the  β2-adrenoceptor induced by PKC was not involved in the short lasting effect of 
isoprenaline.  
The results indicate that acute β-agonist-induced homologous desensitization of the β2-
adrenoceptor in bovine tracheal smooth muscle cells is markedly amplified by muscarinic 
agonist-induced PKC activation. 
 
Introduction 
Inhaled β2-adrenergic agonists are by far the most effective bronchodilators used to control 
airway function in patients with asthma [1-3]. The efficacy of these drugs is mainly due to 
functional antagonism, counteracting the bronchoconstrictor effects of neurotransmitters 
and mediators released in airway inflammation [4]. However, it is well known that patients 
with asthma have a reduced bronchodilator response to β-agonists during a severe 
exacerbation [5,6]. Moreover, it has been shown that chronic β-agonist therapy can 
diminish the efficacy of these drugs [7,8], resulting in a loss of bronchoprotection against 
contractile stimuli and allergens [9]. 
Several protein kinases, including G protein-coupled receptor kinases (GRKs), protein 
kinase A (PKA) and protein kinase C (PKC) have been implicated in modulating β2-
adrenoceptor function. Homologous desensitization of the β2-adrenoceptor is mediated by 
activation of GRKs. GRKs phosphorylate the agonist-occupied form of the receptor, after 
translocation to the plasma membrane by anchoring to free Gβγ subunits generated upon 
receptor activation. This  results in binding of β-arrestins and subsequent uncoupling of the PKC potentiates β-agonist induced desensitization 
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receptor from its stimulatory G protein (Gs), which is followed by sequestration and/or 
downregulation of the receptor [10,11]. The GRK family consists of seven isoforms that 
share a number of structural and functional similarities and GRKs 1-6 have been shown to 
phosphorylate the β2-adrenoceptor in its C-terminal cytoplasmatic tail [12,13].  
Another possible mechanism of reduced β2-adrenoceptor function is heterologous 
desensitization, which may be induced by PKC and PKA. Agents which activate PKC, 
including muscarinic agonists and phorbol esters, have been shown to attenuate β-agonist-
induced cAMP accumulation in airway smooth muscle slices [14], presumably involving 
phosphorylation of the third intracellular loop of the β2-adrenoceptor and subsequent 
uncoupling from Gs [15]. Recently, we have presented direct functional evidence for the 
involvement of PKC in the cross-talk between muscarinic M3 receptor stimulation and β2-
adrenoceptor-induced relaxation in bovine tracheal smooth muscle [16] and rat oesophagus 
smooth muscle [17]. PKA, which is activated by agents that increase intracellular cAMP 
levels, has also been identified as an important mediator of heterologous desensitization by 
phosphorylating the β2-adrenoceptor in the third intracellular loop [10,18,19].  
Interestingly, some studies have indicated that homologous and heterologous 
desensitization are not completely independent processes. Thus, in mononuclear 
leukocytes, it has been shown that activation of PKA and PKC can induce changes in the 
cellular expression and activity of GRKs and β-arrestins [20]. Moreover, it has been 
demonstrated that PKC-induced phosphorylation increased the activity of GRK2 by 
targeting the kinase to the plasma membrane [21]. Importantly, this novel form of cross-talk 
could contribute to the reduced bronchodilator response to β-agonists in patients with 
asthma during a severe exacerbation. We have recently demonstrated that PKC-activation 
by the phorbol ester PMA (phorbol 12-myristate 13-acetate) indeed enhances β-agonist-
induced desensitization of bovine tracheal smooth muscle relaxation by isoprenaline [22]. 
In the present study we explored this concept into further detail at the level of intracellular 
Ca
2+-homeostasis in enzymatically dispersed bovine tracheal smooth muscle cells. 
Investigating the effect of the specific PKC-inhibitor GF 109203X on the inhibition by 
isoprenaline of methacholine-induced Ca
2+-influx, the present study revealed that the acute 
homologous  β2-adrenoceptor desensitization is being amplified heterologously by PKC. 
Therefore, this finding may represent a novel target for therapeutic strategy in patients with 
asthma. 
 
Materials and methods 
Tissue preparation 
Fresh bovine tracheas were obtained from the slaughterhouse and were transported to the 
laboratory within 30 min at room temperature in Krebs-Henseleit (KH) buffer of the 
following composition (nM): NaCl 177.5, KCl 5.6, MgSO4 1.2, CaCl2 2.5, NaH2PO4 1.3, 
NaHCO3 25.0, glucose 5.5, pregassed with 95% O2 and 5% CO2; pH 7.4. The tracheal 
smooth muscle was dissected carefully and prepared free of mucosa and serosal connective Chapter 4 
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tissue in KH buffer gassed with 95% O2/5% CO2  at room temperature. Subsequently, the 
tracheal smooth muscle was chopped, using a McIlwain tissue chopper, two times at the 
size of 300 μm and three times at 100 μm. Tissue fragments were washed under sterile 
conditions (three times) and maintained overnight in Dulbecco’s modified Eagle’s medium 
(DMEM; 2.5 mg/ml) supplemented with 10 mM NaHCO3, 20 mM HEPES, 100 U/ml
 
penicillin, 100 μg/ml streptomycin and 10% fetal bovine serum (FBS) at 37° (55 rpm). 
 
Isolation of tracheal smooth muscle cells 
Tissue fragments were washed three times in Krebs-Ringer-Henseleit (KRH) buffer 
containing (mM); NaCl 125.0, KCL 6.0, MgCl2 2.5, CaCl2 1.2, NaH2PO4 1.2, NaHCO3 
25.0, glucose 11.0, HEPES 25.0, pH 7.4, supplemented with 2.0 mM (±)-dithiothreitol 
(DTT) and were then resuspended in a digestion mixture of  collagenase P (0.75 mg/ml), 
papain (1 mg/ml) and trypsin inhibitor (1 mg/ml) in KRH buffer. The suspension was 
incubated for 20 min at 37°C (55 rpm) and then gently dispersed with a wide-bored pipette. 
After another 10 min of incubation at 37°C (70 rpm), the suspension was gently dispersed 
again and filtered over a 50 μm gauze and the cells were collected by centrifugation 
(1000g, 10 min). The isolated cells were washed three times with KRH, pH 7.4, 
supplemented with 2 mg ml
-1 fetal bovine serum (KRH/FBS) and were allowed to 
regenerate for 1h at 37°C (55 rpm). Subsequently, the cells were incubated with the 
fluorescent dye, Fura-2/AM (3 μM) for 30 min at 37°C (55 rpm). The loaded cells were 
washed three times in KRH/FBS and resuspended to a density of 1 x 10
6 cells/ml. The cells 
were kept at room temperature on a Rock-N-Roller (Breda Scientific, The Netherlands) and 
used within 2-4 h, during which they remained viable and responsive. 
 
Intracellular Ca
2+ measurements 
Fura-2 fluorescence of the cells (excitation wavelengths: 340 and 380 nm; emission 
wavelength: 510 nm) was measured at 37°C with a Perkin Elmer Spectrometer (LS-50B). 
Each cuvet contained 2 ml of magnetically stirred cell suspension. In all experiments, Ca
2+-
influx and -mobilisation was induced by 100 μM methacholine, added at t = 0 s. To 
establish the inhibitory effect of isoprenaline on Ca
2+-influx, single doses of isoprenaline (1 
nM – 10 μM) were administered on the methacholine-induced sustained rise in intracellular 
Ca
2+ concentration (Ca
2+-plateau) at t = 150 or 340 s. When used, GF109203X (10 μM) was 
added 45 min prior to the methacholine administration. The intracellular Ca
2+-concentration 
([Ca
2+]i) was calculated every 0.2 s according to Grynkiewicz [23]. At the end of the 
experiment, the maximal fluorescence ratio (Rmax) was determined after adding 0.01% of 
Triton-X-100 as a permeabilizing agent. The minimal fluorescence ratio (Rmin) was 
determined by addition of 5 mM EGTA to the permeabilized cells. 
 PKC potentiates β-agonist induced desensitization 
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Data analysis 
The methacholine-induced transient rise of [Ca
2+]i, representing Ca
2+-mobilisation from 
internal stores, was expressed as the maximal increase of [Ca
2+]i above basal after the 
addition of  methacholine. The plateau level of [Ca
2+]i, representing Ca
2+-influx, was 
expressed as the value obtained 2 min after contractile agonist addition.  
The acute inhibitory effect of isoprenaline was expressed as the peak-inhibition of [Ca
2+]-
influx immediately after the administration of isoprenaline. The inhibitory effect of   
isoprenaline on the methacholine-induced Ca
2+-plateau was also expressed as the area 
under the [Ca
2+]i-time curve above basal during 190 s after the addition of isoprenaline 
(AUC150-340 and AUC340-530), calculated by trapezoid integration over 0.2 s periods, 
compared to control in the absence of the β-agonist. Due to isoprenaline-induced 
desensitization, this inhibition was time-dependently reversed. The rate of this Ca
2+-influx 
reversal was expressed as its maximal slope. All data are presented as means ± S.E.M. 
Statistical analysis was performed by means of the two-tailed Student’s t-test for paired 
observations. P values < 0.05 were considered statistically significant. 
 
Materials 
Dulbecco’s modification of Eagle’s Medium (DMEM), NaHCO3  solution (7.5%), 
penicillin/streptomycin solution (5000 U/ml
 ; 5000 μg/ml) and HEPES solution (1 M) were 
obtained from Gibco BRL Life Technologies (Paisley, U.K.). Fetal bovine serum (FBS), 
dithiothreitol (DTT), trypsin inhibitor (type II-S), Fura-2/AM, methacholine chloride and (-
)-isoprenaline hydrochloride were obtained from Sigma Chemical Co. (St. Louis, MO, 
U.S.A.) and GF 109203X (2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) 
maleimide), papain and Collagenase P were purchased from Boehringer (Mannheim, 
Germany). All other chemicals were of analytical grade. 
 
Results 
Figure 1a shows a typical intracellular Ca
2+-response in bovine tracheal smooth muscle 
cells to 100 μM methacholine, characterised by a transient-rise in [Ca
2+]i, followed by a 
sustained plateau level of [Ca
2+]i. As is also demonstrated in this figure, 10 μM isoprenaline 
caused a rapid but short-lasting inhibition of the methacholine-induced Ca
2+-plateau, which 
was almost fully reversed at t = 340 s, i.e. 190 s after β-agonist administration, indicating a 
rapid desensitization of the isoprenaline-induced response.  
In the presence of GF 109203X, basal Ca
2+ level as well as the methacholine-induced 
transient and the sustained rise in [Ca
2+]i were slightly inhibited (Fig. 1b and 2). 
Remarkably, the isoprenaline-induced inhibition of [Ca
2+]i-influx was only partially 
reversed at t = 340 s in the presence of the PKC-inhibitor (Fig. 1b), indicating that GF 
109203X reduced the rate of Ca
2+-recovery after the administration of the β-agonist. 
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Figure 1 Typical intracellular Ca
2+-responses in bovine tracheal smooth muscle cells, showing the effect of 10 
μM (-)-isoprenaline (Iso) on 100 μM methacholine (MCh)-induced Ca
2+-plateau in the absence (a) and presence 
(b) of 10 μM GF 109203X. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using the AUC150-340 as a parameter, it is demonstrated in Figure 3 that isoprenaline dose-
dependently inhibited the methacholine-induced Ca
2+-plateau, which was significantly 
potentiated by GF 109203X. Maximal (Emax) values of isoprenaline-induced inhibition of 
Figure 2 Effect of 10 μM GF 109203X on
basal Ca
2+-level (A) and the 100 μM
methacholine-induced peak-rise in Ca
2+ (B)
and subsequent Ca
2+-plateau (C) in bovine
tracheal smooth muscle cells. Results are
means  ± S.E.M. of 6 experiments.
Significantly different from control:  
* P<0.05; ** P<0.01 PKC potentiates β-agonist induced desensitization 
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Ca
2+-influx in the absence and presence of GF 109203X were 34.5 ± 7.6% and 66.3 ± 
5.0%, respectively (P = 0.02). No differences were found in the potency of isoprenaline 
(pEC50 values of 7.8 ± 0.4 and 7.6 ± 0.3 in the absence and presence of GF 109203X, 
respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The difference in Emax of the isoprenaline-induced inhibition of Ca
2+-influx, using the 
AUC150-340 as a parameter, may well be explained by the different recovery rates of this 
inhibition in the absence and presence of GF 109203X. Figure 4 shows that, after an initial 
rise at 10 nM, compared to 1 nM isoprenaline, the rate of recovery decreased dose-
dependently, both in the presence as well as in the absence of GF 109203X. For all 
isoprenaline concentrations used, GF 109203X significantly reduced this rate of recovery 
compared to control, resulting in a beneficial effect on the isoprenaline-induced inhibition 
of [Ca
2+]i-influx. Interestingly,  from 10 nM isoprenaline on, the fractional reduction by GF 
109203X on the rate of recovery increased with higher concentrations of the β-agonist.  
We also investigated the effect of GF 109203X on the maximal inhibition of the Ca
2+-
influx, immediately after administration of the β-agonist (Fig. 5). This effect was 
concentration-dependent and maximal at 10
-7 M isoprenaline. Interestingly, GF 109203X 
had only a minor effect on this peak-inhibition; Emax values in the absence and presence of 
GF 109203X were not significantly different (85.5 ± 4.5 and 101.6 ± 5.9, respectively; P = 
0.09). No significant differences were found in the potency of isoprenaline (pEC50  values 
of 8.7 ± 0.2 and 8.5 ± 0.1 in the absence and presence of GF 109203X, respectively). 
 
Figure 3 Effect of (-)-isoprenaline on 100
μM methacholine-induced Ca
2+-plateau,
measured as AUC150-340, compared to control,
in the absence (open symbols) and presence
(closed symbols) of 10 μM GF 109203X in
bovine tracheal smooth muscle cells. Results
are means ± S.E.M. of 6 experiments. Chapter 4 
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To assess the role of methacholine-induced PKC activation in heterologous desensitization 
of the β2-adrenoceptor, independent of its effect on the acute β-agonist induced 
desensitization, we compared two different application times of isoprenaline. If a direct 
interaction of activated PKC with the β2-adrenoceptor would be responsible for the 
observed desensitization of the isoprenaline-induced inhibition of Ca
2+-influx, this would 
imply that isoprenaline could hardly or not be able to exert an effect anymore when added 
at 340 s instead of at 150 s.  
Figure 4 Effect of 10 μM GF 109203X on
the recovery of isoprenaline-induced Ca
2+-
influx inhibition. The rate of [Ca
2+]i-recovery
(nM/s) was expressed as its maximal slope.
Results are means ± S.E.M. of 6 experiments.
Significantly different from control: * P<0.05;
** P<0.01; *** P<0.001 
Figure 5 Effect of (-)-isoprenaline on 100
μM methacholine-induced Ca
2+-plateau,
measured as maximal inhibition of [Ca
2+]i
immediately after administration of the β-
agonist, in the absence (open symbols) and
presence (closed symbols) of 10 μM GF
109203X. Results are means ± S.E.M. of 6
experiments. PKC potentiates β-agonist induced desensitization 
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Figure 6 Typical intracellular Ca
2+-responses, showing the effects of 10 μM (-)-isoprenaline added at t = 150 s 
(a) or 340 s (b) on 100 μM methacholine-induced Ca
2+-plateau, in the absence (upper panels) and presence (lower 
panels) of 10 μM GF 109203X. 
 
Typical Ca
2+-responses, showing the effects of 10 μM isoprenaline added at t = 150 s and 
340 s on the methacholine-induced Ca
2+-plateau, as presented in Figure 6, show identical 
peak-inhibition at the two time points, irrespective of the presence of GF109203X. Using 
the AUC150-340 and AUC340-530, we also found almost identical effects of isoprenaline, both 
in the presence and absence of GF 109203X (Fig. 7). Similar results were obtained for 1 
and 10 μM isoprenaline (Fig. 7). Moreover, no differences were found in the immediate 
inhibitory effects of isoprenaline (1 and 10 μM) at t = 150 s and t = 340 s (not shown). 
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Discussion  
The present study indicates that muscarinic agonist-induced PKC activation markedly 
contributes to β-agonist induced β2-adrenoceptor desensitization in bovine tracheal smooth 
muscle cells. Thus, it was shown that isoprenaline caused a transient inhibition of the 
methacholine-induced Ca
2+-influx, indicating a rapid agonist-induced desensitization of this 
response. This β2-adrenoceptor desensitization was markedly attenuated in the presence of 
the PKC-inhibitor GF 109203X, indicating major involvement of methacholine-induced 
activation of PKC, following phosphoinositide metabolism and generation of 
diacylglycerol.  
The heterologous regulation of β-agonist induced desensitization by PKC might involve 
phosphorylation-induced activation of GRK2. Thus, in mononuclear leukocytes it has been 
found that PKC-dependent increase in GRK2 activity enhanced the isoprenaline-induced 
homologous β2-adrenoceptor desensitization [20]. In addition, it has been shown that GRK2 
activity indeed can be increased by PKC-induced phosphorylation, possibly by increasing 
the ability of GRK2 to bind to the plasma membrane [21,24] or by relieving tonic inhibition 
of GRK2 by calmodulin, allowing GRK2 to bind to the β-adrenoceptor [25]. Not only 
GRK2 but also GRK5 has been shown to be a substrate for PKC. However, in contrast to 
GRK2, PKC-induced phosphorylation of GRK5 strongly inhibits its activity [26], 
indicating that this mechanism is not involved in the observed PKC-induced potentiation of 
acute agonist-induced β2-adrenoceptor desensitization. However, irrespective of the 
GRK(s) involved, we very recently demonstrated that direct activation of PKC by the 
phorbol ester PMA potentiates the homologous β-agonist-induced desensitization of intact 
Figure 7 Effect of 1 μM (a) and
10 μM (b) (-)-isoprenaline added at
t = 150 or 340 s on 100 μM
methacholine-induced Ca
2+-plateau,
measured as AUC150-340 and
AUC340-530 , compared to control, in
the absence (open bars) and
presence (filled bars) of 10 μM GF
109203X. Results are means ±
S.E.M. of 4 separate experiments.
Significantly different from control:
* P<0.05; *** P<0.001. PKC potentiates β-agonist induced desensitization 
 
101
bovine tracheal smooth muscle relaxation by isoprenaline [22]. Presently it is unclear which 
PKC-isozyme is involved in the modulation of β2-adrenoceptor desensitization, since GF 
109203X inhibits all conventional (α, β1 and β2) and novel (δ, ε and θ)  PKC isozymes 
present in bovine tracheal smooth muscle [27].  
Remarkably, a possible direct heterologous effect of methacholine-induced PKC activation 
on β2-adrenoceptor function was only small or even absent at t = 150 s, as indicated by the 
minor effect of GF 109203X on the peak-inhibition of Ca
2+-influx immediately after the 
administration of isoprenaline, and by the equal levels of inhibition of Ca
2+-influx by 
isoprenaline at different time points after methacholine addition. In contrast, we have 
previously presented direct evidence for the involvement of PKC in the cross-talk between 
muscarinic M3 receptor stimulation and β2-adrenoceptor function, strongly diminishing β-
agonist-induced bovine tracheal smooth muscle relaxation [16]. However, these effects 
were observed after longer incubation times with methacholine, i.e. after establishment of 
tonic contraction. This strongly suggests that PKC-induced activation of GRK(s) is the 
main cause of the rapid β-adrenoceptor homologous desensitization and that this process 
precedes PKC-induced β2-adrenoceptor (and/or Gs) phosphorylation. 
From 10 nM isoprenaline on, the rate of Ca
2+-recovery decreased dose-dependently with 
higher concentrations of isoprenaline. Although GRK is particularly activated at high β-
agonist concentrations, the GRK-induced desensitization may be partially overruled by the 
efficacy of the agonist to increase cAMP accumulation inhibiting Ca
2+-influx. GF 109203X 
significantly inhibited the rate of recovery for all concentrations of isoprenaline used, which 
is fully in line with the observed effects of GF 109203X on the isoprenaline-induced 
inhibition of Ca
2+-influx, using the AUC150-340 as a parameter. Assuming that PKC enhances 
GRK-induced desensitization, this observation is in line with the fact that GRK-induced 
desensitization becomes quantitatively more important at higher concentrations of 
isoprenaline [13,18,28]. 
It was demonstrated that isoprenaline-induced desensitization was not fully reversed by GF 
109203X, indicating PKC-independent contribution of GRKs and/or PKA to the agonist-
induced desensitization. Notably, in previous studies in bovine tracheal and rat oesophagus 
smooth muscle it has been demonstrated that PKA-dependent, but β-adrenoceptor-
independent, relaxation induced by forskolin and  3-isobutyl-1-methyl-xanthine (IBMX) 
was not inhibited by 10 μM GF109203X [16,17], indicating that PKA-activity is not 
affected by the PKC inhibitor. As shown in Figures 1 and 2, GF 109203X slightly 
diminished both the methacholine-induced Ca
2+-transient and the Ca
2+-plateau, which is in 
agreement with previous observations indicating that methacholine-induced PKC activation 
may potentiate agonist-induced mobilization and influx of Ca
2+ in bovine tracheal smooth 
muscle cells [29]. This effect is relatively small at high concentrations of methacholine 
[29], hence all experiments were performed with 100 μM of the agonist.  
In conclusion, the present study was undertaken to explore the concept of heterologous 
regulation of homologous β2-adrenoceptor desensitization by contractile agonists in airway 
smooth muscle cells. The results indicated that methacholine-induced PKC-activity is 
markedly involved in the acute and rapid desensitization of the β-agonist-induced inhibition Chapter 4 
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of Ca
2+-influx in bovine tracheal smooth muscle. Since it was demonstrated that direct 
heterologous desensitization of the β2-adrenoceptor by PKC was hardly or not involved 
under the conditions used, muscarinic receptor-mediated PKC-activation may indeed 
potentiate the β-agonist-induced (homologous) desensitization, presumably by enhancing 
GRK activity. As many PKC-activating mediators and neurotransmitters are being released 
during an asthma exacerbation, the cross-talk between PKC and GRKs may be of great 
functional importance for the development of a β2-adrenoceptor dysfunction in patients 
with severe asthma, who are frequently using high doses of β-adrenergic drugs to relieve 
bronchoconstriction.  
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Summary 
Regular treatment of asthmatic patients with racemic β2-agonists may lead to increased 
airway reactivity, possibly by an adverse effect of the S-enantiomer on intracellular calcium 
homeostasis in airway smooth muscle. In this study, the effects of R- and S-salbutamol 
were investigated on methacholine- and histamine-induced Ca
2+-responses in bovine 
tracheal smooth muscle cell suspensions and adhered single cells. In cell suspension as well 
as in adhered single cells, no effect on basal intracellular calcium was found for both R- and 
S-salbutamol. In suspension, R- and S-salbutamol dose-dependently inhibited the 1 μM 
MCh-induced Ca
2+-transient to approximately 50%, with a 250 to 400-fold potency 
difference. Up to 10 μM, both R- and S-salbutamol did not inhibit the sustained phase of 
the Ca
2+-influx. In adhered single cells, 1 μM methacholine- and 10 μM histamine-induced 
Ca
2+-transient and -plateau were significantly inhibited by 10 μM R-salbutamol, whereas 
no effect was observed with 0.1 μM R-salbutamol or with S-salbutamol . 
The inhibitory effect of R-salbutamol on methacholine-induced Ca
2+ plateau was mainly 
due to inhibition of the amplitude of Ca
2+ oscillations, which occurred in most of the 
adhered single cells. Histamine-induced Ca
2+-responses of these cells were much more 
sensitive towards inhibition by 10 μM R-salbutamol than those induced by methacholine, 
as demonstrated by the marked inhibition of the Ca
2+-plateau in non-oscillating cells and by 
the complete absence of histamine-induced Ca
2+-oscillations in the presence of 10 μM R-
salbutamol. Overall, both in airway smooth muscle cell suspension and in adhered single 
cells S-salbutamol did not increase basal intracellular Ca
2+-levels and did not potentiate 
methacholine- and histamine-induced Ca
2+-responses. Therefore, the results provide no 
explanation for the observed adverse effects of racemic β2-adrenoceptor agonists in asthma. 
In single cell measurements R-salbutamol preferentially inhibits the contractile agonist-
induced Ca
2+-plateau by decreasing the amplitude of the Ca
2+-oscillations. In addition, there 
is a differential susceptibility to β-agonist-induced inhibition of the Ca
2+-transient and -
plateau, depending both on the cellular condition (attached vs non-attached) and on the 
contractile agonist used. 
 
Introduction  
Regular treatment of asthmatic patients with β2-adrenoceptor agonists may lead to a 
number of adverse effects, including rebound airway hyperreactivity to stimuli, including 
methacholine, histamine and propranolol [1-3]. The mechanisms of these adverse effects 
are presently unknown, but could involve a paradoxical up-regulation of a number of neural 
and non-neural processes that counteract β2-adrenoceptor function, possibly by the S-
enantiomer present in the racemic mixture of β2-agonist drugs that are currently being used 
[4]. In this respect, changes in the cholinergic system may be of importance, as indicated by 
the observation that S-salbutamol-induced airway hyperreactivity to histamine in the guinea 
pig is inhibited by vagotomy [5]. In addition, enhanced contractile responses of isolated Effects of R- and S-salbutamol on intracellular Ca
2+-responses 
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human bronchial rings to histamine [6] and of guinea pig tracheal rings to carbachol [7] 
have been found after incubation with S-salbutamol, as well as enhanced Ca
2+-responses to 
carbachol in isolated bovine tracheal smooth muscle cells [8]. In addition, in bovine 
tracheal smooth muscle cells Mitra and co-workers observed an S-salbutamol-induced 
increase of intracellular Ca
2+ in a concentration-dependent manner and an interaction of the 
S-enantiomer with the muscarinic M3-receptor was suggested [9]. Recently, it has been 
reported that treatment of human bronchial smooth muscle cells for 24 hours with S-
salbutamol significantly increased intracellular Ca
2+-responses of these cells upon 
stimulation with methacholine [10].  
Over the years, clinical data have suggested that the S-enantiomer present in the racemic 
β2-adrenoceptor agonist mixture may cause airway hyperreactivity [11] and even contribute 
to increased asthma death [12].  Results obtained in animal models and in isolated cells 
have substantiated the possible effect of S-salbutamol on airway responsiveness [13-15]. 
Furthermore, studies in children [16-18] and adults [19,20] with asthma or chronic 
obstructive pulmonary disease (COPD) have suggested that R-salbutamol offers efficacy 
and safety benefits compared with racemic salbutamol. 
However, notwithstanding the above-mentioned evidence, adverse effects of the S-
enantiomer in racemic β-agonist drugs are still subject of controversy. Thus, in guinea pigs 
it has been found that both basal airway reactivity and allergen-induced airway 
hyperreactivity towards histamine were not affected by S-salbutamol [21]. In patients with 
mild to moderate asthma, other groups have failed to find any adverse effects of S-
salbutamol on bronchoprotection and bronchodilatation [22,23]. Moreover, several clinical 
studies in patients with asthma or COPD were unable to demonstrate advantage of R-
salbutamol over the racemate regarding bronchodilation and airway reactivity [24-28]. 
Among the observations made, the finding that S-salbutamol increases the intracellular free 
Ca
2+-concentration and enhances agonist-induced Ca
2+-mobilization in dissociated cells 
from airway smooth muscle, particularly through an effect on muscarinic receptors, is 
fascinating and deserves further investigation. To this purpose, we have thoroughly 
compared the effects of R- and S-salbutamol on methacholine- and histamine-induced Ca
2+-
responses in Fura- 2AM-loaded bovine tracheal smooth muscle cells, using both cell 
suspension spectrofluorometry and single cell fluorescence microscopy. 
 
Materials and Methods 
Tissue preparation 
Fresh bovine tracheas were obtained from the slaughterhouse and were transported to the 
laboratory within 30 min at room temperature in Krebs-Henseleit (KH) buffer of the 
following composition (nM): NaCl 177.5, KCl 5.6, MgSO4 1.2, CaCl2 2.5, NaH2PO4 1.3, 
NaHCO3 25.0, glucose 5.5, pregassed with 95% O2 and 5% CO2; pH 7.4. The tracheal 
smooth muscle was dissected carefully and prepared free of mucosa and serosal connective 
tissue in KH buffer gassed with 95% O2/5% CO2  at room temperature. Subsequently, the Chapter 5 
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tracheal smooth muscle was chopped, using a McIlwain tissue chopper, two times at the 
size of 300 μm and three times at 100 μm. Tissue fragments were washed under sterile 
conditions (three times) and maintained overnight in Dulbecco’s modified Eagle’s medium 
(DMEM; 2.5 mg/ml) supplemented with 10 mM NaHCO3, 20 mM HEPES, 100 U/ml 
penicillin, 100 μg/ml streptomycin and 10% FBS at 37°C (55 rpm). 
 
Isolation of tracheal smooth muscle cells 
Tissue fragments were washed three times in Krebs-Ringer-Henseleit (KRH) buffer 
containing (mM); NaCl 125.0, KCL 6.0, MgCl2 2.5, CaCl2 1.2, NaH2PO4 1.2, NaHCO3 
25.0, glucose 11.0, HEPES 25.0, pH 7.4, supplemented with 2.0 mM (±)-dithiothreitol 
(DTT) and were then resuspended in a digestion mixture of  collagenase P (0.75 mg/ml), 
papain (1 mg/ml) and trypsin inhibitor (1 mg/ml) in KRH buffer. The suspension was 
incubated for 20 min at 37°C (55 rpm) and then gently dispersed with a wide-bored pipette. 
After another 10 min of incubation at 37°C (70 rpm), the suspension was gently dispersed 
again and filtered over a 50 μm gauze and the cells were collected by centrifugation 
(1000g, 10 min). The isolated cells were washed three times with KRH, pH 7.4, 
supplemented with 2 mg/ml fetal bovine serum (KRH/FBS) and were allowed to regenerate 
for 1h at 37°C (55 rpm). 
 
Intracellular Ca
2+ measurements in cell suspensions 
The freshly isolated dispersed bovine tracheal smooth muscle cells were incubated with the 
fluorescent dye, Fura-2/AM (3 μM) for 30 min at 37°C (55 rpm). The loaded cells were 
washed three times in KRH/FBS and resuspended to a density of 1 x 10
6 cells/ml. The cells 
were kept at room temperature on a Rock-N-Roller (Breda Scientific) and used for 
measurement of the intracellular calcium concentration ([Ca
2+]i) within 2-4 h, during which 
they remained viable and responsive. Fura-2 fluorescence of the cells (excitation 
wavelengths: 340 and 380 nm; emission wavelength: 510 nm) was measured at 37ºC with a 
Perkin Elmer Spectrometer (LS-50B). Each cuvet contained 2 ml of magnetically stirred 
cell suspension. In all experiments, Ca
2+-transient (initial rise in [Ca
2+]i) and -plateau 
(sustained rise in [Ca
2+]i) were induced by 1 μM methacholine, added at t = 360 seconds 
after starting the Ca
2+-measurement. To establish the effects of R- and S-salbutamol on 
methacholine-induced Ca
2+-responses, single doses of R- or S-salbutamol (1 nM – 100 μM) 
were administered 5 minutes before methacholine (t = 60 seconds). The first 60 seconds 
were used to measure basal Ca
2+-level. [Ca
2+]i was calculated every 0.2 s according to 
Grynkiewicz [29]. At the end of the experiment, the maximal fluorescence ratio (Rmax) was 
determined after adding 0.01% of Triton-X-100 as a permeabilizing agent. The minimal 
fluorescence ratio (Rmin) was determined by addition of 5 mM EGTA to the permeabilized 
cells. 
 Effects of R- and S-salbutamol on intracellular Ca
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Intracellular Ca
2+ measurements in single cells 
Freshly isolated bovine tracheal smooth muscle cells were adhered to poly-L-lysine-coated 
round coverslips (1 h, 37ºC), after which they were loaded with Fura-2AM (0.5 μM; 1 h, 
37ºC). The coverslips were transferred to a thermostatted (37ºC) microscope recording 
chamber equipped with a special perfusion system, and Ca
2+-responses to 1 μM 
methacholine or 10 μM histamine were measured after preincubation (5 min, 37º) with 
buffer solution or 0.1 and 10 μM R-, and S-salbutamol, using a Zeiss Axiovert 35M 
fluorescent imaging microscope with an on-line SensiCam cooled imaging System. 
Fluorescence ratio’s (excitation wavelengths: 340 and 380 nm; emission wavelength 510 
nm) were plotted for each individual cell. 
 
Data analysis 
In cell suspension measurements, the methacholine-induced transient rise of [Ca
2+]i, 
representing Ca
2+-mobilization from internal stores, was expressed as the maximal increase 
of [Ca
2+]i above prestimulatory level after the addition of 1 μM methacholine. The plateau 
level of [Ca
2+]i, representing Ca
2+-influx, was expressed as the [Ca
2+]i  above prestimulatory 
level at 2 min after contractile agonist addition. 
In single cell measurements, methacholine- and histamine-induced Ca
2+-transients were 
expressed as the maximal increase of [Ca
2+]i (fluorescence ratio) above prestimulatory level 
following the addition of agonist. Due to methacholine- and histamine-induced slow Ca
2+-
oscillations in many cells, Ca
2+-plateau (influx including oscillations) was expressed as the 
area under the curve above prestimulatory level using a fixed period of 20 seconds (AUC20) 
for each cell, starting from the inflection point after the first Ca
2+-transient. This fixed 
period of 20 seconds was used because not all cells responded at the same time after 
stimulation with methacholine or histamine. The oscillation frequency was measured using 
the same period of 20 seconds.  
All data are presented as means ± s.e.m. Statistical analysis was performed by means of the 
two-tailed Student’s t test for paired or unpaired observations as appropriate. P values < 
0.05 were considered statistically significant. 
 
Materials 
Dulbecco’s modification of Eagle’s Medium (DMEM), NaHCO3  solution (7.5%), 
penicillin/streptomycin solution (5000 U/ml
 ; 5000 μg/ml) and HEPES solution (1 M) were 
obtained from Gibco BRL Life Technologies (Paisley, U.K.). (S)-, (R)- and (R/S)-
salbutamol were obtained from Sepracor Inc. (Marlborough, MA, U.S.A.). Fetal bovine 
serum (FBS), dithiothreitol (DTT), trypsin inhibitor (type II-S), Fura-2/AM, methacholine 
chloride and histamine were obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.) 
and papain and collagenase P were purchased from Boehringer (Mannheim, Germany). All 
other chemicals were of analytical grade. 
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Results  
Cell suspension measurements 
Figure 1a shows a typical intracellular Ca
2+-response to 1 μM methacholine in bovine 
tracheal smooth muscle cells in suspension. The response is characterised by a transient-rise 
in [Ca
2+]i representing Ca
2+-mobilization, followed by a sustained plateau level of [Ca
2+]i 
representing Ca
2+-influx. Obviously, 10 μM S-salbutamol had no effect on basal Ca
2+-level, 
while a clear inhibition of the methacholine-induced Ca
2+-transient was observed at this 
concentration (Fig. 1b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Typical intracellular Ca
2+-responses in bovine tracheal smooth muscle cell suspensions, showing the 
effect of 1 μM methacholine (MCh) in the absence (a) and presence (b) of 10 μM S-salbutamol. 
 
 
Whereas no significant effects were found on basal [Ca
2+]i after preincubation with various 
concentrations of both R- and S-salbutamol, both enantiomers dose-dependently inhibited 
the 1 μM methacholine-induced Ca
2+-transient by approximately 50% (Fig. 2b). However, 
S-salbutamol inhibited the Ca
2+-response at approximately 250 to 400-fold higher 
concentrations than R-salbutamol (pEC50 R-salbutamol = 7.8, estimated pEC50 S-
salbutamol = 5.4). No significant inhibition of the Ca
2+-plateau level was observed for both 
R- and S-salbutamol up to 10 μM, although the plateau level tended to be reduced in the 
presence of increasing concentrations of R-salbutamol (Fig. 2c). At the highest 
concentration used (100 μM), however, both enantiomers significantly decreased the Ca
2+-
plateau by about 25%. 
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Figure 2 Effects of five minutes preincubation with various concentrations R- and S-salbutamol on basal 
intracellular Ca
2+-levels (a) and on methacholine (1 μM) induced Ca
2+-transient (b) and -plateau (c) in bovine 
tracheal smooth muscle cell suspensions. Ca
2+-transient and -plateau were measured above prestimulatory level 
and expressed as percentage of control without salbutamol preincubation. Results are means ± S.E.M. of 3 
experiments. 
 
 
Single cell measurements 
Figure 3a illustrates that, as in cell suspension, no effects were found of 0.1 and 10 μM R- 
and S-salbutamol on basal Ca
2+-levels in adhered single cells. In addition, the 1 μM 
methacholine-induced Ca
2+-transient was unaffected by 0.1 and 10 μM S-salbutamol as 
well as by 0.1 μM R-salbutamol, whereas a significant decrease was observed in the 
presence of 10 μM R-salbutamol (Fig. 3b). The Ca
2+-transient in response to 10 μM 
histamine was also inhibited by 10 μM R-salbutamol, whereas 10 μM S-salbutamol tended 
to reduce this response.  
In a fraction of the cells, the methacholine- and histamine-induced Ca
2+-transient was 
followed by slow Ca
2+-oscillations with varying characteristics. Figure 4 illustrates typical 
registrations of the most prevalent oscillation patterns induced by methacholine; similar 
patterns were observed for histamine. To determine the effects of R- and S-salbutamol on 
methacholine- and histamine-induced Ca
2+-plateau (influx including oscillations), we 
calculated the area under the curve above prestimulatory level for a period of 20 seconds 
immediately after the first Ca
2+-transient. As is demonstrated in Figure 3c, only 10 μM R-
salbutamol inhibited methacholine- and histamine-induced Ca
2+-plateau. No effects were 
observed for 0.1 and 10 μM S-salbutamol and for 0.1 R-salbutamol. Further analysis of the 
Ca
2+-oscillations indicated that both R- and S-salbutamol had no significant effects on 
methacholine-induced oscillation frequency, though 10 μM R-salbutamol tended to reduce 
it (Fig. 3d). Interestingly, in the presence of 10 μM R-salbutamol histamine-induced Ca
2+-
oscillations were completely abolished.   
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Figure 3 Effects of five minutes preincubation with 0.1 and 10 μM R- and S-salbutamol on basal intracellular 
Ca
2+-levels (a) and on methacholine (1 μM)- and histamine (10 μM)-induced Ca
2+-transient (b), -plateau (c) and -
oscillation frequency (d) in single bovine tracheal smooth muscle cells. The Ca
2+-transient was measured as the 
maximal increase in [Ca
2+]i above prestimulatory level. The Ca
2+-plateau was measured as the area under the curve 
above prestimulatory level, using a fixed period of 20 seconds (AUC20) for each cell after the first Ca
2+-transient. 
The oscillation frequency was measured using the same fixed period of 20 seconds. Results are means ± S.E.M. of 
6-7 experiments for methacholine (5-15 cells per experiment) and 3 experiments for histamine (8-17 cells per 
experiment). Significantly different from control: * P<0.05; *** P<0.001. 
 
 
Given the observation that 10 μM R-salbutamol inhibited the methacholine-induced Ca
2+-
plateau, whereas the oscillation frequency remained unaffected, we sought to determine 
which effect of 10 μM R-salbutamol was responsible for the observed inhibition of the 
Ca
2+-plateau. First, for each preincubation condition we pooled the results from all 
individual cells (from 6-7 animals), and calculated the average Ca
2+-plateau (AUC20) per 
condition. Not surprisingly, qualitatively similar results were obtained as described above. 
Thus, 10 μM R-salbutamol significantly inhibited both methacholine- and histamine-
induced Ca
2+-plateau, but no effects were observed for 10 μM S-salbutamol (Fig. 5). Effects of R- and S-salbutamol on intracellular Ca
2+-responses 
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Figure 4 Typical registrations of methacholine (1 μM)-induced Ca
2+-responses in single bovine tracheal smooth 
muscle cells, demonstrating non-oscillating (a) and oscillating (b-d) cells. 
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Figure 5 Effects of five minutes
preincubation with10 μM R- or S-
salbutamol on methacholine (1
μM)- and histamine (10 μM)-
induced Ca
2+-plateau in single
bovine tracheal smooth muscle
cells. The Ca
2+-plateau was
measured as the area under the
curve above prestimulatory level,
using a fixed period of 20 seconds
(AUC20) for each cell after the first
Ca
2+-transient. Individual cells
from all experiments were pooled
and results are means ± S.E.M. of
53-72 cells for methacholine and
33-37 cells for histamine.
Significantly different from
control: * P<0.05; *** P<0.001. Chapter 5 
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Next, we divided the cells into two groups. In the first group all non-oscillating cells (see 
Fig. 4a) were pooled. The second group was represented by the remaining cells, which 
showed different oscillating patterns (see Figures 4b-d). Both under control condition and 
after pretreatment with 10 μM R-salbutamol, the fraction of oscillating cells was much 
higher for methacholine, as compared to histamine. Thus, for methacholine and histamine 
we found 46 and 13 oscillating cells, respectively, in the absence and 40 and 0 oscillating 
cells in the presence of 10 μM R-salbutamol, whereas 26 and 22 non-oscillating cells were 
found in the absence and 27 and 37 non-oscillating cells in the presence of 10 μM R-
salbutamol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Effects of five minutes preincubation with 10 μM R-salbutamol on methacholine (1 μM)- and 
histamine (10 μM)-induced Ca
2+-plateau in non-oscillating (a) and oscillating (b) single bovine tracheal smooth 
muscle cells. The Ca
2+-plateau was measured as the area under the curve above prestimulatory level, using a fixed 
period of 20 seconds (AUC20) for each cell after the first Ca
2+-transient. Individual oscillating cells (46 and 13 
cells in the absence and 40 and 0 cells in the presence of 10 μM R-salbutamol for methacholine and histamine, 
respectively) and non-oscillating cells (26 and 22 cells in the absence and 27 and 37 cells in the presence of 10 μM 
R-salbutamol for methacholine and histamine, respectively) from all experiments were pooled and results are 
means ± S.E.M. Significantly different from control: **P<0.01; *** P<0.001. 
 
 
Remarkably, in non-oscillating cells 10 μM R-salbutamol did not inhibit the methacholine-
induced Ca
2+-plateau (Fig. 6a), whereas a significant effect was found in the oscillating 
cells (Fig. 6b), without an effect on oscillating frequency (not shown). This indicates that 
the overall inhibition of the methacholine-induced Ca
2+-plateau by 10 μM R-salbutamol 
shown in Figure 5 refers to oscillating cells only. Although the methacholine-induced Ca
2+-
plateau in non-oscillating cells was not affected by 10 μM R-salbutamol, the histamine-Effects of R- and S-salbutamol on intracellular Ca
2+-responses 
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induced Ca
2+-plateau was significantly inhibited in these cells. Moreover, in the presence of 
10 μM R-salbutamol all histamine-induced oscillation patterns were abolished, indicating 
that histamine-induced Ca
2+-responses are more sensitive towards 10 μM R-salbutamol as 
compared to methacholine. 
 
Discussion  
The present study indicated that S-salbutamol does not have adverse effects on basal [Ca
2+]i 
and agonist-induced Ca
2+-responses in bovine tracheal smooth muscle cells, using 
measurements both in cell suspensions and in single cells.  
In cell suspension it was demonstrated that 1 μM methacholine-induced Ca
2+-transient was 
effectively and dose-dependently inhibited by R-salbutamol, as may be expected from 
previous observations using R-salbutamol in single bovine tracheal smooth muscle cell 
measurements [8] and (racemic) isoprenaline in bovine tracheal smooth muscle cell 
suspensions [30]. S-salbutamol also inhibited the methacholine-induced response, but at 
250-400-fold higher concentrations, illustrating the stereoselectivity of action of salbutamol 
at the β-adrenoceptor. The latter observation does not agree with the previous observation 
of Yamaguchi and McCullough (1996), in single cells, showing that S-salbutamol caused 
potentiation of carbachol-induced Ca
2+-responses. In addition, in our study S-salbutamol 
did not enhance basal Ca
2+-level in airway smooth muscle cell suspension, whereas such 
effects were observed by others using single bovine tracheal smooth muscle cells [8,9]. 
Therefore, we decided to assess the effects of the enantiomers under single cell conditions 
as well. In line with our findings in cell suspension, however, no effects of 0.1 and 10 μM 
S- and R-salbutamol were observed on basal Ca
2+-levels, indicating that in both 
experimental setups S-salbutamol is not able to elevate intracellular calcium levels by itself.  
In our single cell measurements, the 1 μM methacholine-induced Ca
2+-transient was 
significantly inhibited by 10 μM R-salbutamol, whereas 0.1 μM R-salbutamol and 0.1 and 
10 μM S-albuterol had no effect. This is in contrast with the cell suspension measurements, 
where both 0.1 μM R- and 10 μM S-salbutamol significantly inhibited the 1 μM 
methacholine-induced Ca
2+-transient, indicating the methacholine-induced Ca
2+-transient to 
be more resistant to inhibition by R- and S-salbutamol in single cells as compared to cell 
suspension. However, similar to cell suspension, no enhanced methacholine-induced Ca
2+-
transient was found in the presence of S-salbutamol. Similarly, only R-salbutamol 
significantly inhibited the Ca
2+-transient induced by 10 μM histamine, whereas 
preincubation with S-salbutamol had no effect. Collectively, our data clearly indicate that 
both in cell suspension and in single cell measurements S-salbutamol does not enhance 
contractile agonist-induced Ca
2+-transients. 
Interestingly, after stimulation with methacholine or histamine a considerable number of 
the attached cells showed slow Ca
2+-oscillations with different patterns (Fig. 4), irrespective 
of the preincubation conditions used. Several studies have investigated the nature and origin 
of contractile-agonist induced intracellular Ca
2+-oscillations. Initially, in airway smooth 
muscle cell suspension [30-32] and intact tissue [33,34], changes in intracellular Ca
2+-Chapter 5 
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concentration upon contractile agonist stimulation were shown to be biphasic. The rapid 
transient rise of intracellular Ca
2+, representing Ca
2+-release from the sarcoplasmic 
reticulum store [35], was found to be mediated by IP3-receptors [36], while the subsequent 
sustained elevation (plateau) of intracellular Ca
2+, representing extracellular Ca
2+-influx 
[31,37], is considered to be mediated by store-operated Ca
2+-channels [38,39]. However, in 
additional studies using real-time confocal microscopy, both in intact airway smooth 
muscle [40] and in adhered airway smooth muscle cells [41-43] many contractile agonists 
have been shown to induce intracellular Ca
2+-oscillations, superimposed on the plateau 
phase. It has been demonstrated that activation of IP3-receptors is critical for the initiation 
of these oscillations and that ongoing oscillations are mediated by ryanodine receptors 
(RyRs), localized in the sarcoplasmic reticulum as well [44,45]. The release of Ca
2+ through 
RyRs appears to be sensitive to Ca
2+ (calcium-induced calcium release; CICR) [46] and 
there is recent evidence that agonist-induced cADP-ribose (cADPR), an endogenous 
calcium-releasing messenger, may be involved in activating RyRs and modulating CICR 
[47].    
The agonist-induced intracellular Ca
2+-oscillations observed in our single bovine tracheal 
smooth muscle cells are in line with these findings, while the observed Ca
2+-plateau in 
response methacholine in suspension most likely reflects the integrated oscillations of all 
individual cells. Indeed, integration of all Ca
2+-signals collectively obtained in our single 
cell experiments showed a biphasic overall response with no oscillation patterns (data not 
shown). It was also found that only 10 μM R-salbutamol inhibited methacholine- and 
histamine-induced Ca
2+-plateau (influx plus oscillations), whereas other preincubations had 
no effect (Fig. 3c). Remarkably, the inhibitory effect of 10 μM R-salbutamol on the Ca
2+-
plateau from adhered cells was not observed in suspension measurements. The differences 
in susceptibility of the Ca
2+-plateau as well as the Ca
2+-transient to modulation by β-
adrenoceptor stimulation might be explained by different arrangements of the cytoskeleton 
and intracellular Ca
2+ pools in attached versus non-attached cells [48]. In line with the 
suspension measurements, however, S-salbutamol had no adverse effects on methacholine- 
or histamine-induced Ca
2+-plateau.  
Analysing the methacholine-induced Ca
2+-oscillations, we found no significant effect of R- 
and S-salbutamol on the fraction of oscillating cells (data not shown) and on oscillation 
frequency (Fig. 3d). In addition, when we pooled all non-oscillating cells and all oscillating 
cells, we found that 10 μM R-salbutamol did not inhibit the methacholine-induced Ca
2+-
plateau in non-oscillating cells (Fig. 6a), whereas this plateau was significantly inhibited in 
oscillating cells (Fig. 6b), without effect on the oscillation frequency (data not shown). 
Therefore, it can be concluded that the observed inhibition of the methacholine-induced 
Ca
2+-plateau by 10 μM R-salbutamol only affects the amplitude of the Ca
2+-oscillations. 
Interestingly, the histamine-induced Ca
2+-responses were more sensitive towards 10 μM R-
salbutamol than those induced by methacholine. Thus, no histamine-induced Ca
2+-
oscillations were found at all in the presence of 10 μM R-salbutamol. Furthermore, in the 
non-oscillating cells the histamine-induced Ca
2+-plateau was markedly inhibited by 10 μM Effects of R- and S-salbutamol on intracellular Ca
2+-responses 
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R-salbutamol. This is in line with previous observations in bovine tracheal smooth muscle 
showing that histamine-induced Ca
2+-responses and contraction are more susceptible to β-
agonist-induced inhibition than those induced by methacholine [30,49] which may be 
explained by the higher potency of methacholine in inducing inositol phosphates formation 
and subsequent intracellular Ca
2+-changes [30].  
Interestingly, both under control condition and after pretreatment with 10 μM R-
salbutamol, the fraction of oscillating cells was much higher for methacholine as compared 
to histamine. Recently, it has been demonstrated that signalling pathways involved in 
intracellular Ca
2+-oscillations may operate in an agonist-specific manner in airway smooth 
muscle. Thus, in porcine airway smooth muscle cells preincubated with 100 μM 8Br-
cADPR (an antagonist of cADPR) the intracellular Ca
2+-responses to acetylcholine were 
significantly attenuated, whereas responses to histamine were not [50]. The presence of this 
additional signalling pathway might explain why methacholine induces a higher fraction of 
oscillating cells and might also be an additional explanation why histamine-induced Ca
2+-
oscillations are more sensitive towards R-salbutamol.  
In conclusion, both in airway smooth muscle cell suspension and in adhered single cells S-
salbutamol does not increase basal intracellular Ca
2+-levels and has no potentiating effect 
on methacholine- and histamine-induced intracellular Ca
2+-responses. In this respect, our 
results offer no explanation for the observed adverse effects of β2-adrenoceptor agonists in 
asthma. In addition, in single cell measurements we have demonstrated that R-salbutamol 
preferentially inhibits contractile agonist-induced Ca
2+-plateau by decreasing the amplitude 
of the Ca
2+-oscillations. Finally, the susceptibility of the Ca
2+-transient and -plateau for 
modulation by β-adrenoceptor agonists appears to depend both on the cellular condition 
(attached vs non-attached) and the contractile agonist used. 
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Abstract 
Methacholine-induced activation of protein kinase C (PKC) has been found to reduce the 
functional antagonism of bovine tracheal smooth muscle contraction by β-adrenoceptor 
agonists. In addition, catechol-o-methyltransferase (COMT) is able to inactivate 
endogenous and exogenous catecholamines. By reducing the β-adrenergic response, 
increased PKC and COMT activities could play an important role in asthma. In this study, 
we examined the effects of a COMT-inhibitor (OR 486) and a PKC inhibitor (GF 
109203X) on isoprenaline- and fenoterol-induced relaxation of bovine tracheal smooth 
muscle. In the presence of OR 486 (10 μM), the isoprenaline concentration-relaxation-
curve from 1 μM methacholine-induced smooth muscle tone was shifted to the left by over 
one log-unit (pD2 of 7.58 ± 0.15 vs 6.37 ± 0.14 in controls, P<0.001). Maximum relaxation 
(Emax) remained unchanged, indicating that COMT only decreases the potency of 
isoprenaline. Very similar results were found using the classical COMT-inhibitor tropolone. 
GF 109203X (10 μM) induced a leftward-shift of the relaxation curve of isoprenaline of 
very similar magnitude as OR 486 and tropolone (pD2 of 7.46 ± 0.13 vs 6.37 ± 0.14 in 
controls, P<0.001); however Emax was also significantly increased (92.3 ± 1.8 vs 82.8 ± 
3.3% in controls, P<0.01). In the combined presence of OR 486 and GF 109203X no 
additive effects were found on the pD2 value of isoprenaline (7.56 ± 0.13), indicating a 
common pathway for PKC and COMT in attenuating the β-adrenoceptor responsiveness 
towards the β-agonist, presumably through activation of COMT by PKC. As expected, OR 
486 did not affect relaxation by the β-agonist fenoterol, which lacks the catechol moiety. 
GF 109203X, however, significantly enhanced Emax (78.7 ± 3.9 vs 58.4 ± 7.6 in controls, 
P<0.05), while the potency of fenoterol remained unchanged. For both isoprenaline and 
fenoterol, similar results were found with the COMT and PKC inhibitors and their 
combination when 10 μM, instead of 1 μM, methacholine was used to induce maximal 
smooth muscle contraction. The results indicate that, in bovine tracheal smooth muscle 
preparations, activation of COMT by PKC reduces functional antagonism of methacholine-
induced contraction by catecholamines. Both PKC and COMT, as well as the interaction 
between the two, may therefore play a substantial role in attenuating an important, 
endogenous β-adrenoceptor-mediated, defence in patients with (severe) asthma. 
 
Introduction 
It is widely accepted that the efficacy of endogenous and exogenous β-adrenoceptor 
agonists in asthma is mainly due to functional antagonism counteracting the 
bronchoconstrictor effects of neurotransmitters and mediators released in airway 
inflammation [1]. In patients with asthma, circulating adrenaline is importantly involved in 
controlling airway smooth muscle tone [2], as indicated by the detrimental effects of β-
adrenoceptor antagonists, including bronchospasm and aggravation of the disease, as well 
as increased bronchial responsiveness to methacholine and histamine [3-8]. In contrast, in 
non-asthmatics even high doses of β-blockers have little or no effect on airway function PKC amplifies catecholamine inactivation by COMT 
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and -responsiveness [9,10]. Inhaled β2-adrenoceptor agonists are first choice in the acute 
relief of asthma symptoms [11]. However, a diminished effectiveness of β-adrenoceptor 
agonists is observed during a severe exacerbation of asthma [12]. This is presumably due to 
mediator- and/or neurotransmitter- induced activation of protein kinase C (PKC) and 
subsequent uncoupling of the β-adrenoceptor from the effector system, as indicated by our 
recent observation in bovine tracheal smooth muscle that contractile agonist-induced PKC-
activation importantly reduced the relaxant responsiveness towards isoprenaline [13]. 
However, in additional experiments we observed a marked difference in the involvement of 
PKC in modulating isoprenaline- and fenoterol-induced relaxation. Thus, in bovine tracheal 
smooth muscle preparations contracted with methacholine, inhibition of PKC enhanced 
both potency (pD2) and efficacy (Emax) of isoprenaline [13], whereas with fenoterol the 
potency but not the efficacy was increased after PKC-inhibition (Boterman et 
al.,unpublished observations). Isoprenaline, like adrenaline being a catecholamine, is a 
substrate for catechol-O-methyltransferase (COMT), which transfers a methyl group from 
5-adenylyl methionine to the 3-OH substituent. The conjugated compound has no 
adrenergic activity and may be either excreted or further metabolized by monoamine 
oxidase [14]. High COMT activities have been described in human  and rat  lung [15,16] 
and COMT has proved functionally operative in airway smooth muscle of various animals. 
Thus,  O-methylation of both 3H-noradrenaline and 3H-isoprenaline [16-18] as well as 
increased potency of isoprenaline-induced relaxation after inhibition of COMT has been 
reported [19,20].  
Since, fenoterol, a resorcinolamine, is not a substrate for COMT, it is tempting to speculate 
that COMT could account for the differences between isoprenaline and fenoterol mentioned 
above. In addition, by reducing the β-adrenergic response, both PKC and COMT, as well as 
a possible interaction between the two enzymes, may play an important role in decreasing 
the effectiveness of circulating adrenaline, a major endogenous β-adrenoceptor mediated 
defence in severe asthma. In this study we found functional evidence for the involvement of 
COMT, and its activation by PKC, in isoprenaline-induced relaxation of methacholine-
contracted bovine tracheal smooth muscle, by using a specific, nonselective PKC inhibitor 
GF 109203X [21] and two potent and specific COMT-inhibitors, OR 486 [22]  and 
tropolone [23,24].  
 
Materials and Methods 
Tissue preparation 
Fresh bovine tracheas were obtained from the slaughterhouse and were transported to the 
laboratory within 30 min at room temperature in Krebs-Henseleit (KH) buffer of the 
following composition (nM): NaCl 177.5, KCl 5.6, MgSO4 1.2, CaCl2 2.5, NaH2PO4 1.3, 
NaHCO3 25.0, glucose 5.5, pregassed with 95% O2 and 5% CO2; pH 7.4. The tracheal 
smooth muscle was dissected carefully and smooth muscle strips (12x3 mm) were prepared 
free of mucosa and serosal connective tissue in KH buffer gassed with 95% O2/5% CO2 at Chapter 6 
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room temperature. Subsequently, all strips were maintained overnight in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10 mM NaHCO3, 20 mM HEPES, 
100 U/ml penicillin, 100 μg/ml streptomycin and 10% fetal calf serum at 37°C (55 rpm). 
 
Experimental procedure 
After washing in several volumes of KH-buffer, gassed with 95% O2 and 5% CO2, pH 7.4 
at 37°C, the bovine tracheal smooth muscle preparations were mounted in 20 ml organ 
baths containing gassed KH-buffer (37°C) for isotonic recording, using a preload of 500 
mg. No basal myogenic tone was observed in bovine tracheal smooth muscle. After a 60 
min equilibration period the strips were precontracted twice with methacholine (0.1, 1, 10 
and 0.1, 1, 10, 100 μM, respectively) with a 60 min washing period in between. Maximal 
relaxation was established with isoprenaline (0.1 μM), immediately followed by a 30 min 
washing period.  
Cumulative concentration response curves were made with methacholine (1 nM – 100 μM) 
in the absence and presence of 1 μM OR 486 and/or 10 μM GF 109203X. In separate 
experiments it was found that the concentration of GF 109203X caused complete inhibition 
of 10 μM phorbol 12-myristate 13-acetate (PMA)-induced contraction. In addition, in 
bovine tracheal [13] and rat oesophagus [25] smooth muscle it has been demonstrated that 
PKA-dependent, but β-adrenoceptor independent relaxation, induced by either forkolin or 
IMBX, is not affected by GF 109203X, indicating no nonspecific effects of the PKC-
inhibitor in both airway and oesophagus smooth muscle relaxation.  
For relaxation studies, the preparations were preincubated with KH-buffer (45 min), 1 μM 
OR 486 (30 min) or 100 μM tropolone (30 min) or 10 μM GF 109203X (45 min) or the 
combination of 1 μM OR 486 and 10 μM GF 109203X. Subsequently, smooth muscle tone 
was raised with methacholine at 1 or 10 μM, which was gradually built up in 3 or 4 
concentration steps, respectively. Cumulative concentration-relaxation-curves (CRCs) were 
constructed using (-)-isoprenaline (0.1 nM – 100 μM) or fenoterol (0.1 nM – 10 μM), 
added in 0.5 log increments. At the end of each experiment the smooth muscle strips were 
washed twice and maximal relaxation was re-established with 10 and 100 μM isoprenaline. 
In all experiments, the slight reduction of methacholine-induced smooth muscle tone, as a 
consequence of the preincubation condition, was carefully compensated for by additional 
administration of small amounts of the contractile agonist, before relaxation curves were 
obtained. 
 
Data Analysis 
Responses were expressed as percentages of the response to 100 μM methacholine in the 
second precontraction in each experiment, with reference to basal tone as established at the 
end of each experiment. All data are presented as mean ± S.E.M. Curves were fitted using 
the logistic 4-parameter model (Sigmaplot 9.0). Statistical analysis was performed by 
means of the two-tailed Student’s t-test for paired or unpaired observations. P values < 0.05 
were considered statistically significant. PKC amplifies catecholamine inactivation by COMT 
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Materials 
Dulbecco’s modification of Eagle’s Medium (DMEM), foetal bovine serum, NaHCO3 
solution (7.5%), penicillin/streptomycin solution (5000 U/ml
 ; 5000 μg/ml) and HEPES 
solution (1 M) were obtained from Gibco BRL Life Technologies. (Paisley, U.K.). 
Methacholine chloride and (-)-isoprenaline hydrochloride were obtained from Sigma 
Chemical Co. (St. Louis, MO, U.S.A.), GF 109203X (2-[1-(3 imethylaminopropyl)-1H-
indol-3-yl]-3-(1H-indol-3-yl) maleimide) was purchased from RBI (Natick, MA, USA) and 
fenoterol hydrobromide was a generous gift from Boehringer-Ingelheim (Ingelheim, 
Germany). OR 486 was obtained from Tocris Bioscience (Avonmouth, UK) and tropolone 
was a gift from Prof. B.H.C. Westerink (Groningen University, The Netherlands). All other 
chemicals were of analytical grade. 
 
Results 
Effect of OR 486 and GF 109203X on methacholine-induced contraction 
GF 109202X caused a small shift to the right of the cumulative concentration-contraction 
curve of methacholine in bovine tracheal smooth muscle, with a reduction in pD2 (–log 
EC50) value from 7.01 ± 0.01 to 6.58 ± 0.04, while the maximal contractile effect (Emax) 
was unchanged (Fig. 1). For OR 486 no effect was observed on the methacholine-induced 
contraction (pD2 = 6.99 ± 0.04). In addition, OR 486 had no further effect on the small 
rightward shift of methacholine-induced contraction in the presence of GF 109203X 
(Fig.1).  
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Figure 1  Cumulative concentration-
response curves of methacholine-induced
bovine tracheal smooth muscle contraction in
the absence and presence of 10 μM GF
109203X, 1 μM OR 486 and the combination
of 10 μM GF 109203X and 1 μM OR 486.
Results are obtained from 2 experiments
performed in duplicate. Chapter 6 
 
126
[Isoprenaline] (-log M)
0 1 0 98765
C
o
n
t
r
a
c
t
i
o
n
 
(
%
)
0
20
40
60
80
100
120
[Isoprenaline] (-log M)
0 1 0 98765
0
20
40
60
80
100
120
AB
10 µM MCh
10 µM MCh + 1 µM OR 486
  1 µM MCh
  1 µM MCh + 1 µM OR 486
10 µM MCh
10 µM MCh + 100 µM tropolone
  1 µM MCh
  1 µM MCh + 100 µM tropolone
Effect of OR 486 and tropolone on isoprenaline- induced relaxation 
To determine the effect of COMT on isoprenaline-induced relaxation, we used two 
different COMT inhibitors. In the presence of the potent COMT inhibitor OR 486 (1 μM), 
the pD2 but not Emax values of isoprenaline-induced relaxations were significantly enhanced 
at the two methacholine-induced contraction levels applied (Fig. 2A ), pD2 values 
increasing from 6.15 ± 0.08 to 7.44 ± 0.16 (P<0.05) for 10 μM methacholine-induced 
contraction and from 6.95 ± 0.09 to 7.96 ± 0.14 (P<0.01) for 1 μM methacholine-induced 
contraction. Similarly, in the presence of the classical COMT inhibitor tropolone (100 μM), 
similar increases in the isoprenaline pD2 values were found (Fig. 2B), the left shifts being 
from 6.24 ± 0.01 to 7.39 ± 0.06 (P<0.01) and from 6.91 ± 0.09 to 7.77 ± 0.01 (P<0.05) for 
10 and 1 μM methacholine-induced contraction, respectively. Again, Emax values were not 
affected, indicating that inhibition of COMT only enhanced the potency of isoprenaline, not 
the efficacy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 (-)-Isoprenaline-induced relaxation of bovine tracheal smooth muscle preparations precontracted with 
1 and 10 μM methacholine (MCh) in the absence and presence of 1 μM OR 486 (Panel A) and 100 μM tropolone 
(Panel B). Results are means ± S.E.M. of 3 experiments each performed in duplicate. 
 
 
Effect of OR 486 and GF 109203X on isoprenaline-induced relaxation  
In the presence of GF 109203X (10 μM) isoprenaline-induced relaxation from a 10 μM 
methacholine-induced smooth muscle tone, is also significantly potentiated, to a similar 
extent as with OR 486, as no significant difference was found between the two pD2 values 
(Fig. 3A; Table 1). Interestingly, and in contrast to the inhibition of COMT, PKC-inhibition PKC amplifies catecholamine inactivation by COMT 
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      1 μM MCh  10 μM MCh   
  Preincubation      Emax (%)  pD2 (-log M)    Emax (%)    pD2 (-log M)   
              
  Control      82.8 ± 3.3  6.37 ± 0.14    34.9 ± 3.5     5.96 ± 0.13    
  GF 109203X      93.0 ± 1.8
*** 7.46 ± 0.13
***    45.4 ± 2.9
*     6.63 ± 0.19
*      
  OR 486      81.6 ± 3.2  7.58 ± 0.15
***    29.6 ± 2.9     7.20 ± 0.24
***     
  GF 109203X + OR 486      91.2 ± 1.6
*** 7.56 ± 0.13
***    48.6 ± 2.4
**    7.09 ± 0.20
***    
 
also increased Emax of isoprenaline, indicating that, in addition to potency, PKC is also 
reducing the efficacy of the β-agonist. Furthermore, in the presence of both OR 486 and GF 
109203X no additional effects were found on pD2 and Emax values of isoprenaline (Table 1), 
compared to treatment with GF 109203X alone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 (-)-Isoprenaline-induced relaxation of bovine tracheal smooth muscle preparations precontracted with 
10 (Panel A) and 1 (Panel B) μM methacholine in the absence and presence of 10 μM GF 109203X, 1 μM OR 486 
or the combination of 10 μM GF 109203X and 1 μM OR 486. Results are means ± S.E.M. of 4-6 experiments 
each performed in duplicate. 
 
 
Table 1 Maximal effect (Emax) and potency (pD2) of  (-)-isoprenaline-induced relaxation of bovine tracheal 
smooth muscle contracted by 1 or 10 μM methacholine (MCh), in the absence and presence of 10 μM GF 
109203X , 1 μM OR 486 and the combination of 10 μM GF 109203X and 1 μM OR 486. 
 
 
 
 
 
 
 
Data represent means ± S.E.M. of 4-6 experiments, each performed in duplicate. Significantly different from 
control: * P<0.05; ** P<0.01; *** P<0.001. 
At the lower submaximal contraction level induced by 1 μM methacholine, at which the 
isoprenaline-induced relaxation is much more pronounced, again, the potency of Chapter 6 
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isoprenaline is significantly enhanced in the presence of OR 486, with no effect on maximal 
relaxation (Table 1). GF 109203X induced a marked leftward shift of the isoprenaline-
induced relaxation, similar to that by OR 486, and significantly increased maximal 
relaxation of isoprenaline as well. Again, combined treatment with OR 486 and GF 
109203X had no additional effects on pD2 and Emax values of isoprenaline (Table 1), 
compared to GF 109203X alone. 
 
Effect of OR 486 and GF 109203X on fenoterol-induced relaxation 
We used fenoterol to dessect the effects of COMT- and PKC-inhibition on the relaxation 
induced by a β2-adrenoceptor agonist because fenoterol is lacking the catechol moiety. As 
expected, fenoterol-induced relaxation from both the 1 and 10 μM methacholine-induced 
contraction level was not affected by OR 486 (Fig. 4A, B; Table 2). Remarkably, for both 1 
and 10 μM methacholine-induced contractions, maximal relaxation of fenoterol was 
significantly enhanced in the presence of GF 109203X, with no effect on the potency (Fig. 
4A, B; Table 2). This is in striking contrast with isoprenaline-induced relaxation, where 
inhibition of PKC also markedly enhanced the potency of isoprenaline. Again, in 
accordance with the results described above, the combined treatment with OR 486 and GF 
109203X had no additional effects on fenoterol-induced relaxation for both contraction 
levels, compared to GF 109203X alone (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Fenoterol-induced relaxation of bovine tracheal smooth muscle preparations precontracted with 10 
(Panel A) and 1 (Panel B) μM methacholine in the absence and presence of 10 μM GF 109203X, 1 μM OR 486 or 
the combination of 10 μM GF 109203X and 1 μM OR 486. Results are means ± S.E.M. of 4 experiments each 
performed in duplicate. PKC amplifies catecholamine inactivation by COMT 
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      1 μM MCh  10 μM MCh   
  Preincubation      Emax (%)  pD2 (-log M)    Emax (%)    pD2 (-log M)   
              
  Control      58.4 ± 7.6  7.34 ± 0.11    15.7 ± 2.5     7.09 ± 0.11    
  GF 109203X      78.7 ± 3.9
*  7.20 ± 0.16    34.5 ± 4.6
*     6.89 ± 0.10      
  OR 486      59.5 ± 6.8  7.27 ± 0.13    19.3 ± 2.2     7.07 ± 0.10      
  GF 109203X + OR 486      81.1 ± 0.8
*  7.23 ± 0.13    31.1 ± 3.4
**    6.88 ± 0.14    
 
Table 2 Maximal effect (Emax) and potency (pD2) of  fenoterol-induced relaxation of bovine tracheal smooth 
muscle contracted by 1 or 10 μM methacholine (MCh), in the absence and presence of 10 μM GF 109203X , 1 μM 
OR 486 and the combination of 10 μM GF 109203X and 1 μM OR 486.  
 
 
 
 
 
 
 
Data represent means ± S.E.M. of 4 experiments, each performed in duplicate. Significantly different from control: 
* P<0.05, ** P<0.01. 
Discussion 
The present study has established that COMT is importantly involved in restraining the 
potency of isoprenaline-induced relaxation of bovine tracheal smooth muscle precontracted 
with methacholine, as indicated by the marked leftward shift of the concentration-response-
curves of isoprenaline after inhibition of COMT (Fig 2A and 2B). Moreover, for the first 
time we have provided functional evidence for the possibility that activation of COMT by 
PKC may be involved in the reduced functional antagonism of methacholine-induced 
contraction by catecholamines. Thus, inhibition of COMT, PKC or the combined inhibition 
of COMT and PKC all enhanced the potency of isoprenaline-induced relaxation to a similar 
extent, strongly suggesting a common pathway for COMT and PKC, which could involve 
activation of COMT by PKC.  
First, we assessed the effects of 10 μM GF 109203X and 1 μM OR 486 on methacholine-
induced contraction. It was found that GF 109203X slightly reduced the potency of 
methacholine, with no effect on maximal contraction (Fig.1), fully in line with previous 
observations [13]. These findings indicate that PKC-activation by sn-1,2-diacylglycerol 
(DAG) is supporting contractile agonist-induced airway smooth muscle contraction 
mediated by Gq-coupled receptors, which has also been demonstrated by others [26-29]. As 
expected, OR 486 did not have any effect on methacholine-induced contraction and no 
additional effect on the treatment with GF 109203X either, ruling out the possibility that 
COMT is involved in or is interfering with methacholine-induced contraction.  
Second, we demonstrated that the potency of isoprenaline on both 1 and 10 μM 
methacholine-induced contraction was markedly and similarly increased in the presence of 
the two COMT-inhibitors OR 486 and tropolone, indicating that inactivation of 
isoprenaline by COMT is importantly involved (Fig. 2A and B). These findings are fully in 
line with other observations in pig bronchus [19] and guinea pig trachea [20], showing an 
increased potency of isoprenaline after inhibition of COMT using U-0521. In accordance 
with our results, inhibition of COMT did not effect maximal relaxation in these studies 
either, which of course can be explained by the fact that COMT only decreases the amount Chapter 6 
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of isoprenaline available for stimulating the β2-adrenoceptors present. In line with previous 
observations [13], with GF 109203X significant leftward shifts of the concentration-
response-curve of isoprenaline, both from 1 μM and 10 μM methacholine-induced 
contraction, were observed which were remarkably similar to those obtained with OR and 
tropolone. These results indicate the involvement of PKC in the acute functional 
antagonism of contractile agonist-induced airway smooth muscle contraction by β-
adrenoceptor agonists. As the gain in potency of isoprenaline was very similar after 
inhibition of COMT and PKC, the possibility could be envisaged that PKC and COMT may 
have a common pathway in reducing the β2-adrenergic response of isoprenaline. Therefore, 
we treated the smooth muscle strips with a combination of GF 109203X and OR 486. If 
PKC and COMT exert their effects independently, then an additive, potentiating effect on 
the isoprenaline-induced relaxation by the combination of the inhibitors could be expected. 
From both the maximal and the submaximal methacholine-induced contraction, the results 
showed that the combined treatment with OR 486 and GF 109203X did not give any 
additive effect on the relaxant potency of isoprenaline (Fig. 3A and B; Table 1), strongly 
suggesting a common pathway for PKC and COMT, which could involve activation of 
COMT by PKC-mediated phosphorylation. Interestingly, in contrast to OR 486 and 
tropolone, GF 109203 also increased maximal relaxation of isoprenaline, indicating an 
additional effect of PKC independent of COMT. To further investigate this we also studied 
the non-catecholamine fenoterol, which is not a substrate for COMT. As expected, OR 486 
had no effect on fenoterol-induced relaxation, both from 1 and 10 μM methacholine-
induced contraction, whereas GF 109203X only increased the maximal relaxation by 
fenoterol. This finding confirms the idea that the observed enhanced potency of 
isoprenaline after inhibition of PKC is fully due to prevention of COMT-activition.  
Interestingly, in patients with nocturnal asthma a temporal relationship has been observed 
between decreases in plasma adrenaline and decreases in peak expiratory flow rate during 
the early morning hours [30,31]. In contrast, the plasma histamine concentration, used as an 
indicator of allergic mediator secretion, rises at night in asthmatic patients and is inversely 
correlated with the peak flow and with the plasma adrenaline level [30]. Knowing that 
histamine and other mediators and neurotransmitters, released in airway inflammation, are 
able to activate PKC, it could be envisaged that PKC-induced activation of COMT, as 
found in the present study, could play a role in the decreased plasma levels of adrenaline in 
the early morning in patients with nocturnal asthma. Indeed, enhanced COMT-activity has 
been observed in children with asthma [32].  
In conclusion, the results indicate that, in bovine tracheal smooth muscle preparations, 
activation of COMT by PKC attenuates the functional antagonism of methacholine-induced 
contraction by catecholamines. In addition, methacholine-induced PKC-activation is also 
directly involved in a reduced β-adrenergic response towards β-agonists. By reducing the 
β-adrenoceptor responsiveness, both PKC and COMT, as well as an interaction between the 
two, may therefore play a substantial role in attenuating an important, endogenous β-
adrenoceptor-mediated, defence in patients with (severe) asthma. PKC amplifies catecholamine inactivation by COMT 
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Summary 
In airway smooth muscle (ASM), full and partial muscarinic receptor agonists have been 
described to have large differences in their ability to induce signal transduction, including 
Ca
2+-mobilization. Despite these differences, partial agonists are capable of inducing a 
submaximal to maximal ASM contraction.  
To further elucidate transductional differences between full and partial muscarinic receptor 
agonists, we investigated the contribution of Rho-kinase (an important regulator of Ca
2+-
sensitization) to methacholine-, pilocarpine- and McN-A-343- induced bovine tracheal 
smooth muscle contraction, using the selective Rho-kinase inhibitor Y-27632. In addition, 
we measured Ca
2+-mobilization and -influx in bovine tracheal smooth muscle cells in 
response to these agonists in the absence and presence of Y-27632.  
Whereas treatment with Y-27632 (1 μM) significantly decreased potency (pEC50) for all 
agonists, maximal contraction (Emax) was reduced  by 23.4 ± 2.8 % and 50.4 ± 7.9 % for the 
partial agonists pilocarpine and McN-A-343, respectively, but was unaffected for the full 
agonist methacholine. However, Emax of methacholine became Rho-kinase dependent after 
taking away its receptor reserve using the irreversible muscarinic receptor antagonist 
propylbenzilylcholine mustard. 
Pilocarpine and McN-A-343 induced a very small Ca
2+-mobilization and -influx as 
compared to methacholine. In addition, an inverse relationship of these two parameters with 
the Rho-kinase dependency was observed. Interestingly, no inhibitory effects of Y-27632 
were observed on Ca
2+-mobilization and-influx for all three agonists, indicating that the 
effects of Y-27632 on contraction are most likely on the level of Ca
2+-sensitization. 
In conclusion, in contrast to the full agonist methacholine, the partial muscarinic receptor 
agonists pilocarpine and McN-A-343 are dependent on Rho-kinase for their maximal 
contractile effects, presumably as a consequence of differences in transductional reserve, 
indicating an agonist-dependent role for Rho-kinase in ASM contraction. Moreover, an 
inverse relationship exists between Rho-kinase dependency and both Ca
2+-mobilization and 
Ca
2+-influx for these agonists. 
 
Introduction 
Muscarinic receptor stimulation in airway smooth muscle (ASM) results in the activation of 
phospholipase C, subsequently followed by the production of sn-1,2-diacylglycerol and 
inositol1,4,5- trisphosphate (IP3) [1-3]. In response to IP3, Ca
2+ is being mobilized from 
intracellular stores [4] causing a rapid, transient rise in intracellular Ca
2+-concentration 
[Ca
2+]i [5], which is followed by a sustained influx of extracellular Ca
2+. Smooth muscle 
contraction is then initiated through the formation of Ca
2+-calmodulin and subsequent 
activation of myosin light chain kinase (MLCK), resulting in the phosphorylation of the 
20kDa regulatory myosin light chain (MLC20) [6,7]. Recently, it has been established that 
contractile stimuli do not exert their effects only by increasing [Ca
2+]i, but also by 
increasing Ca
2+-sensitivity of the smooth muscle. One of the main regulators involved in Rho-kinase dependency of muscarinic agonists 
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this so called Ca
2+-sensitization is Rho-kinase, which acts through inhibition of myosin 
light chain phosphatase, resulting in an enhanced MLC20  phosphorylation and thus an 
increased level of contraction at a certain [Ca
2+]i [8,9].  
Contraction of ASM preparations by muscarinic receptor agonists is mediated primarily 
through M3-receptor stimulation. Several studies have demonstrated that the involvement of 
the M2-receptor in ASM contraction is minor or negligible [10-12]. Meurs et al (1988) 
compared concentration response curves (CRCs) for contraction and inositol phosphate 
accumulation in response to partial and full muscarinic receptor agonists and demonstrated 
that a strong linear correlation between these two parameters exists. In addition, they 
showed a considerable reserve of inositol phosphate production for the full agonists 
methacholine and oxotremorine, but not for the partial agonist McN-A-343 [13]. This 
transduction reserve is in accordance with studies showing that acetylcholine induces 
maximal force development by only occupying 4 % of the available muscarinic receptors 
(large receptor reserve), whereas McN-A-343 has to occupy 80 % of the receptors (low 
receptor reserve) to achieve the same degree of force [14,15]. Furthermore, it has been 
demonstrated that canine tracheal smooth muscle shortens at a significantly faster rate when 
contracted with acetylcholine than with McN-A-343 [16]. Large differences between full 
and partial M3-agonists regarding Ca
2+-mobilizing capacity have been described, whereas 
no differences in dependency on Ca
2+-influx through voltage-dependent channels appear to 
be present [17]. To further elucidate mechanisms underlying the differences between full 
and partial M3-receptor agonists, we investigated the contribution of Rho-kinase to ASM-
contraction, Ca
2+-mobilization and Ca
2+-influx in response to the full muscarinic agonist 
methacholine and the partial muscarinic agonists pilocarpine and McN-A-343 [18,19]. We 
demonstrate that these agonists are differentially dependent on Ca
2+-mobilization/-influx 
and Rho-kinase for their contractile effects, and that the functional dependency on Ca
2+-
mobilization and -influx is inversely correlated with Rho-kinase dependency. 
 
Materials and methods 
Tissue preparation and organ-culture procedure 
Bovine tracheae were obtained from local slaughterhouses and rapidly transported to the 
laboratory in Krebs-Henseleit (KH) buffer of the following composition (mM): NaCl 117.5, 
KCl 5.60, MgSO4 1.18, CaCl2 2.50, NaH2PO4 1.28, NaHCO3 25.00 and glucose 5.50, 
pregassed with 5% CO2 and 95% O2; pH 7.4.  After dissection of the smooth muscle layer 
and careful removal of mucosa and connective tissue, tracheal smooth muscle strips were 
prepared while incubated in gassed KH-buffer at room temperature. Care was taken to cut 
tissue strips with macroscopically identical length (1 cm) and width (2 mm). Tissue strips 
were washed once in sterile Dulbecco’s modification of Eagle’s medium (DMEM), 
supplemented with NaHCO3 (10 mM), HEPES (20 mM), sodium pyruvate (1 mM), 
nonessential amino acid mixture (1:100), gentamicin (45 μg/ml), penicillin (100 U/ml), 
streptomycin (100 μg/ml) and amphotericin B (1.5 μg/ml). Next, tissue strips were Chapter 7 
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transferred into suspension culture flasks (containing 2.5 ml medium per tissue strip) and 
maintained overnight. 
 
Isometric tension measurements 
Tissue strips, collected from suspension culture flasks, were washed with several volumes 
of KH-buffer pregassed with 5% CO2 and 95% O2, pH 7.4 at 37 ˚C. Subsequently, strips 
were mounted for isometric recording (Grass force-displacement transducer FT03) in 20 ml 
water-jacked organ baths, containing KH-buffer at 37 ˚C, continuously gassed with 5% 
CO2 and 95% O2, pH 7.4. During a 90 min equilibration period, with washouts every 30 
min, resting tension was gradually adjusted to 3 g. Subsequently, muscle strips were 
precontracted with 20 mM and 40 mM isotonic KCl solutions. Following two wash-outs, 
maximal relaxation was established by the addition of 0.1 μM (-)-isoprenaline. In over 95% 
of the experiments, no basal myogenic tone was detected. Tension was now re-adjusted to 3 
g, immediately followed by two changes of fresh KH-buffer. After another equilibration 
period of 30 min, cumulative CRCs were constructed to stepwise increasing concentrations 
of methacholine, pilocarpine or McN-A-343 (1 nM - 100 μM). When maximal agonist-
induced tension was obtained, the strips were washed several times and maximal relaxation 
was established using (-)-isoprenaline (10 μM). When used, the Rho-kinase inhibitor Y-
27632 (1 μM) was applied to the organ bath 30 min before agonist addition. This 
concentration has been shown to be effective and selective in smooth muscle [20-22]. In a 
separate set of experiments, 100 μM of the alkylating muscarinic receptor antagonist 
propylbenzilylcholine mustard (PrBCm) was preincubated for 15 minutes, followed by 
several washouts, prior to the construction of a cumulative CRC of methacholine. 
 
Isolation of bovine tracheal smooth muscle cells 
After the removal of mucosa and connective tissue, tracheal smooth muscle was chopped 
using a McIlwain tissue chopper, two times at the size of 300 μm and three times at 100 
μm. Tissue fragments were washed under sterile conditions (three times) and maintained 
overnight in DMEM supplemented with NaHCO3 (10 mM), HEPES (20 mM), penicillin 
(100 U/ml), streptomycin (100 μg/ml) and 10 % fetal bovine serum (FBS) in an incubator 
shaker (Innova 4000) at 37 ˚C, 55 rpm.  
Tissue fragments were washed three times in Krebs-Ringer-Henseleit (KRH) buffer 
containing (mM): NaCl 125.0, KCl 6.0, MgCl2 2.5, CaCl2 1.2, NaH2PO4 1.2, NaHCO3 25.0, 
glucose 11.0, HEPES 25.0, pH 7.4, supplemented with 2.0 mM (±)-dithiothreitol (DTT) 
and resuspended in a digestion mixture of collagenase P (0.75 mg/ml), papain (1 mg/ml) 
and trypsin inhibitor (1 mg/ml) in KHR buffer. The suspension was incubated for 20 min at 
37
oC (55 rpm) and then gently dispersed with a wide-bored pipette. After another 10 min of 
incubation at 37
oC (70 rpm), the suspension was gently dispersed again and filtered over a 
50 μm gauze. The cells were collected by centrifugation (1000 g, 10 min), washed three 
times with KHR, pH 7.4, supplemented with 2 mg/ml FBS (KRH/FBS) and were allowed 
to regenerate for 1 h at 37
oC (55 rpm). Subsequently, the cells were incubated with the Rho-kinase dependency of muscarinic agonists 
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fluorescent dye, Fura-2/AM (3 μM) for 30 min at 37
oC (55 rpm). The loaded cells were 
washed three times in KRH/FBS and resuspended to a density of 1 x 10
6 cells/ml. The cells 
were kept at room temperature on a Rock-N-Roller (Breda Scientific, The Netherlands) and 
used within 2-4 h, during which they remained viable and responsive. 
 
Intracellular Ca
2+-measurements 
Fura-2 fluorescence of the cells (excitation wavelengths: 340 and 380 nm; emission 
wavelength: 510 nm) was measured at 37 
oC with a Perkin Elmer Spectometer (LS-50B). 
Each cuvet contained 2 ml of magnetically stirred cell suspension. Ca
2+-mobilization and –
influx induced by methacholine (30 nM-300 μM), pilocarpine (100 nM – 300 μM) or McN-
A-343 (100 nM – 300 μM), added at t= 60 s, was measured. When used Y-27632 (1 μM) 
was added 30 min prior to agonist addition. The intracellular Ca
2+-concentration ([Ca
2+]i) 
was calculated every 0.2 s according to Grynkiewicz [23]. At the end of the experiment, the 
maximal fluorescence ratio (Rmax) was determined after adding 0.01% of Triton-X-100 as a 
permeabilizing agent. The minimal fluorescence ratio  (Rmin) was determined by addition of 
5 mM EGTA to the permeabilized cells. 
 
Data analysis 
All data represent means ± S.E.M. from n separate experiments. CRCs of contractile 
responses were analyzed by measuring myogenic tension. No corrections were made for 
basal tone. Maximal tension (Emax) and pEC50 were calculated from the CRCs. Curves were 
fitted using the logistic 4-parameter model (Sigmaplot 9.0, SPSS Inc.). 
Agonist-induced transient rise of [Ca
2+]i, representing Ca
2+-mobilization from internal 
stores, was expressed as the maximal increase above basal after addition of the agonist. The 
plateau level of [Ca
2+]i, representing Ca
2+-influx, was measured 2 min after agonist addition 
and expressed as [Ca
2+]i above basal. CRCs for Ca
2+-mobilization and -influx were 
expressed as a percentage of the maximal methacholine-induced Ca
2+-mobilization. 
Statistical significance of differences between data was determined using the two-tailed 
Student’s t-test for paired observations or one-way analysis of variance, where appropriate. 
Differences were considered to be statistically significant when P < 0.05. 
 
Materials 
Dulbecco’s modification of Eagle’s Medium (DMEM) and methacholine hydrochloride 
were obtained from ICN Biomedicals (Costa Mesa, CA, U.S.A.). Foetal bovine serum, 
NaHCO3 solution (7.5%), HEPES solution (1 M), sodium pyruvate solution (100 mM), 
non-essential amino acid mixture, gentamycin solution (10 mg/ml), penicillin/streptomycin 
solution (5000 U/ml; 5000 μg/ml) and amphotericin B solution (250 μg/ml) (Fungizone) 
were obtained from Gibco BRL Life Technologies (Paisley, U.K.). Dithiothreitol (DTT), 
soybean trypsin inhibitor, Fura-2/AM, pilocarpine hydrochloride and (-)-isoprenaline Chapter 7 
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hydrochloride were from Sigma Chemical Co. (St. Louis, MO, U.S.A.). McN-A-343 was 
purchased from RBI,(Natick, MA.) 
(+)-(R)-Trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexane carboxamide (Y-27632) was 
obtained from Tocris Cookson Ltd. (Bristol, UK.). L(+)ascorbic acid was from Merck 
(Darmstadt, Germany). Propylbenzilylcholine mustard was from NEN products (Boston, 
U.S.A.). Papain and Collagenase P were from Boehringer (Mannheim, Germany). All other 
chemicals were of analytical grade. 
 
Results 
Effects of Rho-kinase-inhibition on methacholine-, pilocarpine- and McN-A-343-induced 
airway smooth muscle contraction 
In bovine tracheal smooth muscle strip preparations, pilocarpine and McN-A-343 reached 
up to 87 %  and 84 %, respectively, of the maximal contraction (Emax) induced by 
methacholine, indicating that both pilocarpine and McN-A-343 are partial agonists (Fig. 1, 
Table 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Effects of Rho-kinase inhibition on contraction induced by full and partial M3-receptor agonists. 
Methacholine (MCh), a)-, pilocarpine (b)- and McN-A-343 (c)-induced contraction in the absence (open circles) 
and presence (closed circles) of 1 μM Y-27632 of bovine tracheal smooth muscle strips. Data represent means ± 
S.E.M. of 3-7 experiments, each performed in duplicate. 
 
 
To determine the contribution of Rho-kinase, we used the selective Rho-kinase inhibitor Y-
27632 (1 μM). With methacholine, no effect of Rho-kinase inhibition was observed on 
Emax, but a significant decrease in potency (pEC50) was observed. Interestingly, treatment 
with Y-27632 significantly decreased Emax of pilocarpine and McN-A-343 by 23,4 ± 2.8 % 
and 50,4 ± 7.9 %, respectively, and also significantly decreased potency (Fig. 1, Table 1). Rho-kinase dependency of muscarinic agonists 
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Remarkably, the effect of Y-27632 in decreasing pEC50-values diminished in the order 
methacholine>pilocarpine>McN-A-343. 
 
 
Table 1 Effects of Rho-kinase inhibition on contractile properties of bovine tracheal smooth muscle preparations 
following administration of muscarinic receptor agonists. 
 
Vehicle 
 
Y-27632 
  pEC50 
(-log M) 
Emax 
(g) 
  pEC50 
(-log M) 
Emax 
(g) 
Methacholine  6.73 ± 0.15  25.4 ± 2.5      6.19 ± 0.15 
* *  24.2 ± 2.4 
after PrBCm  3.59 ± 0.14  21.8 ± 1.2    2.91 ± 0.17
 *    16.3 ± 1.6 
* 
Pilocarpine  6.52 ± 0.08  22.2 ± 3.6    6.09 ± 0.02 
*    17.1 ± 3.1 
* 
McN-A-343  5.26 ± 0.09
   21.3 ± 0.2     4.93 ± 0.04
 *    10.5 ± 1.7 
* 
Data represent means ± S.E.M. of 3-7 experiments each performed in duplicate. 
 * P<0.05, 
* * P<0.01 vs vehicle-
treated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  Ca
2+-mobilization and –influx in response to full and partial M3-receptor agonists. Methacholine 
(circles)-, pilocarpine (squares)- and McN-A-343 (triangles)-induced Ca
2+-mobilization (a) and –influx (b) in 
bovine tracheal smooth muscle cells. Data are expressed as percentage of maximal Ca
2+-mobilization induced by 
methacholine and  represent means ± S.E.M. of 3 experiments each performed in duplicate. 
 Chapter 7 
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Effects of Rho-kinase-inhibition on intracellular Ca
2+
  homeostasis in response to 
methacholine, pilocarpine and McN-A-343 
Ca
2+-mobilization and -influx were determined in response to several concentrations of 
methacholine, pilocarpine and McN-A-343 (Fig. 2). Both mobilization and influx were 
calculated as a percentage of the maximal methacholine-induced Ca
2+-mobilization, which 
amounted to 349.7 ± 53.9 nM Ca
2+. Mobilization induced by pilocarpine and McN-A-343 
(Fig. 2a) was significantly lower as compared to that induced by methacholine and reached 
up to only 10.0 ± 0.8 % and 5.8 ± 1.6 %, respectively (P<0.001, both). Ca
2+-influx in 
response to these agonists  was also significantly lower (8.9 ± 1.1 % and 7.1 ± 1.7 %, 
respectively; Figure 2b) as compared to methacholine-induced influx (13.9 ± 0.5 %; 
P<0.01, both).  
Next, to determine whether the effects of Rho-kinase-inhibition on contraction (Fig. 1) 
could be linked to effects on Ca
2+-mobilization or -influx, we measured Ca
2+-responses 
induced by 100 μM methacholine, pilocarpine and McN-A-343 in the presence and absence 
of 1 μM Y-27632. As shown in Figure 3, Y-27632 had no inhibitory effect on Ca
2+-
mobilization or -influx induced by either agonist, indicating that the inhibitory effects of Y-
27632 on maximal pilocarpine- and McN-A-343-induced contractions are not caused by 
changes in Ca
2+-mobilization or -influx. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Effects of Rho-kinase inhibition on Ca
2+-responses induced by full and partial M3-receptor agonists. 
Ca
2+-mobilization (a) and –influx (b) in response to methacholine (MCh), pilocarpine and McN-A-343 in the 
absence (white bars) and presence (grey bars) of 1 μM Y-27632 in bovine tracheal smooth muscle cells. Data are 
expressed as percentage of maximal Ca
2+-mobilization induced by methacholine and represent means ± S.E.M. of 
3 experiments, each performed in duplicate. Rho-kinase dependency of muscarinic agonists 
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Effects of muscarinic receptor alkylation on the Rho-kinase dependency of the 
methacholine-induced contraction 
To determine whether differences in receptor reserve could be responsible for the 
difference in Rho-kinase dependency of the contraction induced by full and partial agonists, 
we removed receptor reserve of the full agonist methacholine by using the alkylating agent 
propylbenzilylcholine mustard (PrBCm). In contrast to methacholine-induced contraction 
of untreated strips (Fig. 1a), maximal methacholine-induced contraction was Rho-kinase 
dependent after treatment with PrBCm (24.8 ± 9.2 % inhibition  of Emax in the presence of 
Y-27632; P<0.05; Fig. 4). These results suggest that the contribution of Rho-kinase to 
muscarinic agonist-induced contraction is dependent on receptor/transduction reserve. 
Interestingly, after PrBCm-pretreatment, the reduction of the pEC50 value of methacholine 
by Y-27632 was of similar magnitude as in non-alkylated preparations (Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Relationship between Rho-kinase dependency and Ca
2+-mobilization and -influx 
For several agonist concentrations we have plotted the effectiveness of Y-27632 in 
decreasing contraction (% inhibition) against the induced Ca
2+-mobilization and the Ca
2+-
influx (Fig. 5). An inverse relationship between Rho-kinase-dependency and Ca
2+-
mobilization (Fig. 5a) as well as Ca
2+-influx (Fig. 5b) was found. 
Figure 4  Effects of Rho-kinase inhibition
on methacholine-induced contraction after
pretreatment with propylbenzilylcholine
mustard (PrBCm). Methacholine (MCh)-
induced contraction in the absence (closed
circles) and presence (triangles) of 1 μM Y-
27632 of PrBCm-treated bovine tracheal
smooth muscle strips. Data represent means ±
S.E.M. of 3-4 experiments, each performed in
duplicate. Chapter 7 
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Figure 5 Relationship between methacholine (circles)-, pilocarpine (squares)- and McN-A-343 (triangles)-
induced Ca
2+-mobilization (a) and -influx (b) in bovine tracheal smooth muscle cells and Rho-kinase dependency 
of methacholine-, pilocarpine- and McN-A-343-induced contraction of bovine tracheal smooth muscle strips. Data 
represent means ± S.E.M. of 3-7 experiments, each performed in duplicate. 
 
 
Discussion 
In the present study, we demonstrate that full and partial muscarinic agonists are 
differentially dependent on Rho-kinase and Ca
2+-mobilization for their contractile effects. 
Moreover, we show that there is an inverse (exponential) relationship between the Rho-
kinase-dependency of the contraction and the Ca
2+-mobilization as well as the Ca
2+-influx 
induced by different concentrations of the agonists. These findings correspond to 
observations in canine tracheal smooth muscle using acetylcholine and McN-A-343, 
indicating that differences in Ca
2+-kinetics possibly are a consequence of differences in 
potency of muscarinic agonists to activate the same subcellular pathways, rather than from 
the activation of distinct subcellular mechanisms [24].  
A receptor-dependent role of Rho-kinase in agonist-induced ASM contraction appears to 
exist. Both in guinea pig [25] and human [26] ASM it was found that growth factors, which 
are coupled to receptor tyrosine kinases, induce contractions which are fully Rho-kinase 
dependent, whereas contractions elicited by histamine, which are mediated through Gq/11-
coupled H1 receptors, are not [27,28]. In addition, potency and maximal contraction 
induced by PGF2α are governed by Rho-kinase activity in guinea pig tracheal smooth Rho-kinase dependency of muscarinic agonists 
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muscle to an important extent, whereas histamine-induced contractions are not [29]. The 
agonists used in the present study all function through activation of the M3-receptor in order 
to induce ASM contraction. The observed differential involvement of Rho-kinase by partial 
and full agonists therefore implies that there is not only a receptor-dependent, but also an 
agonist-dependent role for the participation of Rho-kinase in ASM contraction.  
Rho-kinase inhibition resulted in a decrease in potency of methacholine, pilocarpine and 
McN-A-343, whereas Emax was affected only for pilocarpine and McN-A-343. Remarkably, 
the strongest decrease in potency was observed for methacholine and the smallest for McN-
A-343; in contrast to the effects on Emax which were absent for methacholine and most 
pronounced for McN-A-343. This indicates that methacholine is only dependent on Rho-
kinase for its contractile effects in the lower concentration range, without requiring Rho-
kinase to achieve its maximal contractile response.  In bovine tracheal smooth muscle there 
is a considerable reserve of inositol phosphate production (transduction reserve) for 
methacholine but not for McN-A-343 [30]. If the maximally stimulated M3-receptor 
generates more Rho-kinase activity than ‘required’ for maximal contractile effect, 
inhibition of this signal transduction will affect the potency, not the efficacy, of the agonist. 
In other words, methacholine induces the largest IP3-dependent Ca
2+-mobilization and -
influx , which is probably sufficient to achieve maximal contraction independent of Rho-
kinase-mediated Ca
2+-sensitization. In contrast, very low levels of  Ca
2+-mobilization are 
observed in response to pilocarpine and McN-A-343, presumably as a consequence of a 
small and neglectable transduction reserve, respectively, [31], and therefore these agonists 
do rely on Rho-kinase for their maximal contractile response. Also, fully in line with this 
interpretation, maximal methacholine-induced contraction becomes Rho-kinase dependent 
after pretreatment with the irreversible muscarinic receptor antagonist PrBCm, 
demonstrating  that the contribution of Rho-kinase to muscarinic agonist-induced 
contraction is dependent on transductional reserve. Remarkably, in the presence of Y-27632 
a similar decrease of potency is observed in PrBCm-treated strips as in untreated strips. An 
additional explanation for the differences between full and partial agonists in the 
modulation of the maximal contraction, might therefore be that partial agonists have 
different relative activation profiles for Gq- and Gi/o-proteins as compared to full agonists, 
as demonstrated in Chinese hamster ovary cells [32]. 
The inverse relationship between Rho-kinase dependency and both Ca
2+-mobilization and 
Ca
2+-influx, as shown in Figure 5, might suggest that Y-27632 is capable of reducing these 
Ca
2+-responses. However, we demonstrate that Y-27632 does not inhibit Ca
2+-mobilization 
or Ca
2+-influx for all three agonists at their maximal concentration. In addition, no effect of 
Rho-kinase inhibition was observed when a submaximal concentration of methacholine (1 
μM) was applied (data not shown), corresponding to findings in guinea pig trachealis, 
which showed no effects of Y-27632 (1-10 μM) on methacholine (1μM)-induced Ca
2+-
mobilization [33]. This strongly suggests that the effects of Rho-kinase-inhibition are on the 
level of Ca
2+-sensitization rather than on Ca
2+-mobilization or -influx. 
In conclusion, this study shows that full and partial muscarinic receptor agonists are 
differentially dependent on Rho-kinase for their contractile effects, indicating an agonist-Chapter 7 
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dependent role for Rho-kinase in ASM contraction. Furthermore, we demonstrate that there 
is an inverse relationship between both Ca
2+-mobilization and Ca
2+-influx and the 
functional Rho-kinase dependency, presumably as a consequence of differences in 
transduction reserve between full and partial M3-receptor agonists. Moreover, Ca
2+-
mobilization and -influx in response to M3-receptor stimulation seem to be independent of 
Rho-kinase, suggesting that differences in functional Rho-kinase dependency are on the 
level of Ca
2+-sensitization rather than on Ca
2+-mobilization or -influx. 
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Summary and conclusions 
Asthma is a serious global health problem, of which the incidence worldwide is increasing. 
Despite the marked heterogeneity of the asthma phenotype, a consensus definition for 
asthma has been developed that recognizes this disease to be a chronic inflammatory 
disorder of the airways in which many cells play a role, including, mast cells, eosinophils, T 
lymphocytes, neutrophils, epithelial and airway smooth muscle cells. In susceptible 
individuals, this inflammation causes recurrent episodes of wheezing, breathlessness, chest 
tightness, and cough, particularly at night and/or in the early morning. These episodes are 
usually associated with widespread but variable airflow obstruction that is often reversible 
either spontaneously or with treatment. The inflammation also causes an associated 
increase in the existing bronchial hyperresponsiveness to a variety of stimuli [1]. β-
Adrenoceptor agonists have been used to treat asthma for more than a century. The 
mechanisms of action of β2-adrenoceptor agonists are well characterized and involve 
cAMP-dependent and -independent processes, finally resulting in airway smooth muscle 
relaxation, enhanced mucociliary clearance, decreased vascular permeability and reduced 
mediator release from inflammatory cells, such as mast cells and basophils [2]. Over the 
years, β2-adrenoceptor agonists have proven to be very effective bronchodilators [3,4], and 
belong to the mainstay of asthma therapy [2,5]. However, despite the fact that β2-
adrenoceptor agonists are the most effective bronchodilator drugs presently available, there 
have been concerns about adverse effects of chronic use of these drugs. Thus, it has been 
shown that chronic β2-adrenoceptor agonist therapy can diminish the efficacy of these 
drugs and may induced rebound airway hyperresponsiveness [6-8]. Moreover, it is well 
known that patients with asthma have a reduced bronchodilator response to β2-adrenoceptor 
agonists during a severe exacerbation [9,10]. The mechanistic basis for the changes in β2-
adrenoceptor responsiveness observed in asthma has not been fully established yet. 
Therefore, the main purpose of this thesis was to elucidate some of the mechanisms that 
influence β2-adrenoceptor responsiveness in airway smooth muscle.   
One of the mechanisms that may be involved in the reduced β2-adrenoceptor 
responsiveness in airway smooth muscle of asthmatic patients is heterologous 
desensitization of the receptor. The term heterologous (or receptor-nonspecific) 
desensitization indicates that stimulation of one receptor attenuates the response to multiple 
(distinct) receptors operating through the same or different signalling pathways. For 
example, phosphorylation of the β2-adrenoceptor by second-messenger kinases such as 
protein kinase A (PKA) and protein kinase C (PKC) may contribute to heterologous 
desensitization by uncoupling the receptor from the stimulatory G-protein Gs. Evidence has 
emerged suggesting that inflammatory mediator- and neurotransmitter-induced activation 
of PKC could be importantly involved in the observed reduced β2-adrenoceptor 
responsiveness in airway smooth muscle of asthmatic patients, especially during a severe 
exacerbation. Thus, in various cells and tissues it has been found that activation of PKC via 
agonist-induced phophoinositide (PI) metabolism or phorbol esters is able to desensitize the 
β2-adrenoceptor, presumably via phosphorylation of the receptor and/or Gs [11-17]. Summary and conclusions 
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However, the specific role of contractile agonist-induced PKC-activation in functional 
antagonism of β2-adrenoceptor agonists has never been addressed in the airways.  
To this purpose, in chapter 2 we examined the effects of the specific PKC-inhibitor GF 
109203X [18] on isoprenaline-induced relaxation of bovine tracheal smooth muscle 
contracted by various concentrations of methacholine or histamine. Both muscarinic M3- 
and histamine H1-receptors are coupled to Gq which activates phosphatidylinositide 
hydrolysis. This results in the formation of inositol trisphosphate (IP3) which releases Ca
2+ 
from internal stores to initiate contraction, followed by a sustained influx of extracellular 
Ca
2+ which is implicated in the tonic phase of contraction. In addition, diacylglycerol 
(DAG) is formed, which activates PKC. PKC is also considered to be involved in the tonic 
phase of contraction [19,20], possibly by inducing Ca
2+-sensitization. In addition, it has 
been demonstrated in bovine tracheal smooth muscle that activation of PKC exerts a 
feedforward control of both the methacholine- and histamine-induced Ca
2+-mobilization 
and influx, which suggests that PKC may be involved in the phasic contraction as well [21]. 
β2-Adrenergic agonists mediate relaxation of airway smooth muscle by stimulation of Gs-
coupled β2-adrenoceptors, which results in the activation of adenylyl cyclase to generate 
cAMP, which in turn activates of PKA [22]. Phosphorylation of specific target proteins by 
PKA results in various biochemical responses that induce smooth muscle relaxation, by 
reducing intracellular calcium concentration and diminishing the Ca
2+-sensitivity of the 
contractile elements. In our study we found that in the absence of GF 109203X, the potency 
of isoprenaline (pD2) was gradually reduced at increasing methacholine- and histamine-
induced smooth muscle tones, but the maximal relaxation (Emax) was decreased only at 
higher concentrations of methacholine. Several other studies have shown that exaggerated 
contractile agonist-induced stimulation of airway smooth muscle, both of human [23,24] 
and animal [22,25-27] origin, causes a reduced relaxability of the muscle by β2-
adrenoceptor agonists. Such diminished functional antagonism has also been observed in 
vivo [28] and may explain why β2-adrenoceptor agonists become less effective during 
severe asthmatic episodes, whereas their efficacy is unchanged in patients with mild or 
asymptomatic asthma [29,30]. In the presence of GF 109203X (10 μM), pD2-values of 
isoprenaline were significantly increased for both methacholine- and histamine-induced 
contractions. Moreover, isoprenaline Emax-values in the presence of high concentrations of 
methacholine were also increased. Both findings show a significant increase in 
isoprenaline-induced relaxation when PKC was inhibited by GF 109203X. Although 
methacholine- and histamine-induced contractions themselves were reduced by GF 
109203X to some extent, the enhanced responsiveness to the β2-adrenoceptor agonist could 
only partially be explained by the reduced smooth muscle tone. Moreover, when the 
reduced contractile tone in the presence of GF 109203X was carefully compensated for by 
additional agonist administration to reach the same contraction levels compared to controls, 
still significantly enhanced pD2 values of isoprenaline were obtained, both for methacholine 
and histamine-induced contractions. In addition, at all histamine-evoked contraction levels, 
in the absence and presence of GF 109203X maximal relaxation by isoprenaline was 
achieved, whereas with  methacholine the Emax values of isoprenaline were consistently Chapter 8 
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enhanced in the presence of GF 109203X.  This enhancement increased with increasing 
levels of contraction, supporting the idea that β-adrenoceptor function worsens in parallel 
with increasing DAG-induced PKC activation. In contrast to isoprenaline, relaxations 
induced by forskolin, which directly activates adenylyl cyclase, were not affected by GF 
109203X. This indicates that the β-adrenoceptor is functionally uncoupled from the effector 
system, in line with the presumed effect of PKC on the β-adrenoceptor or Gs. Since many 
mediators and neurotransmitters in allergic airway inflammation can activate PKC, 
heterologous β2-adrenoceptor desensitization by these agents may indeed be important in 
the reduced bronchodilator response of patients with severe asthma. 
Another mechanism responsible for the reduced β2-adrenoceptor responsiveness of airway 
smooth muscle of asthmatic patients, which chronically use β2-adrenoceptor agonists, may 
involve homologous desensitization of the β2-adrenoceptor. The term homologous (or 
receptor specific) desensitization indicates that when a receptor is activated by an agonist, 
only this receptor is becoming refractory to subsequent agonist application, without 
affecting other receptors or receptor systems present in the same cell. Moreover, 
homologous desensitization requires binding of an agonist to the receptor. Homologous 
desensitization of the β2-adrenoceptor is characterized by a rapid loss in agonist-stimulated 
cAMP generation, primarily mediated by G protein-coupled receptor kinases (GRKs), 
which recognise the agonist-occupied form of the receptor, and induce phosphorylation of 
the receptor. Such phosphorylation results in the binding of β-arrestins which prevent 
coupling with Gs, subsequently followed by sequestration and/or downregulation of the 
receptor [31,32]. Interestingly, heterologous and homologous desensitization are not 
necessarily independent processes. Thus, it has been shown that PKC can mediate changes 
in the cellular expression and activity of GRKs [33]. PKC-mediated phosphorylation not 
only upregulates the activity of GRK2 [34] but also targets this kinase to the plasma 
membrane [35]. In addition, it has been suggested that PKA can induce β-arrestin1 
expression [36,37] and PKA-mediated phosphorylation has also been shown to promote the 
translocation of GRK2 to the plasma membrane [38]. Little is known, however, about the 
functional consequences of these interactions.  
In  chapter 3, we investigated the effect of phorbol ester-induced PKC activation on 
fenoterol-induced desensitization of the β2-adrenoceptor in bovine tracheal smooth muscle. 
First, fenoterol-induced desensitization of the receptor was indicated by a concentration-
dependent decrease in isoprenaline-induced maximal relaxation of methacholine-contracted 
preparations after preincubation (30 min) with various concentrations (0.1, 1 and 10 μM) of 
the  β-agonist. In addition, phorbol ester-induced, PKC-mediated heterologous 
desensitization of the β2-adrenoceptor was indicated by a small but significant decrease in 
isoprenaline-induced Emax after preincubation with 1 μM phorbol 12-myristate 13-acetate 
(PMA). To investigate the capacity of activated PKC to regulate fenoterol-induced 
desensitization, we incubated the smooth muscle preparations with the combination of both 
1  μM PMA and 1 μM fenoterol. Interestingly, the combined treatment synergistically 
attenuated the isoprenaline-induced maximal relaxation, indicating a common pathway for 
the observed effects. Moreover, GF 109203X markedly inhibited the synergism between β-Summary and conclusions 
 
151
agonist and phorbol ester-induced desensitization, indicating that activated PKC is also able 
to indirectly reduce the β-adrenergic responsiveness of bovine tracheal smooth muscle by 
potentiating the homologous desensitization of the β2-adrenergic receptor. For the first 
time, we have provided evidence that the concept of heterologous regulation of homologous 
desensitization of the β2-adrenoceptor is functionally operative in airway smooth muscle, 
and it may explain the reduced bronchodilator response to β2-adrenoceptor agonists in 
patients with severe asthma, who regularly use high doses of β2-adrenoceptor agonists. 
In chapter 4, we explored this concept into further detail at the level of intracellular Ca
2+-
homeostasis, by investigating the effect of the specific PKC-inhibitor GF 109203X on the 
inhibition by isoprenaline of methacholine-induced Ca
2+-influx in enzymatically dispersed 
bovine tracheal smooth muscle cells. Single concentrations of isoprenaline (1 nM - 10 μM) 
were administered on the methacholine (100 μM)-induced Ca
2+-plateau at t = 150 or 340 
seconds after methacholine. We found that isoprenaline caused a rapid but transient 
inhibition of the methacholine-induced Ca
2+-influx at all concentrations of the β2-
adrenoceptor agonist, which indicated a rapid desensitization of the β2-adrenoceptor 
response. In the presence of GF109203X, this desensitization was markedly reduced, 
indicating an important role for methacholine-induced activation of PKC. Remarkably, a 
possible direct heterologous effect of methacholine-induced PKC activation on β2-
adrenoceptor function was only small or even absent, as indicated by the minor effect of GF 
109203X on the peak-inhibition of Ca
2+-influx immediately after the administration of 
isoprenaline, and by the equal levels of inhibition of Ca
2+-influx by isoprenaline at the 
different time points after methacholine addition. This observation seems to be in contrast 
with previous observations presented in chapter 2, demonstrating that methacholine-
induced PKC-activation is directly involved in heterologous desensitization of the β2-
adrenoceptor in bovine tracheal smooth muscle. However, these effects were observed after 
establishment of tonic contraction, i.e. after longer incubation times with methacholine 
ranging from 15 to 45 min., before and during the concentration-response-curve. In support 
of the findings made in chapter 3, the observations in chapter 4 demonstrate that in isolated 
airway smooth muscle cells activated PKC potentiates the acute β2-adrenoceptor agonist-
induced homologous desensitization, presumably by enhancing GRK activity. In addition, 
the data also indicate that this process precedes PKC-induced heterologous desensitization 
of the β2-adrenoceptor. 
In recent years, the suspicion has been raised that the inactive S-enantiomer present in the 
racemic mixture of β2-adrenoceptor agonist drugs could be involved in the induction of 
airway hyperreactivity and increased asthma morbidity and mortality [39-43]. Concerns 
about potential adverse effects of S-salbutamol appear to be supported by results obtained 
in animal and in vitro models [44-50], demonstrating enhanced pro-inflammatory effects 
and airway hyperresponsiveness associated with S-salbutamol. In addition, clinical data 
have suggested that the S-enantiomer of racemic β2-adrenoceptor agonists may indeed 
cause airway hyperreactivity in asthmatic patients [51] and even contribute to increased 
asthma death [43]. Furthermore, studies in children [52-54] and adults [55,56] with asthma 
or COPD have suggested that R-salbutamol offers efficacy and safety benefits compared Chapter 8 
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with racemic salbutamol. However, notwithstanding these observations, adverse effects of 
the S-enantiomer in racemic β2-adrenoceptor agonist drugs are still subject of controversy. 
Thus, in guinea pigs it has been found that both basal airway reactivity and allergen-
induced hyperreactivity towards histamine were not affected by S-salbutamol [57]. In 
patients with mild to moderate asthma, other groups have failed to find any adverse effects 
of S-salbutamol [58,59] and several studies in patients with asthma or COPD were unable 
to demonstrate advantage of R-salbutamol over the racemate [40,60-63]. Among all these 
observations, the finding that S-salbutamol increases the intracellular free Ca
2+-
concentration [47,64] and enhances contractile agonist-induced Ca
2+-mobilization [65] in 
dissociated cells from airway smooth muscle, possibly by means of a cholinergic 
mechanism [64], is a fascinating observation which was further investigated. 
In  chapter 5, we have thoroughly compared the effects of R- and S-salbutamol on 
methacholine and histamine-induced Ca
2+ responses in Fura- 2AM-loaded bovine tracheal 
smooth muscle cells, using both cell suspension spectrofluorometry and single cell 
fluorescence microscopy. In our study, S-salbutamol did not enhance basal Ca
2+ levels in 
cell suspensions or in single cells of bovine tracheal smooth muscle. These observations 
were in contrast to effects observed by others using single cells [64,65]. In cell suspension, 
we found that R-salbutamol inhibited the 1 μM methacholine-induced Ca
2+-transient in a 
dose dependent fashion. S-salbutamol inhibited the methacholine-induced response at 250-
400-fold higher concentrations, demonstrating the stereoselectivity of action of salbutamol 
at the β-adrenoceptor. In single cells, the 1 μM methacholine-induced Ca
2+-transient was 
more resistant to inhibition by R- and S-salbutamol, with only an effect of the highest R-
salbutamol concentration used (10 μM). However, in line with our findings in cell 
suspension, no enhanced methacholine-induced Ca
2+-transient was found in the presence of 
S-salbutamol. To further extend our data, we also determined the effects of 10 μM S- and 
R- salbutamol on 10 μM histamine-induced Ca
2+-responses. Again only R-salbutamol 
significantly inhibited the histamine-induced Ca
2+-transient, whereas preincubation with S-
salbutamol had no effect. Collectively, in contrast to the previous observations [65], our 
data clearly indicate that both in cell suspension and in single cell measurements S-
salbutamol did not enhance contractile agonist-induced Ca
2+-transients. 
Interestingly, after stimulation with methacholine or histamine a considerable number of 
cells showed slow Ca
2+-oscillations. Using real-time confocal microscopy, many contractile 
agonists have been shown to induce intracellular Ca
2+-oscillations in airway smooth muscle 
[66-69]. IP3-receptors appear to be critical for the initiation of these oscillations and 
ongoing oscillations are mediated by ryanodine receptors, which are localized in the 
sarcoplasmic reticulum [70,71]. In our experiments, the methacholine- and histamine-
induced Ca
2+-plateau in single cells was calculated as the area under the curve immediately 
after the first Ca
2+-transient. It was demonstrated that only 10 μM R-salbutamol inhibited 
the methacholine- and histamine-induced Ca
2+-plateau (influx and oscillations), whereas 
other conditions had no effect. The inhibitory effect of 10 μM R-salbutamol on the 
methacholine-induced Ca
2+-plateau from adhered cells was not observed in suspension 
measurements. R- and S-salbutamol had no effect on the number of methacholine-induced Summary and conclusions 
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oscillating cells or the oscillating frequency. Since 10 μM R-salbutamol did not inhibit the 
methacholine-induced Ca
2+-plateau in non-oscillating cells, the results imply that R-
salbutamol inhibited this plateau by decreasing the amplitude of the individual oscillations. 
The number of histamine-induced oscillating cells was not affected by R- and S-salbutamol 
either. Interestingly, in contrast to methacholine, the histamine-induced Ca
2+-plateau in 
non-oscillating cells, purely representing Ca
2+-influx, was markedly inhibited by 10 μM R-
salbutamol and no histamine-induced Ca
2+-oscillations were found in the presence of 10 
μM R-salbutamol, indicating that histamine-induced Ca
2+-responses were apparently more 
sensitive towards R-salbutamol compared to methacholine-induced responses. This is in 
line with previous observations in bovine tracheal smooth muscle, demonstrating that both 
methacholine-induced Ca
2+-responses and contraction are more resistant to β2-adrenoceptor 
agonist-induced inhibition than those induced by histamine [19] and may be explained by 
the higher efficacy of methacholine in inducing inositol phosphates formation and 
subsequent intracellular Ca
2+-changes [19]. Interestingly, the fraction of oscillating cells 
was much higher for methacholine compared to histamine. However, an additional 
signalling pathway for intracellular Ca
2+-oscillations, involving cADPR [72], has been 
demonstrated for methacholine, but not for histamine [73], which might explain the higher 
fraction of methacholine-induced oscillating cells. This could be an additional explanation 
for histamine-induced Ca
2+-oscillations being more sensitive towards R-salbutamol. 
Overall, both in airway smooth muscle cell suspension and in adhered single cells S-
salbutamol did not increase basal intracellular Ca
2+-levels and had no potentiating effect on 
methacholine- and histamine-induced intracellular Ca
2+-responses. In this respect, our 
results offer no explanation for the claimed adverse effects of racemic β2-adrenoceptor 
agonists in asthma. In addition, our single cell measurements showed that R-salbutamol 
preferentially inhibits contractile agonist-induced Ca
2+-plateau by decreasing the amplitude 
of the Ca
2+-oscillations. Finally, the susceptibility of the Ca
2+-transient and -plateau for 
modulation by β-adrenoceptor stimulation appears to depend both on the cellular condition 
(attached vs non-attached) and the agonist used.   
The study presented in chapter 6 is based on our initial finding presented in chapter 2, 
demonstrating that contractile agonist-induced PKC-activation importantly reduces the 
relaxant responsiveness towards isoprenaline in bovine tracheal smooth muscle. 
Interestingly, in additional experiments we observed a marked difference in the 
involvement of PKC in modulating isoprenaline- and fenoterol-induced relaxation. Thus, in 
bovine tracheal smooth muscle preparations contracted with methacholine, inhibition of 
PKC enhanced both the potency and the efficacy of isoprenaline, whereas of fenoterol the 
efficacy but not the potency was increased after PKC-inhibition. Isoprenaline, being a 
catecholamine, is a substrate for catechol-o-methyl transferase (COMT), which transfers a 
methyl group from 5-adenylyl methionine to the 3-OH substituent, thereby causing its 
inactivation [74]. Since fenoterol, a resorcinolamine, is not a substrate for COMT, it is 
tempting to speculate that COMT could account for the differences between isoprenaline 
and fenoterol mentioned above. In addition, by reducing the β-adrenergic response, both 
PKC and COMT, as well as a possible interaction between the two enzymes, may therefore Chapter 8 
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play an important role in decreasing a major endogenous β-adrenoceptor-mediated defence 
by the catecholamine adrenaline in severe asthma. 
Thus, in chapter 6 we investigated the putative interactive role of PKC and COMT in 
reducing the β2-adrenoceptor responsiveness in bovine tracheal smooth muscle, using the 
PKC-inhibitor GF 109203X and the potent COMT-inhibitors OR 486 [75] and tropolone 
[76,77]. Both with OR 486 (1 μM) and tropolone (100 μM) isoprenaline-induced relaxation 
curve of 1 and 10 μM methacholine-induced tone was markedly shifted to the left, with no 
effect on maximal relaxation, indicating that inactivation of isoprenaline by COMT 
strongly dimminishes its potency, not its efficacy. In addition, GF 109203X (10 μM) 
induced a leftward-shift of the relaxation curve of isoprenaline of very similar magnitude as 
OR 486 and tropolone. If PKC and COMT exert their effects independently, an additive 
effect on the isoprenaline-induced relaxation by the combination of inhibitors may be 
expected. The results showed, both for the maximal (10 μM) and the submaximal ( 1 μM) 
methacholine-induced contraction, the results showed that combined treatment with OR 
486 and GF 109203X did not give any additive effect on the relaxant potency of 
isoprenaline, strongly suggesting a common pathway for PKC and COMT. This common 
pathway presumably involves activation of COMT by PKC-mediated phosphorylation. 
Interestingly, in contrast to OR 486 and tropolone, GF 109203 also increased the maximal 
relaxation by isoprenaline, indicating an additional effect of PKC independent of COMT. 
As expected, OR 486 had no effect at all on the fenoterol-induced relaxation, whereas GF 
109203X only increased the maximal relaxation by fenoterol. This confirms the idea that 
the potency enhancement of isoprenaline, as seen after inhibition of PKC, is completely due 
to prevention of COMT-activation.  
In conclusion, the results revealed that in bovine tracheal smooth muscle, activation of 
COMT by PKC attenuates the functional antagonism of methacholine-induced contraction 
by catecholamines. In addition, methacholine-induced PKC-activation is also directly 
involved in the reduced β-adrenergic response towards both catecholamine and non-
catecholamine β-agonists. By reducing the β-adrenoceptor responsiveness, both PKC and 
COMT, as well as an interaction between the two, may play an important role in attenuating 
β-adrenoceptor-mediated bronchoprotection by the endogenous catecholamine adrenaline 
in patients with (severe) asthma. 
As described previously, the efficacy of β2-adrenoceptor agonists in asthma is importantly 
determined by the functional antagonism of neurotransmitters and mediators released in 
airway inflammation [78]. Most of the receptors inducing bronchoconstriction, including 
muscarinic M3- and histamine H1-receptors, are coupled to the heterotrimeric G-protein Gq 
and stimulation of these receptors ultimately results in Ca
2+-mobilization and -influx in 
airway smooth muscle cells. Smooth muscle contraction is initiated through the formation 
of Ca
2+-calmodulin and subsequent activation of MLCK, resulting in the phosphorylation of 
MLC20 [79,80]. However, contractile agonists do not exert their effects solely by increasing 
intracellular Ca
2+ concentration, but also by increasing the Ca
2+-sensitivity of the contractile 
apparatus, also referred to as Ca
2+-sensitization. One of the main regulators of Ca
2+-
sensitization is Rho-kinase, which acts through inhibition of myosin light chain Summary and conclusions 
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phosphatase, resulting in an enhanced MLC20 phosphorylation and thus an increased level 
of contraction at a certain intracellular Ca
2+ concentration [81,82]. In airway smooth 
muscle, full and partial muscarinic receptor agonists have been described to have large 
differences in their signaling efficacy, including Ca
2+-mobilization. Thus, a strong linear 
correlation has been demonstrated between contraction and inositol phosphates 
accumulation in response to partial and full muscarinic receptor agonists, with a 
considerable reserve of inositol phosphate production for the full agonists methacholine and 
oxotremorine, but with no reserve for the partial agonist McN-A-343 [83]. In addition, 
much higher Ca
2+-mobilizing capacities have been described for full muscarinic receptor-
agonists as compared to partial muscarinic agonists [84]. Despite these differences, partial 
agonists are capable of inducing a submaximal to near maximal airway smooth muscle 
contraction.  
To further elucidate the mechanisms underlying these differences between full and partial 
muscarinic-receptor agonists, in chapter 7 we investigated the contribution of Rho-kinase 
to bovine tracheal smooth muscle contraction, Ca
2+-mobilization and Ca
2+-influx in 
response to the full muscarinic agonist methacholine and the partial muscarinic agonists 
pilocarpine and McN-A-343 [83,85]. In the presence of the selective Rho-kinase inhibitor 
Y-27632 (1 μM) the potency for all agonists was significantly decreased. However, 
maximal contraction was reduced only for the partial agonists pilocarpine and McN-A-343 
and was unaffected for the full agonist methacholine, indicating that methacholine is only 
dependent on Rho-kinase for its contractile effects in the lower concentration range, 
without requiring Rho-kinase to achieve its maximal contractile response. Previously, it 
was already reported that methacholine induced the largest IP3-dependent Ca
2+-
mobilization and -influx, in agreement with its considerable reserve of inositol phosphate 
production (transduction reserve) [83], suggesting that the relatively high Ca
2+-responses 
are sufficient to achieve maximal contraction, independent of Rho-kinase-mediated Ca
2+-
sensitization. In contrast, (very) low levels of  Ca
2+-mobilization were observed in response 
to pilocarpine and McN-A-343, presumably as a consequence of a small and neglectable 
transduction reserve, respectively [83],  and therefore these agonists do rely on Rho-kinase 
for their maximal contractile response. Fully in line with this interpretation, maximal 
methacholine-induced contraction became Rho-kinase dependent after pretreatment with 
the irreversible muscarinic receptor antagonist propylbenzylylcholine mustard (PrBCm), 
demonstrating  that the contribution of Rho-kinase to muscarinic agonist-induced 
contraction is dependent on (lack of) transductional reserve. Furthermore, we found an 
inverse relationship between Ca
2+-mobilization as well as Ca
2+-influx and Rho-kinase 
dependency. No inhibitory effects of Y-27632 were observed on Ca
2+-mobilization and 
Ca
2+-influx for all three agonists, confirming that the effects of Y-27632 on contraction are 
at the level of Ca
2+-sensitization indeed. 
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Main conclusions 
From the studies described in this thesis the following conclusions can be derived: 
 
   Contractile agonist-induced PKC-activation is acutely attenuating the functional 
antagonism of bovine tracheal smooth muscle contraction by β2-adrenoceptor 
agonists, presumably as a result of uncoupling of the β2-adrenoceptor from Gs 
(heterologous desensitization). 
   Homologous desensitization of β2-adrenoceptors, mediating bovine tracheal 
smooth muscle relaxation, is enhanced by the activation of PKC (heterologous 
amplification of homologous desensitization). This mechanism could be involved 
in the reduced responsiveness to β2-adrenoceptor agonists of patients with severe 
asthma. 
   PKC-activition by contractile agonists is responsible to a large extent for the acute 
and rapid homologous desensitization of β2-adrenoceptor mediated inhibition of 
Ca
2+-influx in bovine tracheal smooth muscle (heterologous amplification of 
homologous desensitization). 
   In bovine tracheal smooth muscle the inactive S-enantiomer of salbutamol does 
not enhance basal intracellular Ca
2+-levels and has no potentiating effects on 
methacholine- and histamine-induced intracellular Ca
2+-responses using both cell 
suspension and (adhered) single cell conditions, indicating no adverse effects of 
the S-enantiomer in the modulation of Ca
2+-homeostasis. 
   In single bovine tracheal smooth muscle cells, R-salbutamol, the active 
enantiomer, preferentially inhibits the amplitude of the Ca
2+-oscillations, induced 
by contractile agonists. 
   In bovine tracheal smooth muscle, activation of COMT by PKC strongly 
attenuates the functional antagonism of methacholine-induced contraction by 
catecholamines. 
   The potency enhancement of isoprenaline in methacholine-contracted bovine 
tracheal smooth muscle, as observed after inhibition of PKC, is completely due to 
prevention of COMT-activation, whereas the enhanced maximal relaxation reflects 
uncoupling of the β2-adrenoceptor from Gs. 
   Full and partial muscarinic receptor agonists are differentially dependent on Rho-
kinase for their contractile effects, with an inverse relationship between this Rho-
kinase dependency and Ca
2+-mobilization or Ca
2+-influx. 
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Astma is een wereldwijd voorkomende ziekte, waarvan de prevalentie steeds verder 
toeneemt. Deze ziekte wordt gekenmerkt door een chronische ontsteking van de 
luchtwegen, waarbij vele cellen, zoals mestcellen, eosinofielen, T-lymfocyten, neutrofielen, 
epitheelcellen en luchtweg gladde spiercellen, een belangrijke rol spelen. In gevoelige 
personen leidt deze ontsteking tot telkens terugkerende aanvallen van kortademigheid, 
piepend ademhalen, benauwdheid en hoesten. Een aanval komt vaak 's nachts of 's morgens 
vroeg en is meestal reversibel. De ontsteking van de luchtwegen gaat tevens gepaard met 
een overgevoeligheid voor zowel allergische (zoals: uitwerpselen van de huisstofmijt, 
huidschilfers van dieren, stuifmeel) als niet-allergische (zoals: rook, geuren en mist) 
prikkels.  
Eén van de belangrijkste oorzaken van de benauwdheid bij astma is contractie van de 
gladde spieren in de bronchuswand. Deze bronchoconstrictie treedt onder andere op als 
gevolg van afgifte van mediatoren (zoals histamine) uit ontstekingscellen en afgifte van de 
neurotransmitter acetylcholine uit postganglionaire parasympathische zenuwuiteinden. Na 
afgifte grijpen histamine en acetylcholine aan op receptoren die zich op de celmembraan 
van de gladde spiercellen bevinden. Voor histamine is dat de H1-receptor en voor 
methacholine de M3-receptor. Na binding van deze agonisten aan hun receptor gaat de 
receptor een interactie aan met het G-eiwit Gq, wat leidt tot de activatie van het enzym 
fosfolipase C. Fosfolipase C zorgt vervolgens voor de hydrolyse van fosfatidylinositol-4,5-
bisfosfaat (PIP2) in inositol 1,4,5-trifosfaat (IP3) en diacylglycerol (DAG). IP3 diffundeert 
vanuit de celmembraan naar de cytosol en bindt daar aan specifieke IP3-receptoren op het 
endoplasmatisch reticulum, waaruit vervolgens Ca
2+ wordt afgegeven. Hierdoor ontstaat 
een snelle intracellulaire Ca
2+-toename in de vorm van een Ca
2+-piek, gevolgd door een 
Ca
2+-plateau (dat duidelijk hoger is dan het basale Ca
2+-niveau), als gevolg van Ca
2+-influx 
van buiten de cel. De verhoging van Ca
2+ leidt uiteindelijk tot contractie van de luchtweg 
gladde spieren. Het naast IP3 gevormde DAG blijft achter in de plasmamembraan en zorgt 
voor de activatie van proteïne kinase C (PKC). PKC is in staat om eiwitten te fosforyleren 
en draagt tevens bij aan de contractie.  
β-Adrenerge agonisten worden al meer dan een eeuw gebruikt als geneesmiddel bij astma. 
Ze grijpen aan op β-adrenerge receptoren in de luchtwegen en zorgen onder andere voor 
relaxatie van de luchtweg gladde spieren, verhoogde slijm secretie, verminderde 
permeabiliteit van de bloedvaten en verminderde mediator-afgifte uit ontstekingscellen, 
zoals mestcellen. Geïnhaleerde β-agonisten grijpen in luchtweg gladde spieren aan op de β-
adrenerge receptoren van het β2-subtype. Na binding van een β-agonist aan de receptor 
vindt er een interactie plaats met het stimulatoire G-eiwit (Gs), wat leidt tot de activatie van 
het enzym adenylyl cyclase. Adenylyl cyclase zet vervolgens ATP om in cAMP, waarna 
het cAMP-afhankelijke proteïne kinase A (PKA) wordt geactiveerd. PKA is in staat om 
verschillende intracellulaire eiwitten te fosforyleren, voornamelijk resulterend in relaxatie 
van de gladde spieren door het verlagen van de Ca
2+-concentratie en het verminderen van 
de Ca
2+-gevoeligheid van contractiele eiwitten in de cel.  
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Ondanks het feit dat geïnhaleerde β-agonisten de meest effectieve bronchusverwijders zijn 
die op dit moment beschikbaar zijn, hebben verschillende studies aangetoond dat langdurig 
gebruik van deze middelen gepaard kan gaan met nadelige effecten. Voorbeelden hiervan 
zijn een verminderde bescherming tegen bronchoconstrictieve prikkels, een verminderde 
bronchusverwijdende werking en een verhoogde luchtweggevoeligheid voor 
bronchoconstrictieve prikkels na beëindiging van de behandeling. De mechanismen die ten 
grondslag liggen aan deze nadelige effecten zijn echter nog onvolledig in kaart gebracht. 
Opheldering van een aantal van deze mechanismen was dan ook het voornaamste doel van 
de studies uit dit proefschrift. 
Eén van de mechanismen die verantwoordelijk zou kunnen zijn voor een verminderde 
werking van β2-agonisten is heterologe desensitisatie van de β2-adrenerge receptor. De term 
desensitisatie staat voor elk proces dat leidt tot een verminderde functie van een receptor-
signaal systeem. De term heterologe (of receptor-nonspecifieke) desensitisatie geeft aan dat 
de binding van een agonist aan één receptor ook de functie van andere (verschillende) 
receptoren kan verminderen, die gebruik maken van dezelfde of andere signaal-transductie 
routes. Het enzym PKC, dat geactiveerd wordt door de M3-receptor, zou bijvoorbeeld bij 
kunnen dragen aan heterologe desensitisatie van de β2-adrenerge receptor door deze te 
fosforyleren. Hierdoor wordt de interactie met het Gs-eiwit geremd (ontkoppeling) en kan 
adenylyl cyclase niet meer geactiveerd worden. Naast PKC is ook PKA in staat om de β2-
adrenerge receptor te ontkoppelen door middel van fosforylering. In verschillende studies 
zijn aanwijzingen gevonden dat PKC, dat geactiveerd kan worden door verscheidene 
ontstekingsmediatoren maar ook door acetylcholine, betrokken zou kunnen zijn bij de 
verminderde β2-adrenerge receptor functie in luchtweg gladde spieren van patiënten met 
astma. Inderdaad is gebleken dat activatie van PKC in staat is om de β2-adrenerge receptor 
te desensitiseren, door fosforylering van de β2-adrenerge receptor en/of Gs. Tot nu toe is er 
echter nooit gekeken naar de functionele rol van PKC-activatie door contractiele agonisten 
met betrekking tot de desensitisatie van β2-adrenerge receptoren in de luchtweg gladde 
spier. 
In hoofdstuk 2 hebben we daarom de effecten onderzocht van een specifieke PKC-remmer 
(GF 109203X) op de relaxatie van runder tracheaal glad spierweefsel door de β-agonist 
isoprenaline. Hiertoe werden spierpreparaten gecontraheerd met verschillende concentraties 
methacholine en histamine. Het bleek dat in afwezigheid van GF 109203 de gevoeligheid 
voor isoprenaline geleidelijk minder werd bij toenemende concentraties methacholine en 
histamine. Alleen bij hogere concentraties methacholine was ook de maximale relaxatie 
ook verminderd. Het fenomeen dat contractiele agonisten in hoge concentraties zorgen voor 
een verminderde relaxatie door β2-agonisten was al eerder aangetoond en zou kunnen 
verklaren waarom β2-agonisten bij een zware astma aanval minder effectief worden. 
Na remming van PKC door GF 109203X was de gevoeligheid voor isoprenaline duidelijk 
verhoogd en bij de hogere concentraties methacholine werd tevens een verhoogde 
maximale relaxatie gevonden. Hoewel de methacholine- en histamine-geïnduceerde 
contracties ook zelf wat geremd werden door GF 109203X, kon de verbeterde relaxatie 
slechts ten dele hierdoor verklaard worden: ook na voorzichtig bijtitreren met kleine beetjes Nederlandse samenvatting 
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methacholine of histamine, om zo dezelfde uitgangssituatie te creëren als in afwezigheid 
van de PKC remmer, werden nog steeds verhoogde gevoeligheden gevonden voor 
isoprenaline zowel in de methacholine- als de histamine-gecontraheerde preparaten. Ook 
bleek dat de verhoging van de maximale relaxatie van isoprenaline door GF 109203X 
toenam bij opklimmende methacholine-concentraties wat betekent dat de verslechtering van 
de  β2-adrenerge receptor functie parallel loopt met toenemende PKC activatie. In 
tegenstelling tot isoprenaline werd de relaxatie geïnduceerd door forskoline, dat adenylyl 
cyclase activeert zonder tussenkomst van de receptor, niet beïnvloed door GF 109203X. Dit 
geeft aan dat het effect van PKC tot stand komt door fosforylering van de β2-adrenerge 
receptor en/of het Gs-eiwit, leidend tot ontkoppeling van de receptor van zijn effector 
systeem. Deze studie heeft voor het eerst laten zien dat heterologe desensitisatie van β2-
adrenerge receptoren door PKC een functionele rol kan spelen in de relaxatie van luchtweg 
gladde spieren. Omdat vele mediatoren en neurotransmitters die betrokken zijn bij 
allergische luchtweg aandoeningen in staat zijn om PKC te activeren, zou heterologe 
desensitisatie erg belangrijk kunnen zijn in de verminderde β2-adrenerge receptor functie in 
patiënten met ernstig astma.  
Een ander mechanisme dat verantwoordelijk zou kunnen zijn voor de verminderde β2-
adrenerge receptor functie in patiënten, die langdurig gebruik maken van β2-agonisten, is 
homologe desensitisatie van de receptor. De term homologe (of receptor-specifieke) 
desensitisatie geeft aan dat wanneer een receptor geactiveerd wordt door een agonist, alleen 
deze receptor minder gevoelig wordt, zonder dat andere receptoren of receptor-systemen in 
dezelfde cel worden beïnvloed. Voor het optreden van homologe desensitisatie is het 
noodzakelijk dat de agonist gebonden is aan de receptor. In geval van de β2-adrenerge 
receptor wordt het proces gekarakteriseerd door een snelle vermindering van de agonist-
geïnduceerde cAMP productie en wordt primair gemedieerd door G-eiwit gekoppelde 
receptor kinases (GRK’s). GRK’s herkennen en fosforyleren de agonist-bezette vorm van 
de receptor. Deze fosforylering leidt tot de binding van β-arrestines die er voor zorgen dat 
de interactie met het Gs-eiwit niet meer kan plaatsvinden (ontkoppeling); dit kan worden 
gevolgd door sequestratie en downregulatie van de receptor. Het is gebleken dat heterologe 
en homologe desensitisatie niet noodzakelijkerwijs onafhankelijk hoeven te zijn. In eerder 
onderzoek is namelijk aangetoond dat PKC de cellulaire expressie en activiteit van GRK’s 
kan beïnvloeden. Zo blijkt bijvoorbeeld PKC-gemedieerde fosforylering van GRK2 niet 
alleen de activiteit te verhogen, maar ook de translocatie van dit enzym naar de 
plasmamembraan te bevorderen. Er is echter zeer weinig bekend over de functionele 
consequenties van deze interacties. 
In hoofdstuk 3 hebben we daarom in runder tracheale gladde spierpreparaten onderzocht of 
PKC, naast zijn rol in heterologe desensitisatie, ook in staat is om de β-agonist-
geïnduceerde desensitisatie van de β2-adrenerge receptor te verhogen. Allereerst werd β-
agonist geïnduceerde desensitisatie opgewekt door voorbehandeling met verschillende 
concentraties fenoterol. Na grondig uitwassen werden de preparaten op contractie gebracht 
met methacholine en vervolgens gerelaxeerd met isoprenaline. Voorbehandeling met 
fenoterol bleek de maximale relaxatie van isoprenaline inderdaad dosisafhankelijk te  
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verminderen. PKC-gemedieerde heterologe desensitisatie werd vervolgens geïnduceerd 
door de preparaten voor te behandelen met de PKC-activator forbol 12-myristaat 13-acetaat 
(PMA, 1μM). Dit leidde tot een kleine maar significante vermindering van de maximale 
relaxatie van isoprenaline. Gecombineerde behandeling met zowel 1 μM PMA als 1 μM 
fenoterol leidde tot een sterke vermindering van de isoprenaline-geïnduceerde maximale 
relaxatie, groter dan de optelsom van de afzonderlijke effecten van PMA en fenoterol. In 
aanwezigheid van de PKC-remmer GF 109203X was dit synergistische effect van β-agonist 
en forbol ester op de desensitisatie van de β2-adrenerge receptor echter volledig verdwenen, 
wat aangeeft dat PKC-activatie inderdaad in staat is om in luchtweg glad spierweefsel de 
homologe β2-adrenerge receptor desensitisatie te versterken.  
In hoofdstuk 4 is dit concept nader bekeken op het niveau van de intracellulaire Ca
2+-
huishouding in celsuspensies van geïsoleerde runder tracheale gladde spiercellen. Zoals 
eerder besproken zorgt stimulatie van de muscarine M3-receptor voor een snelle Ca
2+-piek, 
gevolgd door een Ca
2+-plateau. Dit plateau, veroorzaakt door Ca
2+-influx, kan minutenlang 
aanhouden. Een β-agonist is in staat om het Ca
2+-plateau te verlagen door de influx van 
Ca
2+ te verminderen. In deze studie werden individuele concentraties van isoprenaline (1 
nm - 10 μM) toegediend op het methacholine-geïnduceerde Ca
2+-plateau, op 150 sec. en 
340 sec na toediening van methacholine. De remming van het Ca
2+-plateau trad zeer snel 
op, maar liep vrij snel terug, totdat het beginniveau van het Ca
2+-plateau weer was bereikt. 
Hieruit bleek dat na toediening van isoprenaline een snelle desensitisatie van de β2-
adrenerge receptor optrad. In aanwezigheid van de PKC-remmer GF 109203X werd de 
terugkeer naar het oorspronkelijke Ca
2+-plateau aanzienlijk geremd. Dit betekent dat PKC, 
geactiveerd onder invloed van methacholine, een belangrijke rol speelt in deze snelle β2-
adrenerge receptor desensitisatie.  
Opmerkelijk genoeg bleek een direct heteroloog effect van PKC vrijwel afwezig te zijn, 
aangezien GF 109203X slechts een minimaal effect had op de acute verlaging van het Ca
2+-
plateau onmiddellijk na de toediening van isoprenaline. Dit werd ondersteund door de 
waarneming dat isoprenaline, toegediend op twee tijdstippen, 150 en 340 sec na 
methacholine, een vergelijkbaar remmend effect had op het Ca
2+-plateau. Dit lijkt in 
tegenspraak te zijn met hoofdstuk 2, waarin aangetoond was dat methacholine-
geïnduceerde PKC activatie wel degelijk direct betrokken is bij directe heterologe 
desensitisatie van de β2-adrenerge receptor in intact tracheaal glad spierweefsel. Echter, 
deze effecten waren gevonden na langere incubatietijden van methacholine (variërend van 
15 tot 45 minuten, voor en tijdens de dosis-werkings-curve). Geheel in overeenstemming 
met de bevindingen in hoofdstuk 3, laten de resultaten van hoofdstuk 4 zien dat geactiveerd 
PKC in geïsoleerde luchtweg gladde spiercellen in staat is om de acute β2-agonist-
geïnduceerde homologe desensitisatie te potentieren, en dat dit proces vooraf gaat aan de 
directe PKC-geïnduceerde heterologe desensitisatie van de β2-adrenerge receptor.  
β2-Adrenerge agonisten die gebruikt worden bij astma bestaan uit een mengsel van 50% S- 
en 50% R-enantiomeren (ook wel een racemisch mengsel genoemd). Enantiomeren zijn 
exacte spiegelbeelden van elkaar, waarvan de ene vorm wel en de andere niet (of slecht) 
kan binden aan de receptor. In de afgelopen jaren is er bezorgdheid ontstaan over de Nederlandse samenvatting 
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inactieve S-enantiomeer in het racemisch mengsel van β2-agonisten. Deze S-enantiomeer 
zou wellicht betrokken zijn bij het ontwikkelen of verergeren van luchtweg-
hyperreactiviteit en zou zelfs de sterftekans ten gevolge van astma kunnen verhogen. Deze 
bezorgdheid werd ondersteund door dierexperimentele studies, zowel in vivo als in vitro, 
die suggereren dat S-salbutamol ontstekingsprocessen en hyperreactiviteit zou kunnen 
bevorderen. Ondanks deze groeiende evidentie, zijn er ook twijfels over mogelijke adverse 
effecten van de S-enantiomeer. In cavia’s is bijvoorbeeld aangetoond dat zowel de basale 
luchtweg reactiviteit als ook de allergeen-geïnduceerde hyperreactiviteit voor histamine niet 
beïnvloed wordt door S-salbutamol. Ook sommige klinische studies in patiënten met mild 
tot matig astma hebben geen directe adverse effecten van S-salbutamol aangetoond of 
voordelen van het gebruik van R-salbutamol in plaats van het racemaat. Van al het 
onderzoek gedaan met S-salbutamol zijn de bevindingen dat deze enantiomeer in 
geïsoleerde gladde spiercellen de basale intracellulaire Ca
2+-concentratie verhoogt en de 
carbachol-geïnduceerde Ca
2+-mobilisatie versterkt, beide vermoedelijk door stimulatie van 
de M3-receptor, zeer intrigerend.  
In hoofdstuk 5 hebben we daarom het effect van S-salbutamol, in vergelijking met de R-
enantiomeer, op de Ca
2+-huishouding nader onderzocht. Vergeleken zijn de effecten op de 
methacholine- en histamine-geïnduceerde Ca
2+-responsen in runder tracheale gladde 
spiercellen in zowel celsuspensies, als in individuele gehechte cellen met behulp van 
fluorescentie-microscopie. In ons onderzoek bleek S-salbutamol de basale intracellulaire 
Ca
2+-concentratie niet te verhogen, noch in celsuspensies noch in individuele gehechte 
cellen.  
In de suspensie vonden we een concentratie-afhankelijke remming van de 1 μM 
methacholine-geïnduceerde Ca
2+-piek, zowel door R- als bij - 250 tot 400-voudig hogere 
concentraties - S-salbutamol. Hieruit blijkt duidelijk de stereoselectiviteit van salbutamol 
voor de β2-adrenerge receptor. In gehechte cellen bleek de 1 μM methacholine-
geïnduceerde Ca
2+-piek minder gevoelig voor remming door R- en S-salbutamol. Alleen de 
hoogste concentratie van de R-enantiomeer (10 μM) had een remmend effect. Echter, 
evenmin als in celsuspensie werd er geen verhoging van de methacholine-geïnduceerde 
Ca
2+-piek gevonden in aanwezigheid van S-salbutamol. Op de 10 μM histamine-
geïnduceerde Ca
2+-responsen had alleen R-salbutamol een significant remmend effect (op 
de Ca
2+-piek), terwijl S-salbutamol geen enkel effect had. 
Een interessante bevinding was dat onder gehechte condities een groot aantal cellen 
langzame Ca
2+-oscillaties lieten zien na stimulatie met methacholine of histamine. In 
verschillende studies die gebruik maakten van ‘real-time’ confocale microscopie zijn deze 
intracellulaire Ca
2+-oscillaties in luchtweg gladde spiercellen eerder gezien. Stimulatie van 
de IP3-receptoren blijkt betrokken te zijn bij de initiatie van deze Ca
2+-oscillaties, terwijl de 
voortgang van deze oscillaties op rekening komt van ryanodine receptoren in de 
sarcoplasmatisch reticulum membraan. Om toch een methacholine- en histamine-
geïnduceerd Ca
2+-plateau te kunnen berekenen in deze experimenten, hebben we de 
oppervlakte onder de curve berekend na de eerste Ca
2+-piek. Alleen 10 μM R-salbutamol 
was in staat om dit Ca
2+-plateau (bestaande uit de optelsom van Ca
2+-influx en Ca
2+- 
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oscillaties) te remmen. Dit remmende effect van 10 μM R-salbutamol werd echter niet 
gevonden in celsuspensie metingen. R- noch S-salbutamol hadden effect op het aantal 
(methacholine-geïnduceerde) oscillerende cellen. Ook de oscillatiefrequentie werd door 
beiden niet beïnvloed. Bij opsplitsing in oscillerende en niet-oscillerende cellen, bleek dat 
10 μM μM R-salbutamol geen remmend effect had op het methacholine-geinduceerde Ca
2+-
plateau (pure influx) in niet-oscillerende cellen, waaruit geconcludeerd kon worden dat R-
salbutamol dit plateau remt door de amplitude in de oscillerende cellen te verlagen. Ook het 
aantal histamine-geïnduceerde oscillerende cellen werd niet beïnvloed door R- en S-
salbutamol. Echter, in tegenstelling tot methacholine, werd het histamine-geïnduceerde 
Ca
2+-plateau in niet-oscillerende cellen (pure Ca
2+-influx) aanzienlijk geremd door 10 μM 
R-salbutamol en werden er in aanwezigheid van 10 μM R-salbutamol zelfs helemaal geen 
histamine-geïnduceerde
 Ca
2+-oscillaties gevonden. Hieruit blijkt dat de Ca
2+-responsen die 
door histamine werden geïnduceerd veel gevoeliger waren voor R-salbutamol dan de 
methacholine-geïnduceerde Ca
2+-responsen.  
Interessant is ook dat de fractie oscillerende cellen veel groter was voor methacholine dan 
voor histamine. De zeer recente waarneming dat methacholine, maar niet histamine, de 
cADPR route, een additionele transductie route voor het induceren van Ca
2+-oscillaties, kan 
aansturen, zou een verklaring kunnen zijn voor de hogere fractie van oscillerende cellen bij 
methacholine. Het zou mede kunnen verklaren waarom histamine-geïnduceerde Ca
2+-
oscillaties minder gevoelig zijn voor β2-agonisten. 
De studie uit hoofdstuk 6 is gebaseerd op één van de eerste bevindingen uit hoofdstuk 2, 
waaruit bleek dat PKC-activatie de isoprenaline-geïnduceerde relaxatie van de runder 
tracheale gladde spier sterk vermindert. In vervolg experimenten bleek verassenderwijs dat 
er een groot verschil was in de manier waarop PKC de isoprenaline- en de fenoterol-
geïnduceerde relaxaties beïnvloedde. In methacholine-gecontraheerde preparaten 
verhoogde remming van PKC zowel de gevoeligheid als de effectiviteit (maximale 
relaxatie) van isoprenaline, terwijl bij fenoterol alleen de effectiviteit werd verhoogd. 
Aangezien isoprenaline -in tegenstelling tot fenoterol- een catecholamine is, en daardoor 
geïnactiveerd kan worden door het enzym catechol-O-methyl transferase (COMT), zou 
COMT hier mogelijk verantwoordelijk voor kunnen zijn. 
In hoofdstuk 6 hebben we daarom de mogelijk additieve en/of interactieve rol van PKC en 
COMT onderzocht bij het verminderen van de β2-adrenerge receptor respons in runder 
tracheale gladde spieren, gebruikmakend van de PKC-remmer GF 109203X en de COMT-
remmers OR 486 en tropolon. Zowel in aanwezigheid van OR 486 (1 μM) als van tropolon 
(100  μM) schoof de isoprenaline-geïnduceerde relaxatiecurve significant naar links op 
(hogere gevoeligheid voor isoprenaline) bij zowel 1 als 10 μM methacholine-geïnduceerde 
voorcontractie, zonder de maximale relaxatie te veranderen. Dit betekent dat inactivatie van 
isoprenaline door COMT wel de gevoeligheid voor isoprenaline vermindert, maar niet het 
maximale effect. In aanwezigheid van GF 109203X trad ook een linksverschuiving op die 
van  dezelfde orde van grootte was als met OR 486 en tropolon. Mochten PKC en COMT 
hun effecten onafhankelijk van elkaar uitoefenen, dan kan verwacht worden dat er een 
additief effect optreedt wanneer beide enzymen gelijktijdig geremd worden. Uit de Nederlandse samenvatting 
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resultaten bleek dat de combinatie van GF 109203X en OR 486, zowel bij maximale (10 
μM) als submaximale (1 μM) methacholine-geïnduceerde contractie, geen additief effect 
gaven op de gevoeligheid voor isoprenaline. Dit geeft aan dat PKC en COMT hun effect 
via een gemeenschappelijke route uitoefenen, waarschijnlijk activatie van COMT door 
PKC-gemedieerde fosforylering. In tegenstelling tot OR 486 en tropolon werd in 
aanwezigheid van GF 109203X ook de maximale relaxatie van isoprenaline verhoogd, wat 
inhoudt dat PKC ook onafhankelijk van COMT een effect heeft op de isoprenaline-
geïnduceerde relaxatie. Zoals verwacht had OR 486 geen enkel effect op de fenoterol-
geïnduceerde relaxatie, omdat fenoterol geen substaat is voor COMT en in aanwezigheid 
van GF 109203X werd dan ook alleen de maximale relaxatie van fenoterol verhoogd. Dit is 
volledig in overeenstemming met het idee dat de verhoogde gevoeligheid voor isoprenaline, 
gezien na remming van PKC, volledig op rekening komt van het voorkómen van COMT-
activatie.  
Concluderend kan gesteld worden dat in runder tracheaal glad spierweefsel activatie van 
COMT door PKC leidt tot een verminderde gevoeligheid van methacholine-gecontraheerde 
preparaten voor catecholamines en dat activatie van PKC ook direct betrokken is bij de 
verminderde  β2-adrenerge receptor respons van zowel catecholamines als niet-
catecholamines (heterologe desensitisatie). Aangezien circulerend adrenaline (een 
catecholamine) betrokken is bij de lichaamseigen bescherming tegen astma aanvallen, zou 
een verminderde β2-adrenerge receptor respons door PKC en COMT, als ook door een 
mogelijke interactie tussen deze twee enzymen, een belangrijke rol kunnen spelen in de 
verminderde endogene bronchoprotectie bij patiënten met (ernstig) astma.  
Zoals eerder aangegeven berust de effectiviteit van β2-agonisten in astma in belangrijke 
mate op het tegengaan van de contractiele werking van neurotransmitters en (allergische) 
mediatoren. De meeste receptoren die bronchoconstrictie induceren, zoals muscarine M3- 
en histamine H1-receptoren, zijn gekoppeld aan het G-eiwit Gq. Stimulatie van deze 
receptoren leidt uiteindelijk tot Ca
2+-mobilisatie uit intracellulaire opslagplaatsen en 
extracellulaire Ca
2+-influx. Contractie van glad spierweefsel wordt geïniteerd door 
complexvorming van Ca
2+ met calmodulin, en de daarop volgende activatie van myosin 
light chain kinase (MLCK), resulterend in de fosforylering van myosin light chain (MLC). 
Het verhogen van de intracellulaire Ca
2+-concentratie is echter niet de enige manier waarop 
contractiele agonisten contractie kunnen bewerkstelligen. Ze zijn tevens in staat om de 
Ca
2+-gevoeligheid van de contractiele eiwitten te verhogen. Dit mechanisme wordt ook wel 
Ca
2+-sensitisatie genoemd. Eén van de belangrijkste regulatoren van Ca
2+-sensitisatie is 
Rho-kinase. Rho-kinase remt het enzym mysin light chain phosphatase (MLCP), 
resulterend in een verhoogde fosforylering van MLC. Op deze wijze kan een hoger 
contractieniveau bereikt worden bij eenzelfde intracellulaire Ca
2+-concentratie. In luchtweg 
glad spierweefsel zijn eerder grote verschillen aangetoond in de effectiviteit van volle en 
partiële muscarine receptor agonisten in het  aansturen van de signaal transductie route, 
verantwoordelijk voor Ca
2+-mobilisatie en influx. Er blijkt een sterke correlatie te bestaan 
tussen de inositol fosfaat accumulatie en de mate van contractie geïnduceerde door volle en 
partiële muscarine receptor agonisten, waarbij een behoorlijke reserve in inositol fosfaat  
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productie is aangetoond voor de volle agonisten methacholine and oxotremorine en geen 
reserve voor de partiële agonist McN-A-343. Tevens is gebleken dat de maximale Ca
2+-
mobilisatie geïnduceerd door volle muscarine receptor agonisten vele malen groter is dan 
bij partiële agonisten. Ondanks deze verschillen, zijn partiële agonisten toch in staat om 
submaximale tot bijna maximale contracties te induceren in luchtweg glad spierweefsel.  
Om de mechanismen die ten grondslag liggen aan deze verschillen tussen volle en partiële 
muscarine receptor agonisten nader te analyseren, hebben we in hoofdstuk 7 in runder 
tracheaal glad spierweefsel de bijdrage van Rho-kinase bestudeerd aan de contractie, Ca
2+-
mobilisatie en Ca
2+-influx van de volle agonist methacholine en de partiële agonisten 
pilocarpine en McN-A-343. In aanwezigheid van de Rho-kinase remmer Y-27632 (1 μM) 
werd de gevoeligheid voor alle agonisten significant verminderd. Echter, de maximale 
contractie was alleen verlaagd bij de partiële agonisten pilocarpine en McN-A-343 en niet 
bij de volle agonist methacholine. Hieruit kan geconcludeerd worden dat methacholine 
alleen bij lagere concentraties afhankelijk is van Rho-kinase voor zijn contractiele effect, 
maar niet voor het induceren van de maximale contractie. In een eerdere studie hadden we 
al aangetoond dat methacholine de grootste IP3-afhankelijke Ca
2+-mobilisatie en Ca
2+-
influx induceert, in overeenstemming met zijn aanzienlijke reserve van inositol fosfaat 
productie (transductie reserve) en dat deze relatief hoge Ca
2+-responsen volstaan om de 
maximale contractie te bereiken, zonder Rho-kinase-gemedieerde Ca
2+-sensitisatie nodig te 
hebben. In tegenstelling tot methacholine werden met pilocarpine en McN-A-343 (zeer) 
lage effecten op de Ca
2+-mobilisatie gevonden als gevolg van een geringe of 
verwaarloosbare transductie reserve, waardoor deze agonisten in belangrijke mate 
afhankelijk zijn van Rho-kinase om hun maximale contractiele effect te bereiken. Volledig 
in overeenstemming met deze interpretatie bleek ook de methacholine-geïnduceerde 
contractie afhankelijk te worden van Rho-kinase als de receptorreserve werd uitgeschakeld 
door de spierpreparaten voor te behandelen met de irreversibele muscarine receptor 
antagonist propylbenzylylcholine mustard (PrBCm). Tesamen genomen lieten de gegevens 
een fraaie inverse relatie zien tussen de afhankelijkheid van Rho-kinase en zowel Ca
2+-
mobilisatie als Ca
2+-influx. Er werd geen direct effect van Y-27632 op de Ca
2+-mobilisatie 
en Ca
2+-influx gevonden voor alle drie agonisten, wat bevestigt dat de effecten van Y-
27632 op de contractie inderdaad op rekening komen van vermindering van Ca
2+-
sensitisatie. 
 
Belangrijkste conclusies uit dit proefschrift: 
   Activatie van proteine kinase C (PKC) door contractiele agonisten vermindert 
acuut het functionele antagonisme van gecontraheerd runder tracheaal glad 
spierweefsel door β2-agonisten, vermoedelijk als gevolg van ontkoppeling van de 
β2-adrenerge receptor en Gs (heterologe desensitisatie) 
   Homologe desensitisatie van β2-adrenerge receptoren, in runder tracheaal glad 
spierweefsel, wordt versterkt door de activatie van PKC (heterologe amplificatie 
van homologe desensitisatie). Dit mechanisme zou betrokken kunnen zijn bij de Nederlandse samenvatting 
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verminderde relaxeerbaarheid van luchtweg gladde spieren door β2-agonisten in 
patiënten met ernstig astma.  
   PKC-activatie door contractiele agonisten is voor een belangrijk deel 
verantwoordelijk voor de acute en snelle homologe desensitisatie van de β2-
adrenerge receptor-gemedieerde remming van de Ca
2+-influx in runder tracheale 
gladde spiercellen (heterologe amplificatie van homologe desensitisatie). 
   In runder tracheale gladde spiercellen leidt de inactive S-enantiomeer van 
salbutamol niet tot verhoging van de basale intracellulaire Ca
2+-concentratie en 
worden de methacholine- en histamine-geïnduceerde Ca
2+-mobilisatie en -influx 
niet gepotentieerd, noch in celsuspensie, noch in individuele gehechte cellen. 
Hieruit blijkt dat S-salbutamol geen adverse effecten heeft op de (beïnvloeding 
van de) Ca
2+-huishouding. 
   In individuele gehechte cellen blijkt dat de actieve enantiomeer R-salbutamol 
vooral de amplitude van de contractiele agonist-geïnduceerde Ca
2+-oscillaties 
remt. 
   In runder tracheaal glad spierweefsel leidt de activatie van COMT door PKC tot 
een sterke vermindering van het functioneel antagonisme van de methacholine-
geïnduceerde contractie door catecholamine β-agonisten. 
   De gevoeligheidsverhoging van isoprenaline in methacholine-gecontraheerd 
runder tracheaal glad spierweefsel, die optreedt na remming van PKC, komt 
volledig op rekening van het remmen van de COMT activatie, terwijl de 
verhoogde maximale relaxatie veroorzaakt wordt door het voorkomen van de 
ontkoppeling van de β2-adrenerge receptor van Gs. 
   Volle en partiële muscarine receptor agonisten zijn in verschillende mate 
afhankelijk van Rho-kinase voor hun contractiele effecten, waarbij er een inverse 
relatie bestaat tussen deze Rho-kinase afhankelijkheid en de Ca
2+-mobilisatie of 
Ca
2+-influx. 
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Dankwoord 
Het schrijven van dit dankwoord geeft mij een goed gevoel. Het betekent dat het grootste 
gedeelte van mijn proefschrift klaar is, en dat begonnen kan worden met de laatste 
afrondingen. Mijn periode als AIO bij de basiseenheid Moleculaire Farmacologie heb ik 
ervaren als een ontzettend leuke en vooral leerzame tijd. Het feit dat ik vlak na mijn eerste 
jaar geveld werd door een zware vorm van de ziekte van Pfeiffer was destijds een enorme 
domper, en heeft mijn onderzoek zeker met anderhalf jaar vertraagd. Gelukkig werd ik 
ondanks deze tegenslag toch in staat gesteld om mijn onderzoek te hervatten en op een 
goede manier af te ronden, met als eindresultaat het proefschrift dat voor u ligt. U zult 
begrijpen dat het dan ook extra veel voldoening geeft dat het nu daadwerkelijk ook af is. 
Het feit dat ik dit dankwoord pas in het laatste stadium van mijn proefschrift schrijf, 
betekent echter niet dat het minder belangrijk is dan de rest. Een proefschrift schrijf je 
namelijk niet alleen en de totstandkoming van dit proefschrift zou onmogelijk geweest zijn 
zonder de hulp en inspiratie van vele anderen. Daarom wil ik graag van deze gelegenheid 
gebruikmaken om een aantal van deze mensen in het bijzonder te bedanken. 
Allereerst mijn promotor Prof. Dr. Johan Zaagsma. Beste Hans, in de eerste plaats wil ik je 
bedanken voor de persoonlijke betrokkenheid die je getoond hebt, tijdens en na de periode 
dat ik met Pfeiffer thuis zat. De vele telefoontjes, adviezen en gesprekken heb ik enorm 
gewaardeerd. Mede door jouw inzet, creativiteit en vertrouwen in de goede afloop, en 
dankzij de verlenging van mijn onderzoeksperiode die je in de wacht hebt weten te slepen, 
in eerste instantie gefinancierd door de universiteit en vervolgens door de ‘Stichting Astma 
Bestrijding’ heb ik dit proefschrift kunnen schrijven. Ook wetenschappelijk gezien heb je 
veel bijgedragen aan dit proefschrift. Je deskundigheid, je positieve en kritische blik op 
resultaten en je tomeloze gedrevenheid zijn een enorme bron van inspiratie geweest, waar 
ik veel van geleerd heb. Ook wil ik je bedanken voor de grote snelheid en nauwkeurigheid 
waarmee je de laatste maanden een aanzienlijk deel van mijn manuscripten hebt nagekeken 
en bijgeslepen, waardoor je in belangrijke mate hebt bijgedragen aan de kwaliteit van dit 
proefschrift. Je hebt me tevens geleerd om vaker aan de bel te trekken op momenten dat dit 
nodig was. Fijn dat ik met al mijn vragen (wel of niet onderzoeksgerelateerd) altijd bij je 
terecht kon en bedankt voor je steun bij het zoeken naar een nieuwe baan. 
Vervolgens mijn promotor Prof. Dr. Herman Meurs. Beste Herman, ook jij ontzettend 
bedankt voor je persoonlijke betrokkenheid tijdens mijn afwezigheid en in de periode 
daarna. De vele overleggen die we hebben gehad over even zovele data leverden eigenlijk 
altijd wel iets positiefs op om mee verder te gaan en je was daarmee, samen met Hans, een 
stuwende kracht achter mijn promotieonderzoek. Bedankt voor de enorme zorgvuldigheid 
waarmee jij de manuscripten hebt nagekeken die je voorgeschoteld kreeg, ook al had je het 
de laatste periode drukker dan ooit. Ik heb enorm veel geleerd van je grote literatuurkennis 
en je opbouwende kritiek bij het presenteren en opschrijven van de resultaten van mijn 
onderzoek.  
Dr. S.A. Nelemans, beste Ad, graag wil ik ook jou bedanken voor de bijdrage die je 
geleverd hebt aan mijn onderzoek. Door je deskundigheid op het gebied van de  
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intracellulaire Ca
2+-homeostase en je vernieuwende ideeën en concepten ben ik in staat 
geweest om een aantal losse eindjes aan elkaar te knopen. Een leuke bijkomstigheid was dat 
we samen, zonder hulp van het IT-beheer, menig computerprobleem op de afdeling hebben 
weten te tackelen.  
Graag wil ik ook de leden van de beoordelingscommissie, Prof. Dr. H.F. Kauffman, Prof. 
Dr. H.G.W.M. Boddeke en Dr. M. Schmidt, bedanken voor de moeite die zij genomen 
hebben om mijn proefschrift te beoordelen.  
Van mijn naaste collega’s ben ik speciale dank verschuldigd aan Dedmer. Je bent bij mij 
begonnen als bijvakstudent en voelde je al snel geroepen om na je studie een 
promotieonderzoek te starten bij onze basiseenheid. In het afgelopen jaar hebben we een 
idee dat voor een deel voortvloeide uit de resultaten van jouw onderzoeksproject als student 
razend snel om weten te zetten naar een mooie publicatie (hoofdstuk 7 van dit proefschrift). 
Bedankt voor je enorme inzet daarbij, de leuke discussies over van alles en nog wat, en de 
broodnodige ontspanning in de vorm van gezellige partijtjes snooker aan het einde van de 
week en niet te vergeten het vissen. Ik denk dat de woorden “Ja hoor”, “Nee hè” en “Hè hè” 
(en bijbehorende gebaren), mij nog lang bij zullen blijven. Verder wil ik graag Carolina 
bedanken voor het inwerken in de intracellulair Ca
2+-metingen, maar ook voor het 
bijbrengen van alle andere praktische kennis die nodig was om mijn onderzoek op te 
starten. Reinoud, Sophie, Jelte, Irene (afdeling Hematologie) en bijvakstudent Arsen wil ik 
graag bedanken voor de technische en experimentele bijdragen die jullie geleverd hebben 
bij het opzetten van de immunoprecipitatie van COMT en het vervaardigen van de Western 
Blots. De tijd was te kort om deze resultaten te verwerken in het proefschrift. Hopelijk zal 
dit snel gebeuren in de vorm van een publicatie. Mechteld, je werd oorspronkelijk in dienst 
genomen als analist op mijn project. Helaas had je de pech dat ik kort daarop de ziekte van 
Pfeiffer onder de leden kreeg. Gelukkig kon dat ondervangen worden door voor Reinoud 
aan het werk te gegaan. In een later stadium hebben we als elkaars kamergenoot een prima 
tijd gehad. Bedankt voor de gezelligheid en de leuke gesprekken. 
De sfeer op de werkplek is voor een groot deel bepalend voor het plezier waarmee iemand 
zijn werk kan doen. Graag wil ik dan ook alle overige (oud) collega’s: Ad R., Annet, 
Berber, Efi, Fiona, Frans, Froukje, Harm, Haukeline, Jaap, Janneke, Jan Roelof, Margriet, 
Melloney, Peter, Sue, en Susan bedanken voor alle hulp en de gezellige en motiverende 
sfeer, met onder andere de vele gezellige lunch- en koffiepauzes, labuitjes, de geweldige 
belevenissen tijdens de verschillende congressen en niet te vergeten de volleybaltoernooien. 
Natuurlijk wil ik ook mijn overige bijvakstudenten bedanken: Marcel, Steven, Johan, Lous 
en Chau Yee. Ondanks het feit dat niet alle experimenten het proefschrift hebben gehaald 
wil ik jullie graag bedanken voor jullie inzet en de bijdrage die jullie geleverd hebben aan 
mijn onderzoek. Tevens wil ik graag beide bijvakstudenten van Dedmer, Anne-Margreet en 
Iris, bedanken voor hun bijdrage. 
Voor dit onderzoek heb ik gebruik gemaakt van luchtpijpen van de koe, om daar de gladde 
spierlaag uit vrij te prepareren en experimenten mee te doen. Ik wil dan ook de slachthuizen 
in Groningen en  Surhuisterveen en slagerij Hilbrants in Eelde bedanken voor het leveren Dankwoord 
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van dit weefsel. De dag dat ik als student voor de eerste keer samen met Carolina op pad 
ging om, in een bloederig slachthuis, al bukkend onder een lange rij druppende 
koeiekoppen een luchtpijp in ontvangst te nemen staat nog in mijn geheugen gegrift.  
Aan het einde gekomen van dit dankwoord, wil ik uiteraard mijn familie bedanken. Mijn 
ouders wil ik graag bedanken voor het feit dat ze mij altijd hebben geholpen en gesteund in 
de keuzes die ik heb gemaakt om de persoon te worden die ik nu ben. Bedankt voor de 
mogelijkheid die jullie mij geboden hebben om in Groningen te gaan studeren, voor jullie 
enorme betrokkenheid, steun en interesse in het verloop van mijn promotieonderzoek en 
voor het altijd vertrouwde plekje in Dronten, Kesteren en later Wageningen. Dit laatste 
geldt natuurlijk ook voor mijn beide zusjes Sandra en Ingrid. Ontzettend bedankt voor jullie 
betrokkenheid en interesse en niet in de laatste plaats voor jullie begrip als ik het weer eens 
liet afweten vanwege het werk.  
Tot slot draag ik dit werk op aan mijn lieve vrouw Siska. Tijdens mijn AIO-periode hebben 
we heel wat meegemaakt samen. Een dieptepunt was wel dat we samen geveld werden door 
de ziekte van Pfeiffer aan het begin van onze relatie. Achteraf gezien is dat wel een periode 
geweest waarin we elkaar ontzettend goed hebben leren kennen. Twee geweldige 
hoogtepunten waren natuurlijk onze trouwdag en de geboorte van ons dochtertje Anniek. 
Lieve Siska, het is bijna onmogelijk om onder woorden te brengen wat jij voor mij 
betekent. Vooral het laatste jaar heb je het zwaar te verduren gehad met mijn eindeloze 
bezigheden achter de computer op momenten dat het maar even kon (of eigenlijk niet kon). 
Ook het feit dat alles toch elke keer weer langer duurde dan gepland leverde 
teleurstellingen op. Ondanks alles heb je altijd 100% achter me gestaan en mij enorm 
gesteund bij alles wat ik deed. Bedankt voor al je liefde, geduld, toewijding en de persoon 
die je bent. Zonder jou was dit alles niet gelukt en daar mag je absoluut trots op zijn. Het is 
af, we hebben een nieuwe mijlpaal bereikt. Ik zie er naar uit om weer meer samen te zijn en 
te gaan genieten van alles wat nog komen gaat. 
 
 
 
 
 
 
  